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Impact Statement
During the clinically relevant stage of the malaria parasite’s lifecycle in a human host, the
asexual blood stage cycle, the parasite invades and replicates within red blood cells be-
fore the red blood cell ruptures to release the progeny parasites. This process of parasite
release, called egress, is actively controlled by the parasite. Egress has been known to
be protease dependent for more than 25 years but the precise proteases mediating the
cellular events during egress have remained unknown. Herein is presented the work from
my PhD project which ascribes some of the physico-mechanical events during egress to
two essential proteases of the malaria parasite. This work is the first to ascribe any of the
events of egress to specific effectors during the asexual blood stage cycle. Proteases are
attractive targets for the rational design of drugs due to their well characterised mecha-
nisms and active site structures. It is possible that the two proteases investigated in this
project can be targeted with small molecule inhibitors with the aim of developing novel
antimalarial drugs. There is a great need for novel antimalarial drugs due to extensive
resistance to previously used antimalarial compounds and the emergence of resistance
to our current frontline artemisinin based chemotherapies.
Additionally, in this work I present the development and application of a plaque based
approach for assaying malaria parasite growth in vitro. This method is very simple, and
does not require expensive or complex equipment or extensive training. The plaque assay
will therefore be an attractive and valuable approach within the malaria research commu-
nity for analysing the effects of genetic mutation and drugs on parasite growth, including
in resource poor settings.
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Abstract
Malaria parasites invade erythrocytes and replicate inside a parasitophorous vacuole (PV).
Invasive merozoites eventually egress in a process that involves sequential rupture of first
the PV membrane (PVM) then the erythrocyte membrane. Egress is protease-dependent,
with both cysteine and serine proteases implicated. The parasite serine protease SUB1
is stored in merozoite secretory organelles that are discharged into the PV ∼10 minutes
before erythrocyte membrane rupture. Pharmacological inhibition of SUB1 activity or dis-
charge blocks egress, but the mechanism by which SUB1 regulates egress is unclear. In
the PV, SUB1 cleaves multiple substrates including SERA6, a putative cysteine protease.
In asexual blood stages of Plasmodium falciparum, the agent of the most dangerous form
of malaria, SERA6 is believed to be essential but its function and whether this depends on
SUB1 is unknown. Here it is shown that conditional disruption of the P. falciparum SUB1
or SERA6 genes produces two distinct, lethal phenotypes. SUB1-null parasites undergo
none of the morphological changes that precede egress and fail to rupture the PVM. In
contrast, PVM rupture and the typical erythrocyte membrane poration occur normally in
SERA6-null parasites but erythrocyte membrane rupture does not occur. Complemen-
tation studies demonstrate that SERA6 is an enzyme and that processing by SUB1 is
required for its function. This study concludes that SUB1 and SERA6 play distinct, essen-
tial roles in a coordinated proteolytic cascade that enables sequential rupture of the two
bounding membranes leading to egress.
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Chapter 1
Introduction
1.1 Malaria is caused by species of the genus Plasmodium
Malaria is a disease of humans caused by five species of the genus Plasmodium: P. fal-
ciparum, P. vivax [Battle et al. 2014; Kumari and Ghildiyal 2014], P. knowlesi [Singh et al.
2004; Cox-Singh et al. 2008], P. ovale [W. E. Collins and Jeffery 2005] and P. malariae
[I. Mueller, Zimmerman, and Reeder 2007]. Recently however P. ovale has been demon-
strated to actually consist of two non-recombining subspecies: P. ovale curtisi and P.
ovale wallikeri [Sutherland et al. 2010]. Plasmodium is an obligate intracellular parasite is
spread by the bite of Anopheles mosquitoes in tropical and subtropical regions through-
out the world. In 2016, 91 countries reported a total of 216 million cases of malaria and
approximately 445 000 deaths [WHO 2017]. Malaria incidence has fallen globally since
2010 but the rate of decline has stalled and in some regions has even reversed. Indeed 5
million more cases were reported in 2016 compared to 2015, although deaths remained
about the same. The African regions accounts for about 90% of both cases and deaths
globally. Throughout most of history the parasite had an even greater reach than it does
now. Plasmodium belongs to the phylum Apicomplexa, a group of unicellular eukaryotes
defined by the possession of an apical complex structure [Templeton et al. 2004] with most,
including Plasmodium, possessing a plastid like organelle called an apicoplast [Kalanon
and McFadden 2010]. The members of this phylum are exclusively endoparasites with the
exception of Nephromyces, an endosymbiont of marine animals [Saffo et al. 2010]. The
phylum contains various members which cause other diseases of medical and veterinary
importance including toxoplasmosis in humans (Toxoplasma gondii) [Dubey 2009], coc-
cidiosis in livestock, particularly poultry (Eimeria spp) [Macdonald et al. 2017], babesiosis
in livestock (Babesia spp) [Westblade et al. 2017] and cryptosporidiosis in humans and
livestock [Abrahamsen 2004].
Malaria parasites are ancient pathogens of humans and in one form or another have
aﬄicted our ancestors from before our human lineage even diverged from that of our near-
est living relatives, chimpanzees [Carter and Mendis 2002]. Malaria has undoubtedly had
a profound impact on our recent evolution. Its effects are imprinted in the genetics of hu-
man populations across the globe, perhaps more so than for any other single infectious
agent of disease [Carter and Mendis 2002]. Examples of this are the multiple genetic poly-
morphisms that contribute to innate immunity against the disease that have been selected
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for during our evolution. These include: G6PD deficiency, various thalassaemias, sickle
cell trait, haemoglobin C and E and ovalocytosis [Carter and Mendis 2002]. Duffy neg-
ativity has long been considered to render humans refractory to clinical infection with P.
vivax [L. H. Miller, Mason, et al. 1975]. This trait has spread practically to fixation in West
and Central African populations and this has been posited as the reason for the relative
lack of P. vivax transmission from human populations in these regions [Bray 1958]. Rel-
atively recently however cases of P. vivax infection, including clinical malaria, have been
documented in Duffy-negative individuals using PCR based methods in Brazil [Cavasini
et al. 2007; Carvalho et al. 2012], Ethiopia [Woldearegai, Kremsner, and Mordmu 2013;
Lo et al. 2015], Madagascar [D. Me´nard et al. 2010] as well as in the West African coun-
tries of Mauritania [Wurtz et al. 2011], Cameroon [Fru-cho et al. 2014; Mbenda and A. Das
2014], Equatorial Guinea and Angola [Mendes et al. 2011]. In Cameroon, it was found
that 14.9% of malaria infections were caused exclusively or concomitantly by P. vivax,
with 50% of those individuals infected with P. vivax being confirmed as Duffy negative
by gene sequencing. In a different study a P. vivax specific ELISA using recombinant
PvMSP1 (merozoite surface protein 1) and PvCSP1 (circumsporozoite protein 1) was de-
veloped as a cheaper and more scaleable alternative to molecular genetic methods for the
screening of large populations. The performance of this ELISA was assessed in French
travellers testing positive for P. vivax and French blood donors not previously exposed to
Plasmodium [Poirier et al. 2016]. Following this validation with French subjects it was used
to assess the proportion of 1,234 Beninese blood donors positive for P. vivax. Of the total
1,234 individuals tested 13.5% were only positive for antibodies against PvMSP1, 6.4%
were only positive for antibodies against PvCSP1 and 15.2% were positive for antibodies
against both PvMSP1 and PvCSP1. 84 individuals that were seropositive for antibod-
ies against PvMSP1 and/or PvCSP1 were selected for further analysis using a nested-
PCR approach to confirm infection with Plasmodium and determine which species were
responsible for infection. Of 25 individuals that were positive by PCR for Plasmodium
13 were infected with P. vivax either exclusively or concomitantly with other Plasmodium
species and all of these individuals were Duffy negative. These various studies clearly
demonstrate that, contrary to the long held dogma, Duffy negativity does not constitute a
complete barrier to infection with P. vivax and that the burden of P. vivax malaria is greater
than previously appreciated in regions of West and Central Africa. The current epidemio-
logical and treatment efforts are rightly focussed on P. falciparum but it will be important to
consider the impact of P. vivax, especially in the context of elimination/eradication strate-
gies. Clearly further work will be required to ascertain in exactly which populations P.
vivax transmission occurs, and what mechanisms P. vivax uses to invade Duffy negative
erythrocytes. It might be that some strains of P. vivax have evolved to use alternative
blood groups for invasion. Alternatively some human populations might possess a unique
blood group(s) that serves as a substitute for Duffy. Duffy negativity aside however, these
relatively ‘visible’ effects of malaria selection pressure are probably just the tip of the ice-
berg when it comes to how malaria has shaped our biology and immune systems over
evolutionary time [Kwiatkowski 2005].
For some time it was generally believed that P. reichenowi, a chimpanzee infecting
species, was the closest living relative of P. falciparum ( the most common cause of severe
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malaria) and that the two species diverged concurrently with the divergence of the human
and chimpanzee lineages [Prugnolle, Durand, et al. 2010]. However, it is now apparent
that all available human infecting P. falciparum sequences constitute a single lineage that
nests within a clade of western gorilla parasites [W. Liu et al. 2010]. This finding demon-
strated that P. falciparum has arisen due to a host switch event from gorillas to humans. P.
falciparum shows little genetic diversity at certain loci, which led to the suggestion that it
had undergone a recent genetic sweep [Rich et al. 1998] but this may now be understood
in the context of a host switch event leading to a genetic bottleneck. It remains unknown
whether gorillas can act as reservoirs of P. falciparum that can then infect humans [W. Liu
et al. 2010]. The occurrence of chloroquine-resistant P. falciparum (see Section 1.8.2)
in chimpanzees clearly demonstrates a host switch from humans and these might be
transmitted amongst chimpanzees and back to humans [Pacheco et al. 2013]. European
travellers have returned home after visiting regions in West and Central Africa infected
with P. vivax, which as discussed above is not generally transmitted amongst populations
native to these regions due to the prevalence of Duffy negativity. This raises the intriguing
possibility that P. vivax, or P. vivax like parasites, might be transferred zoonotically from
apes or some other reservoir to humans, raising concerns regarding the control of dis-
ease [Prugnolle, Rougeron, et al. 2013]. As will be discussed P. knowlesi is now known to
be transmitted zoonotically. Clearly the diversity of Plasmodium species amongst various
primate hosts is great and host tropisms may be less well defined in reality compared to
what was previously appreciated. Compounding this complexity is the fact that even if
other primate species may harbour human infective malaria parasites, it is not inevitable
that transmission to humans will occur. A host of biological and ecological factors may
conspire against such an occurrence; infection of the animal may be transient, or para-
sitaemias low, gametocytes responsible for transmission may not form (see Section 1.3),
or the mosquito vectors may not readily bite both species. An understanding of the diver-
sity of malaria parasites and an assessment of these biological and ecological questions
is therefore important for informing control strategies including those for local ‘elimination’
and global ‘eradication’. Indeed, these uncertainties raises the somewhat troubling ques-
tion: even if we do eliminate a human malaria parasite from a region or eradicate it from
the globe, will another species just emerge to take its place?
1.2 Malaria remains a significant health burden
As discussed, the enormity of the burden of malaria throughout history is evident from the
selective forces it has exerted on humankind. Malaria has partially or completely stymied
a great many human endeavours, from the building of the Panama Canal to the advance
of armies. The latter led British Army Colonel C H Melville to remark in Ronald Ross’ book
The Prevention of Malaria [Ross 1910] that ‘the history of malaria in war might almost be
taken to be the history of war itself’. Apart from the obvious morbidity and mortality of
individuals, it also inflicts a tremendous socioeconomic burden [Malaney, Sielman, and
Sachs 2004]. In endemic areas of Africa malaria predominantly aﬄicts children. When
a child acquires malaria, they cannot attend school and their parents cannot work. With
children suffering multiple clinical episodes a year in some regions the cumulative effects
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of missed education and loss of adult productivity is a significant brake on non-health
related quality of life and the economic prospects of society generally. While malaria
has been successfully eliminated in Europe and North America, it continues to impose a
great burden on the developing world [Sachs and Malaney 2002]. While this has been
significantly reduced in the last decade by renewed efforts to control the disease, the
disease still causes approximately 500,000 deaths per year. Ninety per cent of these are
in Africa, where P. falciparum predominates and most are of children under five [WHO
2014]. It is also possible that future changes of climate and environment will lead to
increases in malaria transmission in certain regions as well as emergence of the disease
into previously transmission-free regions [Askling et al. 2012; Patz and Olson 2006].
While P. falciparum is considered the most virulent and deadly species causing malaria,
there is an increasing appreciation of the importance of non-falciparum species as causes
of morbidity and mortality [Val et al. 2017]. Due to a focus on falciparum malaria, basic
research into the other species has been largely neglected and there is relatively little un-
derstanding of the epidemiology and biology of these species [Akerele et al. 2017; Bichara
et al. 2017]. This is compounded by the inability to continuously culture the non-falciparum
species in vitro, although P. knowlesi has recently been adapted to culture in human ery-
throcytes [Moon, J. Hall, et al. 2013; Lim et al. 2013]. Furthermore, other species are often
disregarded or misdiagnosed in regions where falciparum malaria exists due to difficulties
in distinguishing species by microscopy, masking their true impact [Mayxay et al. 2004].
P. vivax is capable of causing severe disease and death, particularly in children and preg-
nant women [Kumari and Ghildiyal 2014]. It also causes relapsing disease which will be an
important consideration for elimination and global eradication efforts [Battle et al. 2014].
P. knowlesi is now known to routinely infect humans on the Malaysian peninsular and
Borneo, often giving rise to severe and fatal disease characterised by hyper-parasitaemia
[Ahmed et al. 2014; Singh et al. 2004; Cox-Singh et al. 2008]. New molecular screening
techniques are demonstrating that the prevalence of P. malariae and P. ovale, generally
assumed to be benign and rare, may have been underestimated [Ruas et al. 2017]. P.
malariae and P. ovale may have important biological interactions with other species of
Plasmodium such that control efforts specifically targeting and reducing the burden of P.
falciparum and P. vivax might increase the incidence and burden of P. malariae and P.
ovale [I. Mueller, Zimmerman, and Reeder 2007]. While eradication has reappeared on
the global health agenda there remain significant obstacles to achieving this goal. These
include emerging insecticide and drug resistance, increased human mobility, economic in-
stability/underdevelopment, and inadequate tools to combat relapsing infection resulting
from the dormant hypnozoite forms that can arise from P. vivax infection, not to mention the
continued lack of an efficacious sterilising vaccine [White, Pukrittayakamee, et al. 2014;
Battle et al. 2014; Sachs and Malaney 2002; Feachem et al. 2010].
1.3 Plasmodium lifecycle
Plasmodium, like all Apicomplexans, is predominantly an intracellular pathogen. The peri-
ods of intracellular existence within different cell types in the vertebrate and mosquito host
are interspersed with extremely short periods of extracellular existence when the parasite
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transitions from one cell to the next. Whilst outside of a cell, pathogens are maximally ex-
posed to the host immune system. Therefore, Plasmodium likely faces selection pressure
to limit the time it is exposed to the immune system to a minimum.
Infection of a vertebrate host with the pathogen begins when a female Anopheles
mosquito takes a blood meal (Figure 1.1). In the process it injects ∼10-100 sporozoite
forms of the parasite [Frischknecht and Matuschewski 2017]. These migratory forms move
within the dermis, apparently at random, until they contact a capillary [Amino, Thiberge, et
al. 2006; Amino, Giovannini, et al. 2008]. They then traverse the capillary endothelium to
enter the blood stream and travel to the liver where traverse through the liver sinusoid en-
dothelium and through several hepatocytes in an unusual process involving the breaching
of the plasma membrane followed by rapid repair with no formation of a parasitophorous
vacuole (PV) [Mota et al. 2001]. Eventually they invade a hepatocyte in a process that re-
sults in formation of a parasitophorous vacuole, in which they reside [Risco-Castillo et al.
2015]. Sporozoites use the higher sulfation level of host heparan sulfate proteoglycans on
hepatocytes as a signal to invade a hepatocyte [Coppi et al. 2007]. Over the ensuing 5-10
days, repeated rounds of non-synchronous nuclear replication within this vacuole (termed
schizogony) results in a multi-nuclear syncytium called a schizont. Budding of the parasite
plasma membrane around the nuclei results in several thousand hepatic merozoite forms.
The parasites then rupture the parasitophorous vacuole membrane (PVM) and induce the
death and detachment of the infected hepatocyte from neighbouring cells. The merozoites
are released into the blood stream within host-derived vesicles that bud off from the hep-
atocyte, called merosomes [Sturm 2006]. Merosomes extrude into the lumen of the liver
sinusoid where they flow to the pulmonary capillaries. The parasites appear to suppress
the exposure of phosphatidylserine on the outer leaflet of the host membrane of mero-
somes which normally acts as a signal for phagocytes to phagocytose a cell [Friedrich et
al. 2012a]. As merozoites are readily phagocytosed by the abundant Kupffer cells in the
liver sinusoid, merosomes likely ensure the survival of merozoites until they have exited
the liver. The merosomes eventually lodge in pulmonary capillaries and merozoites are
released. It has been suggested that this is an advantageous site for merozoite release
due to a low macrophage density and reduced blood velocity which reduces shear forces,
allowing the merozoites to invade erythrocytes more successfully [Baer et al. 2007].
The invasion of erythrocytes initiates the asexual blood stage cycle. During this stage
repeated rounds of invasion, replication of daughter merozoites and egress result in expo-
nential proliferation of parasites. It is this stage, with the lytic destruction of erythrocytes
during egress, that results in all the clinical symptoms of malaria [White, Pukrittayakamee,
et al. 2014]. Due to its clinical relevance and the ease with which it can be cultured con-
tinuously in vitro, the asexual blood stage cycle has been the most studied. Invasion of an
erythrocyte begins with initial attachment of the merozoite to the surface of an erythrocyte
(Figure 1.2) [Cowman et al. 2017; Tham et al. 2015]. The merozoite then induces waves
of deformation across the erythrocyte before it reorients such that the apical complex is
in contact with the erythrocyte surface. The merozoite then invades the erythrocyte by
apparently pushing its way into the cell, with force generated by an actinomyosin motor
[Cowman et al. 2017]. This involves the formation of a ‘moving junction’ which was first
observed as an electron dense interface at the point of contact between the merozoite
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and erythrocyte membranes in electron microscopy studies over 30 years ago [Aikawa,
L. H. Miller, and J. Johnson 1978]. The moving junction is known to be formed via in-
teractions between apical membrane antigen 1 (AMA1), an integral protein secreted onto
the merozoite surface from specialised parasite secretory organelles called micronemes
and a complex of RON (rhoptry neck-derived) proteins secreted into the erythrocyte from
another type of specialised secretory organelles called rhoptries [Richard et al. 2010].
Invasion culminates in the resealing of the erythrocyte behind the merozoite and the bud-
ding off of the invaginated erythrocyte membrane to form the parasitophorous vacuole
membrane (PVM) [Paul, Egan, and Duraisingh 2015; Cowman et al. 2017]. For the first
∼14 hours post invasion the parasite resembles a diamond ring in Giemsa stained thin
films, giving rise to the name ring stage. This develops into a trophozoite (feeding) stage,
which digests haemoglobin from the erythrocyte, resulting in the formation of a food vac-
uole that contains crystallised haem called haemozoin. Eventually the parasite undergoes
DNA replication by schizogony as in the liver stage. Multiple rounds of asynchronous nu-
clear division results in a syncytium containing 20-25 nuclei, followed by apportioning of
organelles to each nucleus and budding of the parasite plasma membrane around each
nucleus to form daughter merozoites. A by-product of this is the formation of a ‘residual
body’ consisting of the food vacuole surrounded by membrane. Egress of these mero-
zoites (discussed in more detail in Section 1.13) allows the invasion of fresh erythrocytes
and initiation of the next growth cycle.
Sexual precursor forms called gametocytes are the forms required for transmission to
mosquitos. Their development forms an offshoot of the asexual blood stage cycle. This
switch into either male of female gametocyte development appears to be regulated by
a member of the ApiAP2 family of transcription factors [Lindner et al. 2010]. When this
switch takes place all of the merozoite progeny of a single parasite are destined to develop
into gametocytes of the same sex [Bruce et al. 1990; Inselburg 1983; Williams 1999]. Most
gametocytes of most Plasmodium species reach maturity in two days, however in P. falci-
parum the process takes about 7-10 days [Bousema and Drakeley 2011]. Upon entering
a mosquito midgut, mature gametocytes rapidly activate and transform into gametes in re-
sponse to a combination of environmental stimuli, including a lower temperature compared
to the mammalian host and the presence of the tryptophan metabolite xanthurenic acid
which is present at relatively high levels in the insect midgut [Billker et al. 1998; Chevalley
et al. 2010]. The gametes then undergo egress from the human erythrocyte, with male
gametes first undergoing three rounds of DNA replication to become octaploid. Eight flag-
ellated microgametes result which detach from the residual body of the cell. These fertilise
the female macrogametes to form a zygote which over 20 h develops into an ookinete.
This moves by gliding motility through the midgut wall where it forms an oocyst embedded
in the basal lamina of the mosquito midgut. This eventually ruptures, releasing ∼3000
sporozoites [Rosenberg and Rungsiwongse 1991; Frischknecht and Matuschewski 2017]
which migrate through the haemolymph to the salivary glands and undergo maturation.
Little is known about this maturation process but the proteomes of salivary gland and
midgut sporozoites differ quite markedly [Lasonder et al. 2008]. Eventually these mature
salivary gland sporozoites are transmitted back into a human host when a mosquito takes
a blood meal.
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Figure 1.1: The P. falciparum lifecycle. The lifecycle of Plasmodium is divided between
the Anopheles mosquito vector and the vertebrate host. Infection of a human is estab-
lished by injection of sporozoite forms of the parasites from the mosquito into the skin as
the mosquito takes a blood meal. The sporozoites migrate to the liver and invade hep-
atocytes. The parasite replicates by schizogony to form daughter merozoites which are
released into the bloodstream where they invade erythrocytes, establishing the asexual
blood stage cycle. During the asexual blood stage cycle, repeated rounds of invasion,
replication and egress propagates the parasite population exponentially. This stage of
the lifecycle gives rise to all the clinical symptoms of malaria. Some merozoites that in-
vade fresh erythrocytes develop into male or female gametocytes which are the sexual
forms responsible for transmission back into a mosquito. When a blood meal is taken
the gametocytes undergo gametogenesis in the mosquito midgut to form gametes which
egress from the confines of the erythrocyte. The male gametes fertilise the female ga-
metes to form a zygote which develops into an ookinete. Ookinetes glide through the
midgut, traverse through the midgut wall and embed within the basal lamina to develop
into an oocyst. In the oocyst, many sporozoites form which are eventually released and
migrate to the salivary glands ready to infect a new host when the mosquito takes a blood
meal. From [Koning-Ward, Gilson, and Crabb 2015]
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Figure 1.2: Merozoite invasion of an erythrocyte. Invasion of an erythrocyte begins
with initial attachment of the merozoite to the surface of the erythrocyte and may occur
in any orientation. The merozoite then deforms the erythrocyte as it reorients such that
the apical end is in contact with the erythrocyte. The merozoite then pushes into the cell
using the force of its actin myosin motor, before the erythrocyte membrane pinches off to
reseal on the outside and form the PV on the inside. Echinocytosis, whereby the erythro-
cyte membrane becomes spiky in appearance, occurs transiently before the erythrocyte
returns to its normal state. Adapted from [Yap et al. 2014].
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1.4 All of the pathology of malaria derives from the asexual
blood stage cycle
As mentioned above, malaria infection is initiated by invasion of liver cells. Clinical symp-
toms of malaria only manifest following establishment of the asexual blood stage infection
however. In cases of uncomplicated malaria these include fever, chills, nausea, headache,
vomiting, and diarrhoea. These symptoms are believed to be caused by tumour necro-
sis factor, the release of which is stimulated by production of malaria ‘endotoxin’ from
parasites, which is understood to be a complex of haemozoin and parasite DNA [Wijesek-
era et al. 1996; Karunaweera et al. 1992]. Anaemia results from rupture of erythrocytes
as well as dyserythropoiesis that occurs during infection [Kwiatkowski 2005; L. H. Miller,
Ackerman, et al. 2013; Pathak and Ghosh 2016].
Severe malaria is usually caused by P. falciparum but can also be caused by P. vivax
and P. knowlesi and involves complications including severe anaemia, coma, pulmonary
oedema, hypoglycaemia and acute kidney injury [Phillips et al. 2017]. Severe malaria
occurs in 1% of African children and kills 10% of those aﬄicted and although less com-
mon in adults it kills 20% of those aﬄicted. Severe malaria is more common in individuals
with reduced immune protection such as those in low transmission settings [Phillips et
al. 2017]. The most susceptible however are children between 6 months and 5 years
of age. At this stage they have lost their maternal antibodies but not yet developed im-
munity themselves [Phillips et al. 2017]. In addition, co-infection with various pathogens
is common in malaria endemic regions including HIV, Mycobacterium tuberculosis and
helminths. HIV-infection increases the risk of severe malaria and death and infection with
other pathogens may be associated with adverse outcomes [Hochman and K. Kim 2009].
Our understanding of the pathophysiology and mechanisms of severe malaria remain far
from complete and what causes some individuals to become aﬄicted by severe forms of
the disease while most individuals suffer relatively benign uncomplicated disease is un-
known [Wassmer et al. 2015]. A major source of pathology during severe malaria infection
is the sequestration of infected erythrocytes to the vascular endothelium which results in
the avoidance of parasite clearance by the spleen. Endothelial adherence is achieved
through export of PfEMP1 (erythrocyte membrane protein-1) onto the surface of infected
erythrocytes which mediates binding to endothelia via interactions between endothelial
protein C receptor (EPCR), the endothelial surface marker cluster of differentiation (CD)
36 and intercellular adhesion molecule-1 (ICAM-1) [Maier et al. 2009; Tuikue Ndam et al.
2017]. The sequestration of infected erythrocytes damages endothelial cells as well as
disrupting blood flow, causing tissue hypoxia and tissue acidosis [Brand et al. 2016]. Fur-
thermore, the haemolysis of infected and bystander erythrocytes leads to anaemia which
may be compounded by reduced erythropoiesis [Pathak and Ghosh 2016]. Haemoly-
sis also exacerbates endothelial damage, with free haemoglobin catalysing production of
reactive oxygen species, which results in oxidative damage to cells [Schaer et al. 2013].
These mechanisms are also responsible for organ specific syndromes associated with se-
vere malaria, such as cerebral malaria and placental malaria, when sequestration occurs
in the brain or placenta respectively. Cerebral malaria is a life-threatening event causing
the death of 15-20% of those aﬄicted and∼25% develop long-term neurological sequelae.
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A magnetic resonance imaging study of cerebral malaria patients in India demonstrated
that brain swelling mainly results from loss of brain endothelial integrity [Mohanaty et al.
2017] potentially revealing a mechanism for a symptom of severe malaria that is strongly
associated with death [Gallego-Delgado and Rodriguez 2017]. This is supported by the
finding that rupture of infected erythrocytes over human brain endothelial cell monolay-
ers in vitro resulted in the opening of intercellular gaps [Gallego-Delgado and Rodriguez
2017].
Placental malaria most commonly occurs in Africa, caused by P. falciparum, but also
occurs outside of Africa, where it is generally generally caused by P. vivax [Howes et al.
2016]. Placental malaria often leads to poor outcomes for foetus and mother. Pregnancy
increases a mother’s susceptibility to infection, especially during their first pregnancy, as
they will have yet to acquire immunity to parasites expressing the variant surface anti-
gen VAR2CSA on the erythrocyte surface which binds to placental chondroitin sulfate A
(CSA) and causes sequestration in the placenta [Pereira et al. 2016]. The risk of placen-
tal malaria is reduced in multigravid women from endemic areas who generally possess
antibodies against this antigen. Placental malaria can be asymptomatic or mild but leads
to an increased risk of death for both baby and mother and predisposes the mother to
miscarriage and stillbirth. It also increases the chance of premature delivery or delivery
of babies with low birth rate with the subsequent reductions in survival and quality of life
that these events bring [Phillips et al. 2017].
1.5 Antimalarial vaccines
Vaccines are the most efficacious and cost-effective means of combatting disease, and
have been developed to prevent a number of bacterial and viral diseases including rabies,
smallpox, polio, bacterial meningitis, typhoid and diphtheria to name a few. Mass vaccina-
tions strategies have eradicated smallpox [Okwo-Bele and Cherian 2011; Metzger, Kohler,
and Mordmuller 2015] and eliminated polio from all but a few regions of the world [Kew
et al. 2005; Morales, Tangermann, and Wassilak 2016]. A great benefit of vaccines is
that they prevent the occurrence of disease in the first place, allowing transmission cycles
to be broken which greatly facilitates elimination/eradication strategies. An efficacious
sterilising vaccine against malaria would greatly facilitate regional elimination and even
global eradication of the disease. All of the widely implemented and efficacious vaccines
developed thus far have been for bacterial and viral infections that the immune system is
capable of generating sterilising immunity to naturally. As such, many vaccines effectively
stimulate the immune system into developing immunity by inoculation with inactivated or
attenuated infectious agents, as if during a natural infection, and have often been success-
ful in doing so with little to no prior knowledge of the mechanisms of immunity generated
to these pathogens [Sette and Fikes 2003].
In the case of malaria, while immunity does develop in people in areas of endemic
transmission, it is not sterilising, and protection wanes over time in the absence of contin-
ued exposure to infection [Doolan, Doban˜o, and Kevin Baird 2009]. The malaria parasite
is also antigenically diverse. Such diversity in protective antigens means achieving cross-
strain protection from antibodies is very difficult. Such diversity has also hampered the
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development of vaccines to HIV, Streptococcus pneumoniae, Hepatitis C virus and in-
fluenza virus [Nickle et al. 2007; Takala and Plowe 2009]. Compounding this problem
for the malaria parasite is that it is a highly immune-evasive organism with various anti-
genically distinct stages [Schwartz et al. 2012]. Perhaps because of this, the majority of
the considerable number of attempts made to develop a vaccine against malaria have not
proved widely effective or practical [Schwartz et al. 2012; R. Me´nard 2005]. It has long
been known that irradiated sporozoites are capable of consistently generating sterilising
immunity against malaria infection in a range of hosts. This was first demonstrated in 1941
for a form of avian malaria [P. Russell, Mulligan, and Mohan 1941] and has since been
demonstrated in humans, including cross strain immunity [Clyde et al. 1973; Hoffman,
Goh, et al. 2002]. This protection required that volunteers be bitten by a large number of
irradiated infected mosquitos (more than 1000) however, which is entirely impractical for
clinical application. Even then immunity waned within a year or two. Another study has
also demonstrated that multiple immunisations with sporozoites by mosquito bite while
receiving chloroquine prophylaxis produced antibodies that were capable of disrupting
sporozoite traversal in the liver [Behet et al. 2014].
The impractical nature of whole cell sporozoite inoculations by mosquito bite or other-
wise, along with concerns that safety might be difficult to ensure, has led to an interest in
generating protein based vaccines. A significant number of trials have been conducted,
mostly using blood stage antigens including: AMA1, MSP1, MSP3, SERA5, EBA175,
RESA and GLURP [Schwartz et al. 2012]. To date the most advanced vaccine of any
kind is the RTS,S/AS01 recombinant protein based vaccine developed by GSK which is
a formulation containing a fragment of the sporozoite surface protein CSP [Multiple 2012;
Casares, Brumeanu, and Richie 2010]. In an 18 month phase III clinical trial RTS,S/AS01
was found to reduce the incidence of malaria by about 50% in young children, but did not
reduce mortality rates of those with clinical disease. Nevertheless it must not be forgotten
that this is not only the first ever licensed vaccine for malaria, but the first for any parasitic
disease. Despite the shortcomings of RTS,S/AS01, it has demonstrated that it is possible
to impact the host-parasite interaction during infection through vaccine induced immune
responses to antigenic subunits [Schwartz et al. 2012]. It has also been shown that an-
tibodies generated in mice by inoculation with RTS,S/AS01 in one animal can provide
sterilising immunity against P. berghei when antibodies are transferred to another animal
[Foquet et al. 2013] raising the possibility that this vaccine might serve as a foundation
from which to develop a more efficacious vaccine. Preliminary data from a recent study
has suggested that optimisation of the immunisation regimen may significantly increase
the protection offered by the RTS,S/AS01 vaccine [Regules et al. 2016]. RTS,S/AS01 is
due to be rolled out in three countries in Africa in 2018 in a WHO coordinated programme
to assess the effects and feasibility of the vaccine (which requires 4 doses) in the context
of routine use. The malaria and broader public health communities will no doubt come
up with creative ways of making the best of even this imperfect vaccine. Highly targeted
administration based on predictions of seasonal transmission or for regional elimination
has been suggested for example [Greenwood, Dicko, et al. 2017]. Nevertheless some
significant improvements will be required before we have a vaccine with the potential to
achieve global eradication and this will likely require a better understanding of parasite
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biology and how the host interacts with the parasite during infection.
1.6 Current priorities and strategies for vaccine development
Potential malaria vaccines can be grouped into three broad categories. Those that act
on clinically silent pre-erythrocytic stages to prevent establishment of clinically relevant
asexual blood stage infection, those that act on the erythrocytic stages to facilitate para-
site clearance once they progress to the erythrocytic stages and those that prevent on-
wards transmission from an infected human. The latter would be expected to provide
herd immunity which would reduce malaria incidence [Hoffman, Vekemans, et al. 2015].
An ideal malaria vaccine requires three features. The first is multiple components that
induce an immune response against sporozoites, infected hepatocytes and asexual and
sexual blood stages. The second is multiple epitopes that are restricted to presenta-
tion by different major histocompatibility complex molecules to overcome genetic diversity
and antigenic variation. Thirdly, it should have multi-immunogenicity including more than
one type of immune response including cell-mediated and humoral responses to increase
the chances of achieving a sustainable and effective host-response [Arama and Troye-
Blomberg 2014]. New vaccine candidates being pursued include PfRh5, an essential
erythrocyte invasion ligand of the parasite. PfRh5 has been shown to induce protective
antibodies that are effective across common genetic variants of PfRh5 [Bustamante et al.
2013; Douglas et al. 2011]. As discussed in Section 1.4 VAR2CSA, a member of the
PfEMP1 variant surface antigen family, is responsible for sequestration of P. falciparum
in placenta. With multiple pregnancies women produce antibodies against VAR2CSA
and these antibodies are associated with increased birth weights and better survival and
outcomes for their offspring [Fried and Duffy 2015]. Efforts are underway to develop a
subunit vaccine which will stimulate the production of protective anti-VAR2CSA antibod-
ies with two VAR2CSA based products expected to enter clinical trails in the near future
[Fried and Duffy 2015].
In addition to these promising subunit vaccines attenuated vaccines also continue to
be developed. The Sanaria company was established to translate the mosquito based
immunisation approach discussed above into an injectable whole sporozoite malaria vac-
cine to eliminate malaria from specific regions and protect non-immune travellers. Sa-
naria is engaged in developing an injectable attenuated sporozoite vaccine that is aseptic,
pure, adequately attenuated and potent. Sanaria has demonstrated that it is possible to
achieve protection by intravenous injection of sporozoites cryopreserved in liquid nitrogen
vapour phase which obviates the requirement of electricity for cryopreservation [Seder
et al. 2013]. Sanaria is now moving to scale up manufacturing, suitable for a phase 3
clinical trial [Hoffman, Vekemans, et al. 2015] but for the time being at least this remains
far from practical for widespread use in the clinic given the difficulty in obtaining sporozoite
material in sufficient quantities and the number of doses (more than four doses) required
to achieve protection.
Genetic attenuation is another means by which attenuated whole parasite vaccines
might be developed. With the recent improvements in genetic approaches discussed in
Section 1.11 it is now possible to embark on rational and directed attempts to develop
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genetically attenuated parasites for use in vaccines. It has been shown that knockout of
the UIS3 (up-regulated in sporozoites 3) gene of P. berghei results in parasites that infect
hepatocytes but fail to initiate blood-stage infection and do not lead to disease. Crucially
immunisation with UIS3 parasites provided complete protection against challenge with
sporozoites [A.-K. Mueller, Labaied, et al. 2005]. Similar findings were seen with knock-
out of UIS4 (up-regulated in sporozoites 4) in P. berghei [A.-K. Mueller, Camargo, et al.
2005]. This approach has also been used to produce genetically attenuated P. falciparum
sporozoites by disruption of p52 [Schaijk et al. 2008]. A recent study generated genetically
attenuated P. falciparum sporozoites by deletion of three genes, simultaneously: p52, p36
and sap1 [Kublin, Mikolajczak, et al. 2017]. These parasites were delivered to 10 volun-
teers by means of mosquito bite and all individuals remained free of blood-stage parasites
and developed inhibitory antibodies to sporozoites. This is an important proof of principle
as ensuring sufficient attenuation of parasites, whilst retaining immunogenicity may be
difficult to ensure [Vaughan et al. 2017].
1.7 Control strategies against malaria
In the absence of an efficacious vaccine a wide range of different measures and strategies
have been used to control malaria, targeting both the mosquito vector and parasite itself.
There has long been an interest in controlling mosquito populations given their role as
vectors of various diseases, including malaria. Historically, destruction of mosquito breed-
ing grounds has been a widely implemented and successful strategy for the reduction of
mosquito populations. In the early 20th century this consisted of draining swamps and
emptying, covering or oiling pools of standing water. As an example, such strategies were
implemented by Dr William Gorgas, an American Army surgeon in the Panama Canal
Zone, which resulted in an 80% decrease in cases of malaria amongst canal company
employees [Chapin and Wasserstrom 1981]. Such measures helped achieve reduction
of malaria cases in Southern Europe and the United States of America alongside general
improvements in sanitation and the use of window screens and bed nets.
Insecticides have proved to be the most successful tool for controlling mosquito pop-
ulations. The best known of several chlorine containing pesticides used in the 1940s and
50s was DDT (dichlorodiphenyltrichloroethane). Malaria was a great health concern for
the Allies during the second world war, with considerable numbers of troops debilitated
or killed by the disease. Aerial spraying of DTT was used with considerable success in
the South Pacific against mosquitos carrying malaria and dengue. Starting between 1952
and 1955, the World Health Organisation embarked on a programme to eradicate malaria
with great confidence [Hay et al. 2004]. This programme achieved considerable success.
For example, in Sri Lanka the programme reduced the approximately one million cases
per year to just 18 by 1963. However, failure to sustain the programme due to economic
concerns and political instability as well as the development of behavioural and physio-
logical resistance of mosquitos to DDT, plus concerns about wider environmental effects
of DDT, caused the partial or even total reversal of progress in many regions [Sougoufara
et al. 2017]. In fact, in Central America, where measures were implemented in the late
1960s the incidence of disease was three times higher following the cessation of control
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efforts in 1975 than a decade earlier [Chapin and Wasserstrom 1981]. Nevertheless, in
countries with low to moderate transmission rates and well organised health care systems
to rapidly diagnose and treat patients, the transmission cycle was broken and elimination
was achieved in 37 countries including Taiwan, most of the Caribbean, the Balkans, parts
of North Africa, Northern Australia and large parts of the South Pacific [T. L. Russell et al.
2013].
A diverse range of mosquito control strategies continue to be investigated for the con-
trol of a range of mosquito species. This is not just limited to the malaria carrying Anophe-
line mosquitos but also for mosquito species of the genus Aedes that carry Dengue fever
and other diseases [Benelli and Beier 2017; Macias, Ohm, and Rasgon 2017]. These
include architectural solutions such as ‘eve tubes’ in houses that suck mosquitoes into
insecticide treated nets with fans, insecticide treated clothing, biocontrol through the in-
troduction of aquatic predators of mosquito larvae and treatment of humans with drugs
that kill mosquitos upon taking blood meals [Benelli and Beier 2017]. Another strategy
which continues to attract much interest is the sterile insect technique (SIT). A method of
releasing male screwworms (Cochliomya hominvorax) that were sterilised by exposure to
X-rays led to the elimination of this agricultural pest in North America in 1968 [Bouyer and
Lefranc¸ois 2014]. A similar approach was successful in eradicating a species of tsetse
fly (Glossina austeni), which transmits trypanosomiasis, from Unguja Island in Zanzibar
[Macias, Ohm, and Rasgon 2017]. This success formed the basis for modern attempts to
release genetically engineered sterile mosquitoes. It has also been proposed to combine
SIT with another technique, auto-dissemination whereby wild mosquitos are contaminated
with juvenile hormone in dissemination stations which prevents the maturation of larvae
[Bouyer and Lefranc¸ois 2014]. SIT has achieved promising successes but significant
challenges remain before this approach will allow region-wide, let alone continent-wide,
control [Oliva et al. 2012].
In the absence of a highly efficacious vaccine, current malaria control relies on three
major interventions: insecticide treated bed nets (ITNs), artemisinin combination thera-
pies (ACTs) (as well as other drug treatments) and indoor residual insecticide spraying.
The scaling up of these have been highly successful in reducing the burden of disease;
between 2000 and 2015 the global incidence of malaria fell by 37% and malaria-related
mortality by 60%. It has been estimated that 663 million clinical cases of malaria have
been averted due to interventions during this period, with 69% of the reduction in disease
incidence and mortality attributable to ITNs, 21% to ACTs and 10% to insecticide spraying
[Bhatt et al. 2015].
1.8 Antimalarial chemotherapy
Various drugs exist for the treatment of malaria. Providing they are administered promptly
these can generally be relied upon to provide favourable outcomes with cure rates of 98%
[Phillips et al. 2017]. The drugs all act by killing blood stage parasites, which cause the
clinical symptoms of malaria, to reduce parasite burden and its associated pathology [L. H.
Miller, Ackerman, et al. 2013]. Despite this, lack of availability, high costs, and emergence
of resistance continue to hamper the effective use of chemotherapies against malaria on
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a global scale. Artemisinin based combination therapies (ACTs) are the recommended
first line therapies for uncomplicated falciparum malaria in all endemic regions [Visser,
Vugt, and Grobusch 2014] (discussed in Section 1.8.6). These combine a highly effica-
cious artemisinin derivative with another antimalarial that is slowly eliminated from the
body in order to guard against resistance to the former, which has a short half-life [Kav-
ishe, Koenderink, and Alifrangis 2017]. ACTs are highly efficacious against all forms of
human malaria and are increasingly considered for treatment of non-falciparum malaria.
However clinical resistance to ACTs is beginning to emerge [Docherty et al. 2003]. In
western Cambodia and the Myanmar-Thailand border regions, the same regions where
chloroquine and sulfadoxine-pyrimethamine resistance emerged, reduced rates of par-
asite clearance are being observed [Docherty et al. 2003; Ariey et al. 2014]. This is a
grave threat to control strategies, with the potential to undo much of the progress made
in reducing malaria morbidity and mortality over the last decade. This makes it impera-
tive to stoke the development pipeline and increase our understanding of parasite biology.
There is also the need for drugs which can target the non-erythrocytic hypnozoite stage
of P. vivax to provide ‘radical cure’ and prevent the existence of latent carriers of disease
[Markus 2010; Battle et al. 2014; Wells, Burrows, and Baird 2010]. Currently the only drug
available that targets hypnozoites is primaquine and related 8-aminoquinolines, which are
contraindicated in G6PD deficient patients [Delves et al. 2012]. This is particularly prob-
lematic given that G6PD deficiency is prevalent amongst populations in regions of malaria
transmission precisely because it has been selected for by providing some level of pro-
tection against malaria (see Section 1.1). What follows in this section is a brief summary
of some of the key antimalarials that have been and continue to be used.
1.8.1 Quinine
Quinine is the first drug that was ever used to treat malaria infection, and in fact, the first
chemotherapeutic agent used to treat any infectious disease. From the 1600s onwards the
quinine-containing bark of the cinchona tree was consumed for the treatment of feverous
ailments including malaria. In 1820 quinine was extracted from the bark by Pierre Joseph
Pelletier and Joseph Caventou and this replaced the crude extracts as the standard treat-
ment for malaria. In fact, multiple alkaloids from cinchona bark were found to be effective
at causing the ‘cessation of febrile paroxysms’ [Achan et al. 2011] but quinine became the
primary alkaloid used (Figure 1.3). Quinine contains a quinoline group, various deriva-
tives of which have been developed and deployed as antimalarials. Quinine remained
the predominant treatment for malaria until the 1920s when the more effective synthetic
derivative of quinoline, chloroquine, became available [Achan et al. 2011]. Chloroquine
was used particularly heavily during the Second World War when a great many troops were
exposed to the disease in the South East Asian, Pacific and North African theatres of war.
Resistance began to be seen in Southeast Asia and South America by the late 1950s and
became widespread by the 1980s. With resistance to chloroquine, quinine became an im-
portant treatment for malaria once again. Quinine continues to be an important drug for
the management of malaria infection despite significant drawbacks to its therapeutic use;
side-effects are numerous and can be severe, and treatment regimens are extended (five
to seven days) which hinders compliance [Achan et al. 2011]. Quinine in combination
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with doxycycline, tetracycline or clindamycin is recommended as second-line treatment
for uncomplicated malaria upon failure or unavailability of first-line treatment. Additionally,
even in cases where ACTs should be preferred, a lack of availability as well as the cost of
ACTs means quinine is often administered in Sub-Saharan Africa where it thus remains
a mainstay of malaria treatment. Interestingly despite the centuries of use, emergence of
resistance to quinine has been slow, and usually low-grade. It retains activity with resis-
tance generally extending treatment times rather than causing outright failures. This is in
contrast to resistance against chloroquine. This means that about 400 years later quinine
retains its place in our arsenal of antimalarials. Furthermore the gametocidal activity of
quinine holds potential to develop quinine or related quinoline derivatives as transmission
blocking agents for control and elimination/eradication strategies.
1.8.2 Chloroquine
As mentioned above, chloroquine was developed as a synthetic quinoline derivative (Fig-
ure 1.3). It was found to be highly efficacious, it exhibited low toxicity and is cheap to
manufacture [Greenwood, Bojang, et al. 2005]. It was therefore recommended for the
prophylaxis and treatment of all malaria infections and related compounds were devel-
oped. Chloroquine sequesters in the food vacuole and is believed to act by interfering
with haemoglobin digestion by the parasite [Slater 1993]. During the WHO malaria eradi-
cation programme of the 1950s and 1960s (see Section 1.7) vast amounts of chloroquine
were administered worldwide. As such, parasite populations were subject to substan-
tial selection pressures and resistance emerged, first in South America in 1959 and then
independently in Cambodia in 1960 [Slater 1993]. Chloroquine eventually failed almost
everywhere for the treatment of falciparum malaria [Greenwood, Bojang, et al. 2005] as
well as for vivax malaria [Baird 2004; Tjitra et al. 2008]. Resistance against chloroquine
has been associated with lower concentrations of chloroquine in the food vacuole and has
been linked to a transporter in the food vacuole called chloroquine resistance transporter
(pfcrt) [Fidock, Nomura, et al. 2000]. Interestingly however there have been a number of
reports of increases in chloroquine susceptibility since its removal from front-line use and
loss of the associated selection pressure [Kublin, Dzinjalamala, et al. 2002; Mwai et al.
2009; Gharbi et al. 2013]. Chloroquine has a good safety profile and is cost-effective. The
high costs of artemisinin derivatives and the emergence of resistance to them mean novel
derivatives of chloroquine remain an attractive prospect [Aguiar et al. 2012].
1.8.3 Sulfadoxine-pyrimethamine
Sulfadoxine and pyrimethamine are antifolate drugs, so called as they interfere with the
parasite’s folate biogenesis pathway through inhibition of dihydropteroate synthetase (DHPS)
and dihydrofolate reductase (DHFR) respectively [Ngondi et al. 2017]. The drugs act syn-
ergistically and in the face of widespread treatment failures to chloroquine across the world
sulfadoxine-pyrimethamine combination therapy (SP) was rolled out in the 1990s. In 1993,
Malawi became the first African country to recommend it as first-line therapy, and many
African nations followed suit soon after [C. H. Sibley et al. 2001]. Resistance emerged in
Southeast Asia and South America exceptionally rapidly however. As such the useful ther-
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apeutic lifespan of SP was less than five years [C. H. Sibley et al. 2001]. Interestingly this
resistance emerged out of the same region, Cambodia, from which chloroquine resistance
emerged. Resistance to SP has been shown to result from the ordered accumulation of
point mutations in the DHPS and DHFR genes, as well as copy number increases of these
mutant alleles [Kublin, Dzinjalamala, et al. 2002; C. H. Sibley et al. 2001; Ngondi et al.
2017]. Despite this, the WHO continues to recommend SP (due to its safety) for intermit-
tent preventative treatment in pregnancy in Africa to reduce the burden of adverse effects
that aﬄict malaria infected pregnant women and their foetuses or neonates [Ngondi et al.
2017].
1.8.4 Mefloquine
The antimalarial properties of Mefloquine were discovered as part of the Walter Reed Army
Institute of Research malaria drug discovery programme which ran from 1963-1975; the
largest drug discovery programme ever mounted at the time [Croft 2007]. Mefloquine be-
came available for prophylactic use in Europe in 1985 and in the USA in 1990 [Hagmann
2017]. In the face of widespread chloroquine resistance, at a time when international travel
was increasing exponentially, mefloquine became one of the main drugs recommended for
chemoprophylaxis [Schlagenhauf, Adamcova, Regep, Schaerer, and Rhein 2010]. Impor-
tantly mefloquine is sanctioned by the WHO for use during the second and third trimesters,
and even in the first trimester by some authorities [Schlagenhauf, Adamcova, Regep,
Schaerer, and Rhein 2010; Gonza´lez et al. 2014]. It is also considered safe during breast-
feeding [Schlagenhauf, Adamcova, Regep, Schaerer, and Rhein 2010]. Mefloquine was
(and still is) considered effective against the blood stages of all human malaria species,
including P. knowlesi, apart from in clearly defined regions of multi-drug resistance [Schla-
genhauf, Adamcova, Regep, Schaerer, and Rhein 2010]. The safety of Mefloquine has
been the subject of some considerable controversy. In particular it has allegedly been as-
sociated with adverse psychiatric events including suicide [Croft 2007]. However a recent
Cochrane review of more than 50 randomised and non-randomised studies with more than
1 million patients using mefloquine to prevent malaria found serious side-effects were not
more frequently seen than with atovaquone-proguanil or doxycycline [Tickell-Painter et al.
2017]. Given the concerns over resistance to ACTs there is a desire to have as many
different combinations of drugs available as possible. As such mefloquine, with its long
half life of elimination, is an important partner drug for use with the artemisinin derivative
artesunate [Schlagenhauf, Adamcova, Regep, Schaerer, Bansod, et al. 2011] (discussed
in Section 1.8.6). Artesunate-mefloquine combination therapy is not widely used in Africa
and is even unregistered in many African nations despite being recommended by the
WHO for treatment of uncomplicated malaria [Eziefula 2016]. Artesunate-mefloquine has
been shown to be as effective as artemether-lumefantrine, the most widely used ACT in
Africa, and safe in children so should become a valuable treatment option [Schlagenhauf,
Adamcova, Regep, Schaerer, Bansod, et al. 2011; Sirima et al. 2016].
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1.8.5 Piperaquine
Piperaquine was synthesised independently by both the Shanghai Pharmaceutical Indus-
try Research Institute in China and Rhone Poulenc in France in the 1960s. It was found
to be potent against chloroquine resistant parasites and had good tolerability so in the
face of widespread chloroquine resistance it was recommended by the Chinese National
Malaria Control Programme in 1978 [Davis et al. 2005]. Widespread unregulated use
as monotherapy throughout China since the late 1970s appears to have played a signif-
icant role in the development of resistance to piperaquine. Piperaquine is now used in
combination with dihydroartemisinin (DHA) due to its long half-life, favourable safety and
toxicity profile and relatively low cost, the latter making DHA-piperaquine co-formulations
attractive for resource poor settings [Davis et al. 2005].
1.8.6 Artemisinin combination therapy
In the face of widespread resistance to the antimalarials outlined above a new antimalarial
chemotherapy was desperately needed by the late 1990s and early 2000s. Sweet worm-
wood (Artemesia annua) extracts had historically been used for the treatment of malaria
in China. The active compound of these extracts, called Artemisinin, was first isolated in
1979 (Figure 1.4) [White, Hien, and Nosten 2015]. The road to adoption of artemisinin
derivatives as therapeutic agents was slow and convoluted but they have since become a
mainstay of malaria control, with global adoption in the early 2000s [White, Hien, and Nos-
ten 2015]. In order to achieve better pharmacological properties, including bioavailability,
semi-synthetic derivatives of artemisinin are used as drugs [Paddon and Keasling 2014].
These include: artemether, dihydroartemisinin and artesunate, the latter being injectable
and used for severe malaria (Figure 1.4). Initially these were used as monotherapies, but
the short half-life of artemisinin derivatives and concerns over resistance, as well as the
observation of significant levels of recrudescence (discussed below), prompted the devel-
opment and implementation of artemisinin combination therapies (ACTs). These combine
an artemisinin derivative with a companion drug that has a longer half-life to ensure ad-
equate longevity of parasite killing to prevent the outgrowth of resistant parasites. The
choice of partner drug for use with artemisinins in different settings primarily depends
on tolerability, cost and pre-existing drug resistance [Davis et al. 2005]. Artemisinins are
currently used in combination with lumefantrine, amodiaquine, piperaquine, mefloquine,
sulfadoxine-pyrimethamine and pyronaridine [Tilley et al. 2016].
Artemisinin derivatives undergo intracellular reductive scission of the endoperoxide
bridge by Fe2+-haem [Blasco, Leroy, and Fidock 2017]. In their activated state these drugs
are lethal to parasites, presumably through alkylation of biomolecules including haem, pro-
teins and lipids, causing oxidative stress and cell damage [Tilley et al. 2016]. The high po-
tency of artemisinins may therefore be due to the abundance of Fe+-haem in blood stage
malaria parasites which results from breakdown of haemoglobin in the parasite’s food
vacuole. Artemisinins are highly active against trophozoite forms, in which haemoglobin
catabolism reaches its peak. Unlike other antimalarials they are also active against ring
forms [Xie et al. 2016]. This early activity likely results from the start of haemoglobin
catabolism a few hours after erythrocyte invasion. When used against sensitive parasites
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the artemisinin derivatives can achieve 10,000-fold reductions in parasite biomass every
48 h, providing exceptionally rapid clearance rates [Dondorp et al. 2009]. Unfortunately,
resistance is emerging to ACTs, with parasites becoming resistant to both the artemisinin
derivatives and partner drugs [Blasco, Leroy, and Fidock 2017]. Delays in parasite clear-
ance times were first reported in 2008 in Cambodia [Anderson et al. 2017] and are now ob-
served across Southeast Asia [Thu et al. 2017]. The same region, which was the crucible
for evolution of resistance to both chloroquine and sulfadoxine-pyrimethamine, appears
to be giving rise to resistant parasite strains once again [Blasco, Leroy, and Fidock 2017].
Resistance to ACTs has been linked to mutations in the Kelch-like K13 gene, which have
now swept across Southeast Asia [Ariey et al. 2014; Ghorbal et al. 2014]. The failure of
chloroquine was estimated to have resulted in a six-fold increase in mortality of children
with malaria [Trape 2001] and mathematical modelling has suggested that in the face of
widespread resistance to ACTs an additional 100,000 people will die of malaria every year
[White, Pukrittayakamee, et al. 2014]. The failure of ACTs will therefore represent a public
health disaster. As yet, ACTs are not failing outright and the intrinsic sensitivity of parasites
remains, although some believe it is merely a matter of when, rather than if, this happens.
Even in the absence of outright failures to clear parasites, recrudescence, whereby para-
sites apparently clear and symptoms abate, only to return following cessation of treatment
causes great problems for the treatment of malaria [Rea, Holder, and Tewari 2017]. In-
deed Artemisinin monotherapies, despite their high potency have always been associated
with high rates of recrudescence [Teuscher, Gatton, et al. 2010]. It has been found that
increasing treatment regimen from <5 days to 5-10 days reduces recrudescence rates
[Sy et al. 1993]. Importantly re-treatment with the same artemisinin derivative is as effec-
tive as the initial treatment suggesting that recrudescence arises through a mechanism
other than development of resistance [Teuscher, Gatton, et al. 2010; Docherty et al. 2003;
Noedl, Se, et al. 2008; Phyo et al. 2012]. It is not clear why such a potent drug is asso-
ciated with such high rates of recrudescence and two hypotheses have been formed to
explain this phenomenon. One hypothesis is that the recrudescence occurs because the
very short half-life of artemisinins results in plasma drug concentrations not remaining
above the minimum inhibitory concentration to kill all parasites. There is some in vitro
and clinical evidence to support this. Exposure of parasites to artemisinin in vitro for only
3 h was insufficient to eradicate parasites, which could only be achieved with extended
dosing regimen [Bwijo and Hassan Alinz 1997]. In a clinical trial in Thailand decreased
rates of recrudescence inversely correlated with drug concentration and dosing frequency
[Looareesuwan 1994]. An alternative mechanism has been proposed in which parasites
are able to enter a dormant state of growth arrest similar to that seen for some bacteria
[Odenholt, Lowdin, and Cars 1997]. There is now a significant body of work supporting
the existence of dormant ring stage parasites that can resume normal growth and it has
been shown that this occurs rapidly after exposure to dihydroartemisinin (DHA) [Codd et
al. 2011; Grobler et al. 2014; Lacrue et al. 2011; Teuscher, Gatton, et al. 2010; Teuscher,
Chen, et al. 2012]. Recently a study has shown that phosphorylation of eIF2α (elongation
initiation factor α) by PK4 (protein kinase 4) is associated with DHA treatment and is critical
for DHA induced dormancy of rings by repressing general translation [Zhang et al. 2017].
In fact resistance to artemisinins has been proposed to involve an altered dormancy pro-
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file [Cheng, Kyle, and Gatton 2012]. The emergence of parasites with resistance to ACTs
that take longer to clear, compounds the issue of recrudescence as parasites are then
not exposed to the minimum inhibitory concentration of drug and escape clearance by
the artemisinin derivative. Hopefully a combination of extending the treatment regimens,
administering triple combination therapies, rotating partner drugs (as well as drug classes
more generally) and the development of new synthetic endoperoxides will maintain the
useful therapeutic life of this invaluable class of antimalarials [Phillips et al. 2017; Tilley
et al. 2016].
Figure 1.3: Chemical structure of quinine and the related chloroquine. The widely
used drugs quinine and chloroquine are both based around the heterocyclic aromatic
quinoline scaffold (highlighted yellow).
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Figure 1.4: Chemical structure of artemisinin and some of its derivatives. This shows
the originally discovered artemisinin and some of the common derivatives of this molecule
that are widely administered in artemisinin combination therapies for the treatment of
malaria. The endoperoxide bridge responsible for the mechanism of action of artemisinin
derivatives is shown shaded yellow. This becomes cleaved by Fe2+ haem iron leading to
free radical generation which kills the parasite.
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1.9 The future of antimalarial chemotherapy
Given the emergence of resistance to ACTs there is great interest in developing novel
drugs, particularly ones with novel modes of action in order to circumvent development of
cross resistance. Medicines for Malaria Venture (MMV) lists five target candidate profiles
for new antimalarials: molecules that clear blood stage parasites, molecules that clear
hypnozoites, molecules that clear hepatic stage schizonts, molecules that block trans-
mission by killing gametocytes and molecules that block transmission by targeting the
vector. Drugs are sought that are active against all species and strains of Plasmodium
and active enough, or have a long enough half life that a single dose is required to en-
sure compliance. As valuable as artemisinins are in combatting malaria, they do not kill
mature gametocytes which are responsible for transmission [Tilley et al. 2016] or the dor-
mant hypnozoite form of P. vivax that gives rise to relapsing infection and is an important
reservoir for transmission [Markus 2010; White, Pukrittayakamee, et al. 2014]. With erad-
ication back on the global health agenda, there is great interest that the pipeline of drug
development produces drugs that also act on gametocytes and hypnozoites in order to
break the transmission cycle [Phillips et al. 2017]. While the screening of great numbers
of compounds for their effects on hypnozoites remains some way off, researchers are
taking steps to develop assays including high-content screens that begin to make this a
reality [Wells, Burrows, and Baird 2010; Chattopadhyay et al. 2010].
High throughput phenotypic screening involves the direct assessment of compounds
on proliferation or survival of parasite cells. In an early screening study, researchers as-
sembled a large number of drugs already approved by the FDA or undergoing phase II
clinical trials and examined their effects on Plasmodium [Chong et al. 2006]. The ra-
tionale behind such an approach is that, having undergone approval, these drugs have
already been proven safe and can be ‘clinically repositioned’ and rapidly rolled out if they
possess antimalarial properties. Alternatively, medicinal chemistry studies can be under-
taken on a relatively well understood compound scaffold. In this study the non-sedating
antihistamine astemizole was identified as a promising new inhibitor of Plasmodium. Such
approaches have since been used to screen many small molecules. Such an approach
has identified a number of lead compounds that might be developed as drugs [L. H. Miller,
Ackerman, et al. 2013]. This includes a spiroindolone NITD609 that was produced follow-
ing lead compound identification from a library of 12,000 natural products and synthetic
compounds [Rottmann et al. 2010]. NITD609 kills erythrocytic stages (including game-
tocytes) with nano molar potency, and acts through a novel mechanism, believed to be
inhibition of PfATP4, a transporter in the parasite plasma membrane which regulates Na+
and H+ homeostasis [Phillips et al. 2017].
The two other most commonly-used approaches to drug development are target based
screening, whereby library screening is performed to assess inhibition of a validated tar-
get, and rational design. The former has identified inhibitors of P. falciparum dihydrooro-
tate dehydrogenase, cytochrome bc1 and NDH2 [L. H. Miller, Ackerman, et al. 2013].
As yet, the rational approach has only really been applied to the modification of exist-
ing classes of drugs to generate new variants and overcome specific pharmacological
challenges, such as generating derivatives of artemisinin with improved bioavailability. In
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the drive to develop new drugs that has taken place in the last 10-15 years, phenotypic
screening has been the most successful at uncovering new compound hits. Phenotypic
screening will continue to be important but as more becomes known about the molecular
and cellular biochemistry of the parasite, especially with the advent of new technologies
including CRISPR Cas9 genome editing and Cre recombinase technologies to discover
and validate drug targets, the more these targeted approaches will bear fruit.
1.10 The ability to propagate various malaria parasites enables
the study of this disease
A prerequisite to conducting studies of a pathogen is the ability to propagate it continu-
ously either in vitro or in vivo. The asexual blood stage cycle of P. falciparum has been
propagated in vitro in human erythrocytes since Trager and Jensen developed the can-
dle jar method [Trager and Jensen 1976]. It has been possible to continuously culture
P. knowlesi in cynomolgus macaque erythrocytes but limited access to these precludes
this for most laboratories. Recently however Moon and colleagues adapted P. knowlesi
to propagate efficiently in human erythrocytes which will facilitate work on this species
[Moon, J. Hall, et al. 2013; Moon, Sharaf, et al. 2016]. P. knowlesi is significantly more
amenable to genetic manipulation in addition to having merozoites which are larger and
less labile than those of P. falciparum, which will aid microscopic examination and invasion
studies [Gru¨ring et al. 2014]. Currently it is impossible to propagate any of the other human
infecting species in vitro which hampers the investigation of their biology. In vitro culture
allows the investigation of parasite molecular genetics, biochemistry and cellular biology,
but obviously does not allow investigations of host related phenomena such as pathol-
ogy, immunological responses and population dynamics during infection. This requires
the use of animal models of malaria infection. The human infecting parasite species have
a limited host range however [Siu and Ploss 2015]. Apart from humans, P. falciparum and
P. vivax can probably only infect large apes such as gorillas and chimpanzees. Studies
in chimpanzees led to the demonstration that hypnozoites result from P. vivax infection
[Krotoski et al. 1982] and led to the identification of drug-resistance loci [Walliker et al.
1983]. The fact that P. knowlesi infects macaque monkeys as well as humans has also
meant significant numbers of studies have been performed using macaques [Pasini et al.
2016]. Additionally, some studies have been conducted into P. cynomolgi, a parasite of
Aotus monkeys as it is closely related to P. vivax and P. knowlesi [Joyner et al. 2016].
The use of moneys and apes for research is prohibitive however. They are exceedingly
expensive and difficult to work with, there are ethical concerns and their outbred genetics
limits reproducibility of studies [Siu and Ploss 2015]. As such, most malaria research in-
volving animal models makes use of rodent infecting species including P. berghei, P. yoelii
and P. chabaudi. Given that part of the Plasmodium lifecycle takes place in the mosquito
vector, researchers are often interested in studies of these stages as well. While mosquito
infection can be established in the laboratory with many if not all species of Plasmodium
without the need for animals, it is generally much more amenable with the rodent malaria
species, not to mention considerably safer than working with mosquitos infected with hu-
man malaria parasites. As such the malaria models of infection are typically used for
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studies into aspects of parasite biology during the mosquito stage. Additionally P. berghei
is much more amenable to genetic modification than P. falciparum. Despite how impor-
tant these models have been and will continue to be for understanding malaria, there are
difficulties in translating our discoveries in these models to human disease given the phys-
iological and genetic differences between both the hosts and the parasites. For example,
the rodent parasite genomes lack orthologs for ∼730 genes in P. falciparum [N. Hall et al.
2005]. To help overcome this, a humanised mouse model has been developed in which
the organs and tissues have been engineered to be human-like to allow studies on P. fal-
ciparum in vivo [Siu and Ploss 2015]. This model will require further refinement but holds
great promise. For the foreseeable future though, we will continue to require a combi-
nation of studies using the various existing malaria models, making use of the strengths
and advantages of each to piece together an improved understanding of the disease and
pathogen.
1.11 The use of conditional systems of genetic modification
in P. falciparum
In order to study the cellular biology, biochemistry and molecular genetics of an organ-
ism it is often necessary, or at least desirable, to perturb the genetics of the organism in
some way. Transfection of a malaria parasite was first reported over twenty years ago
in P. gallinaceum, a parasite of birds [Goonewardene et al. 1993]. This was followed by
similar work in P. falciparum [Wu et al. 1995] and P. berghei [Dijk, Waters, and Janse
1995]. Many other species including P. knowlesi, P. cynomolgi, P. yoelii and P. chabaudi
are now routinely transfected with exogenous DNA for overexpression, gene disruption,
reporter gene expression and epitope tagging studies [Koning-Ward, Gilson, and Crabb
2015]. Transfection is always performed in the asexual blood stage cycle due to its acces-
sibility. The first gene disruption in P. falciparum was achieved twenty years ago [Crabb
et al. 1997]. Gene knockouts have become routine, often using the reliable human DHFR
gene as a drug marker to select for parasites in which the desired gene manipulation has
occurred [Fidock and Wellems 1997] and the PlasmoGem project is an example of how
gene knockouts can be used in P. berghei in a powerful and systematic way [Schwach
et al. 2015]. Gene knockouts pose a problem for the investigation of genes essential to
the asexual blood stage cycle however, as perturbations to a gene that affect an essential
function will abrogate the viability of parasites; if they cannot be isolated, they cannot be
studied. In contrast, this is not a problem for the study of genes that are essential only
during the sexual blood stages or the insect stages; parasites can be maintained and loss
of viability will only occur following transition to these other stages. As such, a conditional
system of mutagenesis has been sought for use in P. falciparum and other Plasmodium
spp for some time. Various systems have been developed including the FLP/FRT system
in P. berghei [Lacroix et al. 2011]. What follows is an overview of the different condi-
tional systems of genetic manipulation that have been investigated or implemented in P.
falciparum.
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1.11.1 Transcriptional control: The use of tetracycline-induced systems of
transcriptional control in P. falciparum
One of the most widely used inducible systems for investigating the molecular genet-
ics of eukaryotes is the Tet-repressor (TetR) based system of transcriptional activation.
This system makes use of the tetracycline-dependent binding of TetR protein to 19 nu-
cleotide DNA sequences called Tet operators (TetO). In Gram-negative bacteria in which
this system exists naturally, the TetR, true to its name, functions as a repressor of gene
transcription when bound to TetO repeats upstream of the promoter region by preventing
binding of transcription factors. Tetracycline binds to TetR, preventing it from binding to
the TetO repeats and thus activating transcription of the downstream operon. Gossen
and Bujard made use of the DNA binding function of TetR to transform it from a repres-
sor to an activator of gene expression in mammalian systems by fusing it to a C-terminal
domain of the herpes simplex virus transcriptional activator VP16 [Gossen and Bujard
1996]. This fusion of TetR and VP16 is referred to as the TetR transactivator (tTA). TetO
sequences were placed upstream of a minimal cytomegalovirus (CMV) promoter to drive
expression. The addition of tetracycline (or tetracycline analogues such as anhydrotetra-
cycline) prevents binding of the tTA to the promoter region and significantly reduces gene
expression. Systems that function in this manner are referred to as Tet-off systems as the
effect of tetracycline is to turn expression off. There also exist Tet-on systems whereby
the tTA consists of a mutant TetR which has a reversed Tet-sensitive response. In this
case tetracycline binding to the tTA is necessary for binding to the TetO and activation of
transcription. Therefore addition of tetracycline turns transcription on.
Unfortunately, this widely used TetR/VP16 fusion was found not activate minimal pro-
moters in the related Apicomplexan Toxoplasma gondii [Meissner, Brecht, et al. 2001]
and it is assumed P. falciparum as well. In light of this, these authors attempted trans-
lational repression with TetR alone, as naturally occurs in Gram negative bacteria, but
this was of limited effectiveness. The generation of an artificial transactivator (TATi) was
therefore developed in T. gondii [Meissner 2002] which was used in P. falciparum with suc-
cess [Meissner, Krejany, et al. 2005; Gilson, O’Donnell, et al. 2008; O’Neill et al. 2011].
The Apicomplexan ApiAP2 transcription factors have been used to generate a TetR fused
transactivator [Pino et al. 2012]. A significant drawback to the use of these systems how-
ever is the requirement for transactivator-responsive minimal promoters that mimic the
transcriptional profile of the native promoter, especially important given that Plasmodium
genes are generally regulated at the transcriptional level and highly temporally regulated.
Problematically, every minimal promoter tested in T. gondii has been found to have resid-
ual activity in the absence of bound transactivator [Jime´nez-Ruiz et al. 2014]. The system
is impractical for control of endogenous genes, as modifying the promoter regions of P.
falciparum is technically difficult. Double crossover homologous recombination is ineffi-
cient [Duraisingh, Triglia, and Cowman 2002] and the targeting of integration constructs
into the highly AT rich intergenic sequences by single crossover homologous recombina-
tion also problematic. These sequences are difficult to amplify by PCR and propagate in
E. coli and targeting integration specifically into one of the many highly AT rich regions
is difficult [Epp, Raskolnikov, and Deitsch 2008]. While control of episomal reporter gene
expression has been achieved in P. falciparum using this method, control of endogenous
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genes has not owing to the difficulty in manipulating promoters [Prommana et al. 2013].
1.11.2 Methods of transcript destabilisation
RNA interference (RNAi) does not function in Plasmodium
RNAi is a system of post-transcriptional genetic regulation in many eukaryotes that func-
tions by destroying RNA transcripts. It is hypothesised that the ancestral role of RNAi was
to maintain genome stability by controlling mobile DNA elements but it can also function
as a system of intrinsic immunity against viruses, destroying their genetic material and as
a means of regulating gene expression of an organism’s own genes. RNAi technology has
been utilised extensively in a wide range of organisms as a means of genetic manipula-
tion and there is also much interest in its therapeutic potential [Wilson and Doudna 2013].
RNAi technology has been implemented in various protozoan parasites, most notably in
the African Trypanosome Trypanosoma brucei, where it has enabled the development of a
system for genome wide screening [Alsford et al. 2012]. Double stranded RNA molecules
(dsRNAs) added exogenously or expressed within the cell are cleaved into short interfer-
ing RNA molecules (siRNAs) which target the RNA induced silencing complex (RISC) to
the homologous mRNA transcripts. The endonuclease component called Argonaut (Ago)
then mediates their degradation. Obviously there has been much interest in establishing
the use of RNAi in Plasmodium. Various attempts have been made by multiple laborato-
ries over the years, initially resulting in conflicting and ambiguous results. For example,
one study which cultured P. falciparum in the presence of dsRNAs targeting falcipain-1
concluded this gene was essential to parasite viability [Malhotra et al. 2002]. This finding
was at odds with another study which demonstrated through standard gene disruption by
targeted homologous recombination that falcipain-1 is not essential during the asexual
blood stage cycle [Sijwali, Kato, et al. 2004]. A systematic experimental and comparative
genomics study by Baum and colleagues finally came to the conclusion that Plasmod-
ium lacks the enzymes necessary for RNAi and found no experimental evidence of RNAi
based gene knockdown [Baum et al. 2009].
The glmS ribozyme system has been used successfully in Plasmodium
Ribozymes are RNA molecules capable of acting as enzymes, including with the capacity
to self-cleave through endonuclease activity. The use of ribozymes with ligand-dependent
self-cleaving activity has allowed conditional regulation of gene expression. The first use
of this system was reported by Yen and colleagues who made use of the hammerhead
Sm1 ribozyme of Schistosoma mansoni in a mammalian system [Yen et al. 2004]. This
was engineered for increased activity in order to destabilise the mRNA of a reporter gene
when the Sm1 sequence was fused up-stream of the ORF. The nucleoside analogue toy-
ocamycin was found to abrogate ribozyme self-cleavage, stabilising mRNA transcripts and
so up-regulating reporter gene expression. Agop-Nersesian and colleagues subsequently
attempted to use this same ribozyme to achieve down-regulation of a reporter gene in T.
gondii and P. falciparum [Agop-Nersesian et al. 2008]. Some regulation was achieved in
T. gondii, but unfortunately toyocamycin was highly toxic in this system. This toxicity was
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dependent on adenosine kinase (AK) and could be abrogated by knockout of AK but this
also abolished the transcript stabilising effect of toyocamycin. Plasmodium was found not
to possess AK, consistent with the fact that toyocamycin is not toxic to Plasmodium, but
this also meant that the drug failed to inhibit ribozyme activity. In an improvement of this
system, Promanna and colleagues made use of the glmS ribozyme from Gram-positive
bacteria [Lee and Oh 2015], inserting the sequence downstream of a reporter gene. The
self-cleavage activity of this ribozyme is activated upon addition of glucosamine which re-
sults in reduction of gene expression. This system has been used successfully for gene
knockdown in Plasmodium [Mchugh et al. 2015].
1.11.3 Inhibition of translation: The TetR-aptamer system successfully reg-
ulates gene translation.
A TetR-aptamer system of translational control has been demonstrated to successfully
regulate expression in Plasmodium [Goldfless, Belmont, et al. 2012; Goldfless, Wagner,
and Niles 2014]. In this system TetR-binding RNA ‘aptamers’ are placed within the 5’
UTR of a gene of interest. The binding of TetR to the aptamer region disrupts translation
of mRNA, but the addition of anhydrotetracycline prevents this binding and allows trans-
lation to occur. This system has two significant advantages over both the tetracycline-
sensitive transactivator and DD systems (see below): it requires no prior knowledge of
transcriptional regulation, as the gene of interest remains under control of its native regu-
latory sequences save for the addition of the aptamer sequence; and it does not require
tagging of the protein product. Furthermore, this system has the greatest potential to be
tuneable.
1.11.4 Protein destabilisation: Use of destabilisation domains for knock-
down of protein in P. falciparum.
In 2003, it was found that a mutant version of the rapamycin-binding FRB (fragment of ra-
pamycin binding ) domain of mTOR (mechanistic target of rapamycin) led to degradation
of a fused protein in human fibroblasts, but that it was stabilised in a rapamycin-dependent
manner [Stankunas et al. 2003]. This serendipitous discovery led to an elegant forward ge-
netic study with the aim to create a ’single ligand, single binding domain’ system for rapid,
reversible and tuneable regulation of gene expression. This study identified a mutant
form of another rapamycin binding protein, FKBP12, that is inherently unstable, leading to
degradation of fused proteins. This destabilisation occurs in the absence of, but not in the
presence of the rapamycin analogue shield-1. This mutant FKBP12 domain is therefore
referred to as the destabilisation domain, or ‘DD’ [Banaszynski et al. 2006]. Success-
ful use of this DD system in Plasmodium was established by Armstrong and Goldberg
[Armstrong and Goldberg 2007] and it has subsequently been made use of in numer-
ous studies on P. falciparum [Russo et al. 2009; Dvorin et al. 2010; Ganter et al. 2017;
Blomqvist et al. 2017; Absalon, Robbins, and Dvorin 2016; Muralidharan et al. 2012]. Un-
fortunately, there are significant drawbacks to this system which prevent its universal use.
Most significantly, the requirement to fuse a protein of interest to the DD precludes its use
if doing so alters the function or localisation of the protein adversely. Indeed, in many
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cases it is simply lethal, and therefore impossible, to fuse the DD to a protein. Further-
more, even where this is possible, the degradation relies on targeting the fusion protein to
the proteasome and therefore this system is typically only applicable to cytosolic proteins
[Azevedo et al. 2012]. Proteins trafficked to secretory organelles, membranes or secreted
beyond the parasite (i.e. into the PV, the erythrocyte cytosol, erythrocyte membrane, or
organelles such as Maurer’s clefts) will likely be inaccessible to the proteasome. As such
the DD system is simply not applicable to many proteins of interest as evidenced by the
multiple failures to achieve knockdown using this system not just in Plasmodium but T.
gondii as well [Halle´e and Richard 2015; Jime´nez-Ruiz et al. 2014]. Furthermore, given
that this system acts to down-regulate transcript levels it achieves knockdown rather than
true knockout. While this is clearly satisfactory (and may be useful) in some situations it
is well documented that, with enzymes even significant knockdown can be insufficient to
ablate function to a point where a phenotype can be observed [Me´thot et al. 2007; Methot
et al. 2008]. Furthermore shield-1 is somewhat toxic to Plasmodium at the concentrations
required for protein stabilisation which can complicate the interpretation of results. In an
attempt to overcome the shortcomings of shield-1 another destabilisation tag has been
employed.
In order to overcome the issues of cost and toxicity of shield-1, another destabilisation
tag has been used in Plasmodium falciparum. It is based on the E. coli dihydrofolate re-
ductase (DHFR) enzyme and is termed the DHFR destabilisation domain (DDD) and was
initially developed by Iwamoto and colleagues [Iwamoto et al. 2010]. This tag is stabilised
by inexpensive folate analogues such as trimethoprim and Muralidharan and colleagues
used this tag to achieve conditional destabilisation of both a fluorescent reporter protein
and the RPN6 gene in P. falciparum. A separate study by Beck and colleagues set out to
use the DDD to achieve knockdown of HSP101, a component of the PTEX complex [Beck
et al. 2014]. Disruption of HSP101 function was achieved following removal of trimetho-
prim, resulting in a loss of protein export, but not through any knockdown of HSP101
protein levels. This is likely due to the inability for the PVM resident HSP101 to access
the proteasome in the parasite cytosol for degradation. The authors ascribe the loss of
function observed in this study to interference of the DDD tag with chaperone function
[Muralidharan et al. 2012; Beck et al. 2014].
The auxin inducible degron system is another system of protein destabilisation that
has been implemented in both P. berghei [Philip et al. 2015] and P. falciparum [Kreiden-
weiss, Hopkins, and Mordmu¨ller 2013]. This system, which is naturally present in plants,
achieves ubiquitination and subsequent proteasome mediated degradation of proteins
fused to an auxin inducible degron (AID). Auxin binds to the AID and acts as a ‘molecular
glue’, stabilising interaction of the AID containing protein and a Skp1, Cullin1, F box protein
ubiquitin ligase (SCF) which results in ubiquitination of the AID containing protein by the
SCF. The ubiquitinated AID containing protein is then degraded by the proteasome. The
impetus for the implementation of this system in P. berghei was that the afore mentioned
DD systems rely on constant maintenance of small molecules, shield-1 or trimethoprim,
making them often unsuitable for in vivo applications, especially in the non-erythrocytic
stages of the parasite’s lifecycle [Philip et al. 2015]. Again however, the reliance of this
system on proteasome mediated degradation for gene knockdown means it will likely only
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be applicable for the study of proteins present in the cytosol.
1.11.5 Manipulation of the gene: The dimerisable Cre recombinase system
is a highly rapid and efficient system for conditional gene modifica-
tion in P. falciparum.
Cre recombinase is an enzyme of bacteriophage P1 that mediates excision of DNA be-
tween specific sequences called loxP sites using a topoisomerase I-like mechanism [Stern-
berg and Hamilton 1981]. Cre recombinase was so named because a specific fragment of
the bacteriophage genome containing the gene was found to Cause REcombination, and
loxP sites because they were the LOcation of crossing (Xing), P1 [Sternberg and Hamilton
1981]. Initial attempts were made at adapting the Cre recombinase system to Plasmod-
ium by but regulation of its activity by the Tet-off system proved ineffective [O’Neill et al.
2011]. Andenmatten and colleagues then made use of a rapamycin-induced dimerisable
form of Cre recombinase in T. gondii. The use of this system was pioneered by Jullien
and colleagues [Jullien 2003; Jullien et al. 2007]. At the time Cre recombinase was in-
creasingly widely used to engineer the genomes of mammals, with regulation of its activity
generally controlled using Tet-sensitive expression or hormonal control. A problem with
these systems is that leaky activity of Cre recombinase results in premature excision of
DNA. In the DiCre approach of Jullien and colleagues, the two major helical Cre recom-
binase domains were separated into two fragments, each fused to a different rapamycin
binding domain, FKBP12 or FRB. These fragments displayed a very low level of activ-
ity. Induced dimerisation of the two components of Cre recombinase through addition of
rapamycin rapidly reconstituted Cre recombinase activity, providing a means of inducing
Cre recombinase activity at will.
The DiCre system was adapted for use in P. falciparum by Collins and colleagues
[C. R. Collins, S. Das, et al. 2013], being initially used to inducibly remove the 3'UTR
of the SERA5 gene in anticipation that this would achieve destabilisation of transcripts
and silencing of expression. This did not succeed owing to the presence of cryptic 3'
polyadenylation sequences remaining following Cre-mediated DNA excision, but it clearly
demonstrated the utility of Cre recombinase technology in P. falciparum. Furthermore,
the work produced the 1G5DC clone of P. falciparum which constitutively expresses the
two dimerisable fragments of Cre recombinase. This clone has subsequently been widely
used in number of studies [C. R. Collins, Hackett, et al. 2017; S. Das et al. 2015; Jones
et al. 2016] including the study presented in this thesis. This same technology has also
been implemented in P. falciparum independently [Yap et al. 2014].
1.11.6 The use of plaque assays in studies on infectious organisms includ-
ing Plasmodium spp
Much research on P. falciparum focuses on the identification and characterisation of po-
tential drug targets and therefore requires an assessment of parasite growth in response
to gene disruption or modification. As discussed, the asexual blood stage cycle acts
to amplify the parasite population exponentially, rather like a viral lytic cycle. For many
viruses, this lytic cycle has long been exploited in in vitro assays to determine the con-
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centration of infectious viral particles in a sample by determining the number of areas
of host cell destruction following their infection by suitably titrated aliquots of virus. First
described for animal viruses in 1953 [Dulbecco and Vogt 1953], the assay protocol usu-
ally involves limiting diffusion of the released viral particles through the use of semi-solid
media in order to achieve discrete, highly localised regions of host cell monolayer de-
struction called plaques. The remaining host cell monolayers are then stained to visualise
plaques. Because of their simplicity and broad applicability, plaque assays are amongst
the most valuable and widely-used tools in viral research, allowing facile quantification
of the effects of environmental conditions, drugs, antibodies and genetic manipulation on
viral replication, as well as simplifying isolation of viral clones. Plaque assays have also
been developed for other intracellular pathogens, including several viruses and bacterial
species [Edouard and Raoult 2016] as well as the Apicomplexan T. gondii which readily
infects most nucleated mammalian cells and thus can be cultured in adherent fibroblast
monolayers [Chaparas and Schlesinger 1959]. In contrast, blood stages of Plasmodium
species replicate exclusively in erythrocytes (or reticulocytes), which are not normally ad-
herent. Plaque assays developed for Plasmodium have therefore used monolayers of
erythrocytes adhered to the base of tissue culture wells using concanavalin A [Bruce et
al. 1990; Inselburg 1983], Cell-Tak [Williams 1999], or α-Rhesus D antibodies plus protein
L [Smith et al. 2000], with plaque formation being visualised using either Giemsa staining
of fixed monolayers or immunofluorescence. Such assays were key to the success of el-
egant pioneering experiments demonstrating the phenomenon in which all the merozoite
offspring of a single infected erythrocyte are committed to either continuation of the asex-
ual life cycle or transformation into either male or female gametocytes [Bruce et al. 1990;
Inselburg 1983; Smith et al. 2000]. However, due to the single-cell thick nature of the
adherent erythrocyte monolayers produced by these methods and the need for fixation
and staining to visualise the plaques, the assays are unsuitable for routine quantification
of malaria parasite growth rates. A simple plaque assay for use with Plasmodium species
would be a valuable tool for research into blood stage malaria research.
1.12 Proteases are present throughout the tree of life.
Proteases are enzymes that mediate the hydrolysis of peptide bonds and conduct a wide
variety of regulatory and effector roles across the whole breadth of the tree of life. These
include diverse roles in biological processes such as protein homeostasis, trafficking,
cell signalling, catabolism and cell death. Their roles may involve relatively promiscu-
ous cleavage to degrade proteins to individual amino acids for the digestion of proteins, or
specific cleavage of just one molecule at one site during proteolytic activation ‘cascades’.
Throughout nature, ’cascades’ of proteolytic activation are a commonly used means of
regulating enzymatic activity and amplifying signals. Protease cascades consist of a pro-
tease cleaving and converting a zymogen protease to an active form, which then itself
goes on to activate another zymogen protease and so on. Particularly well understood
examples of proteolytic cascades include those involved in caspase mediated apoptosis
[Martin and Green 1995], blood coagulation [Davie and Ratnoff 1964; Macfarlane 1964],
the matrix metalloproteinase cascade [Lochter et al. 1997] and the complement activation
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cascade [Lynskey et al. 2017]. Proteases are attractive targets for rational drug design
due to their well understood catalytic mechanisms and active site structures [Deu 2017;
Amour et al. 2004]. There is good precedent for the development of inhibitors targeting
proteases with drugs recently brought to market including inhibitors of HIV protease and
hepatitis C virus protease. Proteases are categorised into seven broad classes based on
their mechanism of action, referred to as: cysteine, serine, aspartyl, threonine, metallo,
glutamic and asparagine proteases. This is determined by the residue, or co-ordinating
ion that functions as the active site nucleophile when hydrolysing peptide bonds. Mem-
bers of each class other than the glutamic and asparagine classes have been identified in
Plasmodium, including confirmation of protease activity of multiple members [Deu 2017].
1.12.1 Proteases play roles in a variety of pathways essential to parasite
survival
Proteases have been found to play roles in various biochemical pathways that are essen-
tial for malaria parasite viability, but the roles of many remain uncharacterised. Multiple
proteases are known to be involved in haemoglobin degradation within the parasite food
vacuole which provides amino acids for protein synthesis. In P. falciparum these include
four aspartyl proteases (plasmepsins I-IV), three papain-like cysteine protease (falcipains
2, 2’ and 3), the metalloprotease falcilysin and a cysteine exopeptidase, DPAP1 (dipeptidyl
aminopeptidase-1) [Wang et al. 2011]. As mediators of such a crucial biochemical path-
way there has been great interest in studying these proteases and developing inhibitors
as potential chemotherapeutic agents. Unfortunately, significant redundancy was found to
exist amongst these proteases with every falcipain having been knocked out individually
[Sijwali, Koo, et al. 2006], and all of plasmepsins I-IV being knocked out simultaneously
[Alfredo Bonilla et al. 2007] with only limited impact on parasite viability. As such, mem-
bers of this haemoglobin degradation pathway are unlikely to be good drug targets after
all.
Protein trafficking is a ubiquitous feature of eukaryotic cells that requires proteases.
Most soluble proteins that are secreted are expressed with an N-terminal hydrophobic sig-
nal sequence that inserts into the endoplasmic reticulum (ER) membrane co-translationally.
This is then cleaved from the rest of the protein by the signal peptidase complex. In P.
falciparum, two components of this complex (SP18 and SP21) have been identified and
reported to possess protease activity [Sharma et al. 2005; Tuteja, Pradhan, and Sharma
2008]. Inhibition of prokaryotic signal peptidase activity results in cell death due to accu-
mulation of proteins intended for secretion and as such have been considered potential
novel antibiotic targets for bacteria [Paetzel, Dalbey, and Strynadka 2000] raising the pos-
sibility that inhibitors of Plasmodium homologs might inhibit parasite growth. In addition,
proteases are required to maintain protein homeostasis in the ER. Proteins can become
misfolded and require degradation by the proteasome in a process termed ER-associated
degradation (ERAD). One such component of the pathway in P. falciparum, signal peptide
peptidase (SPP), was identified bioinformatically by homology with mammalian compo-
nents of the system [Harbut et al. 2012]. The number of components in the ERAD pathway
in Plasmodium and other protozoan pathogens is highly reduced compared to mammals
and so this pathway may represent a vulnerable aspect of the parasite’s response to cel-
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lular stress. In the same study, inhibitors of SPP were found to exhibit low nano molar
potency against blood and liver stage parasites with low toxicity in mammalian cells, high-
lighting the potential for the development of drugs to target SPP.
In order to survive inside an erythrocyte the parasite must modify the erythrocyte mem-
brane and cytosol in order to import nutrients, adhere to the vascular endothelium and
evade the immune system. In order to achieve this, approximately 10% of the parasite’s
proteome is exported beyond the PV [Schulze et al. 2015]. Export of proteins across the
PVM is achieved via a still poorly-characterised complex termed the PTEX complex (Plas-
modium translocon for exported proteins) [Gilson, Chisholm, et al. 2017]. Most exported
proteins possess a PEXEL (protein export element) motif downstream of the secretory
signal peptide. As part of the trafficking of PEXEL motif containing proteins the PEXEL
motif is cleaved by P. falciparum plasmepsin V (an aspartyl protease) in the ER and upon
the protein’s arrival in the PV the exposed N-terminus is recognised by the PTEX complex
(Plasmodium translocon of exported proteins)[Boddey et al. 2010; Russo et al. 2009].
Plasmepsin V is therefore an attractive drug target as abolition of its function is likely
to interfere with export of proteins on a global level and consequently block a range of
essential biological processes including metabolite import, haemoglobin internalisation,
Maurer’s cleft formation and modification of the erythrocyte cytoskeleton and erythrocyte
surface.
1.13 Egress
1.13.1 Egress is fundamental to the lifecycle of intracellular pathogens.
Egress generally is the process by which an intracellular pathogen is released from the
host cell in which it resides. All intracellular pathogens including viruses, bacteria and
protist parasites must undergo some form of egress. Egress occurs at multiple points in
the Plasmodium lifecycle: at the end of the liver stage infection, at the end of each intra-
erythrocytic cycle during the asexual blood stage, of the gametocyte upon ingestion by the
mosquito and of sporozoites from the oocyst in the mosquito midgut basal lamina. During
the asexual blood stage cycle the newly formed merozoites must escape the confines of
the depleted erythrocyte to invade fresh cells and propagate their population. Plasmod-
ium egress is cytolytic and the direct destruction of erythrocytes, as well as the systemic
damage caused by the ensuing inflammatory response, is responsible for all the clinical
symptoms of malaria (discussed in Section 1.4) [Yahata et al. 2012]. Being the cause of
pathology, and crucial to the continuation of infection, blood stage egress is an important
aspect of parasite biology and a greater understanding is key to fully comprehending the
pathology of this disease.
Over the years some controversy ensued as to the order of membrane rupture with an
early study suggesting that the erythrocyte membrane ruptures before the PVM [Salmon,
Oksman, and Goldberg 2001]. Over time it has become more apparent that this is in-
correct, with a number of studies contributing to the growing body of evidence that the
PVM ruptures before the host cell membrane not only in blood stage egress [Wickham,
Culvenor, and Cowman 2003; Glushakova, Humphrey, et al. 2010], but also in gameto-
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cyte egress [Sologub et al. 2011; Deligianni et al. 2013; Wirth, Glushakova, et al. 2014]
and liver stage egress [Burda, Roelli, et al. 2015; Burda, Caldelari, and Heussler 2017;
Schmidt-Christensen et al. 2008; Putrianti et al. 2010; Graewe et al. 2011].
1.14 Gametocyte egress, but not asexual blood stage egress,
has been shown to be perforin dependent
Many pathogens use pore-forming proteins to achieve entry into host cells, release from
vacuoles into the host cell cytoplasm or egress from their host cells [Rosado et al. 2008;
Roiko and Carruthers 2009]. In Toxoplasma the perforin like protein TgPLP1 which con-
tains a membrane attack complex/perforin (MACPF) domain has been shown to be in-
volved in egress of tachyzoites from host cells [Kafsack et al. 2007]. While parasites
deficient in this protein eventually egress, apparently through mechanical means, they
show a delay in egress with PVM and host cell plasma membrane remaining intact. This
suggests TgPLP1 plays a role in PVM rupture and potentially that of the host cell mem-
brane as well. There also exists another T. gondii MACPF gene, TgPLP2, but no function
is yet known for this protein [Wade and Tweten 2015].
This finding prompted interest in the five MACPF domain-containing Plasmodium per-
forin like proteins (PPLPs) that are encoded in the P. falciparum genome (PPLP1-5) [Kaiser
et al. 2004]. PPLP1 and/or PPLP2 have been suggested to play a role in asexual blood
stage egress of P. falciparum with both shown to be expressed during this stage and
PPLP1 localised to the micronemes, with secretion into the PV observed [Garg et al.
2013]. Arguing against this, however, studies in P. berghei found that PPLP1 and PPLP2
are dispensable during the asexual blood stage cycle with PPLP1 important only for sporo-
zoite cell traversal [Ishino, Chinzei, and Yuda 2005; Amino, Giovannini, et al. 2008] and
PPLP2 for rupture of the erythrocyte membrane surrounding the gametocyte [Deligianni et
al. 2013; Wirth, Glushakova, et al. 2014]. Furthermore, in a very recent study disruption of
the P. falciparum PPLP1 gene was found to have no phenotypic consequences in asexual
blood stages [Yang et al. 2017]. PPLPs 3-5 are all expressed in the ookinete stage [N. Hall
et al. 2005; Raibaud et al. 2006]. PPLPs 3 and 5 have been shown to have functions in
ookinete traversal of the mosquito midgut in studies on mouse malaria species P. berghei
and P. yoelii [Kadota et al. 2004; Ecker, Pinto, et al. 2007; Ecker, Bushell, et al. 2008]
while the same role has been demonstrated for PPLP4 in P. falciparum [Wirth, Bennink,
et al. 2015]. The existing picture is therefore quite complex, with studies performed across
different species and during different lifecycle stages. Further genetic studies of in vitro
P. falciparum will be required to unambiguously determine whether any of the PPLPs play
a role in egress of asexual blood stages and/or whether there is functional redundancy
amongst these proteins.
1.14.1 Blood stage egress is a kinase and protease-regulated process
Plasmodium blood stage egress (as with egress in other stages of the lifecycle) is an ac-
tive, rapid and highly regulated process taking place over the course of only a few minutes
at the end of each erythrocytic cycle and occurs synchronously, i.e. all daughter mero-
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zoites are released simultaneously [Blackman 2008; Blackman and Carruthers 2013].
The necessity of this regulation and synchronicity is evident from the fact that Plasmod-
ium undergoes replication by schizogony as outlined in Section 1.3. Premature egress
would be catastrophic as only very mature parasites undergo cytokinesis and merozoites
might not have even formed let alone be properly prepared for successful invasion of a
fresh erythrocyte. As evidence of this, a recent study demonstrated that the conditional
disruption of SERA5 results in egress occurring prematurely. These mutants egressed
inefficiently, with merozoites still bound by residual erythrocyte membrane, in turn result-
ing in reduced invasion rates [C. R. Collins, Hackett, et al. 2017]. This suggests that the
kinetics of egress must be tightly controlled, even within the final ∼10 min of the blood
stage cycle, to achieve efficient merozoite release and successful invasion. This is in
contrast to T. gondii tachyzoites which replicate by repeated rounds of binary fission (en-
dodyogeny) which results in the continuous formation of viable progeny. Induced egress
of T. gondii by treatment with the calcium ionophore A23187 results in productive inva-
sion of fresh host cells. What is quite clear is that following activation of the parasite’s
cyclic-GMP (cGMP) dependent protein kinase (PKG) a number of highly choreographed
cellular events take place during the asexual blood stage cycle: the contents of exonemes
and micronemes (specialised secretory organelles of merozoites) are discharged into the
PV [C. R. Collins, S. Das, et al. 2013], the PV swells to fill the erythrocyte as the erythro-
cyte ’rounds up’, transforming almost instantaneously from an irregular shape to a roughly
spherical one [Glushakova, Humphrey, et al. 2010]; the PVM ruptures to release mero-
zoites into the residual erythrocyte cytoplasm [Wickham, Culvenor, and Cowman 2003;
Glushakova, Yin, et al. 2005]; the erythrocyte membrane becomes ’porated’ [Glushakova,
Humphrey, et al. 2010; Glushakova, Busse, et al. 2017] as the cytoskeleton apparently
collapses [Hale et al. 2017]; and finally, the erythrocyte membrane ruptures in an elastic
fashion to achieve merozoite release [Abkarian et al. 1994] (Figure 1.8). It is also apparent
that at some point just prior to or during this pathway the PVM becomes porated, allowing
mixing of the PV contents with those of the residual erythrocyte cytosol [Hale et al. 2017].
Apart from the overarching regulation of these events by PKG however, none of these rel-
atively well-described cellular events have been ascribed to specific molecular effectors
during egress of the asexual blood stage parasite. What follows is a review of what is
known about the cellular and biochemical processes involved in Plasmodium blood stage
egress, with reference to egress during other lifecycle stages and of other species where
relevant.
PKG is a key regulator of Plasmodium egress
PKG is a key signalling hub involved in regulating multiple transitional phases in the par-
asite lifecycle in both the mammalian host and mosquito vector [Alam et al. 2015; Baker
et al. 2017]. PKG is stimulated through an increase in the second messenger cGMP and
its activation is essential for triggering the egress of merozoites during both the liver stage
[Falae et al. 2010] and blood stage [M. C. Taylor, Kaur, et al. 2008; H. M. Taylor et al.
2010; C. R. Collins, S. Das, et al. 2013]. PKG is also involved in regulation of gameto-
genesis [McRobert et al. 2008; M. C. Taylor, Kaur, et al. 2008], ookinete gliding in the
mosquito midgut [Moon, C. J. Taylor, et al. 2009] and sporozoite invasion of the hepato-
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cyte [Govindasamy et al. 2016]. PKG is therefore likely essential across the entire parasite
lifecycle, making it an attractive drug target as inhibition may have transmission blocking
effects in addition to clearing parasites from the patient’s blood stream [Baker et al. 2017].
During the asexual blood stage, pharmacological blockade of PKG with the selective and
reversible inhibitors compound 1 (C1) and compound 2 (C2) [Gurnett et al. 2002; Donald
et al. 2006] abrogates discharge of micronemes and exonemes with a concomitant block
in egress [C. R. Collins, S. Das, et al. 2013]. Wash off of C1/C2 allows merozoite release to
occur within ∼10 minutes, indicating the role of PKG in triggering egress. As such, these
reversible inhibitors of PKG have become invaluable tools in the study of egress. This
will be discussed specifically in Section 1.16. As PKG is stimulated through elevation of
cGMP levels it follows that steady state levels of cGMP must be carefully controlled in the
parasite and this is likely achieved through interplay between cGMP-degrading phospho-
diesterases (PDEs) and guanylyl cyclases (GC) that up-regulate cGMP levels (Figure 1.5).
Collins and colleagues demonstrated that treatment of mature blood stage schizonts with
zaprinast, an inhibitor of PDEs, stimulates egress of wild-type parasites, an effect that
was blocked by the PKG inhibitors C1/C2 [C. R. Collins, S. Das, et al. 2013]. When the
same experiment was performed on parasites expressing a PKG mutant possessing an
enlarged active site gatekeeper residue that abolishes C1/C2 sensitivity, zaprinast was
found to induce egress in the presence of C1/C2. These results are consistent with acti-
vation of PKG occurring through a tightly regulated rise in cGMP levels, triggering egress
(Figure 1.5).
The natural egress signal is unknown but it is likely to be endogenous to the parasite
and probably functions by either down-regulating PDE activity, or up-regulating the activity
of GCs that enhance cGMP levels. The P. falciparum genome contains four putative PDEs,
(α-δ) and two GCs (α and β). PfPDEs α, γ and δ are dispensable during the asexual blood
stage cycle while PfPDEβ is refractory to disruption [Wentzinger et al. 2008; M. C. Taylor,
Kaur, et al. 2008; Moon, C. J. Taylor, et al. 2009]. GCα is refractory to disruption in both P.
falciparum [M. C. Taylor and Kelly 2010] and P. berghei, [Moon, C. J. Taylor, et al. 2009]
suggesting it is required during the asexual blood stage cycle, whereas GCβ has been
disrupted with no phenotype in blood stages [Hirai et al. 2006; Moon, C. J. Taylor, et al.
2009]. As such PDEβ and GCα, both of which are apparently essential during the asexual
blood stage cycle and involved in cGMP homeostasis are good candidates for the target of
the natural egress signal. The PDE inhibitor zaprinast which appears to mimic this egress
signal presumably inhibits PDEβ. An understanding of how PKG triggers egress during
the asexual blood stage, or indeed any of the other lifecycle events mentioned above,
remains obscure but it appears linked to calcium signalling.
Cytosolic calcium signalling has been implicated in the regulation of egress. Toxo-
plasma tachyzoite egress involves mobilisation of calcium from internal stores [Carruthers
and L. D. Sibley 1999; Lovett and L. D. Sibley 2003] and a spike in calcium levels has
been observed just prior to egress of P. falciparum blood stage schizonts [Agarwal et
al. 2013]. Furthermore, a calcium chelator was found to inhibit egress in Plasmodium,
as in Toxoplasma. The inhibitory effects of this chelator were overcome by zaprinast-
induced activation of PKG, suggesting that either PKG acts to increase calcium levels, or
it functions downstream or independently of calcium [C. R. Collins, S. Das, et al. 2013].
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This calcium flux in P. falciparum prior to egress was also investigated by Glushakova
and colleagues. They demonstrated that calcium flux and egress were unaffected by the
presence of the non-cell-permeable calcium chelator EDTA in the culture medium, sug-
gesting that the intracellular calcium flux is derived from internal stores, rather than from
external sources. Corroborating this idea, egress was enhanced by treatment with ei-
ther a calcium ionophore (which allows calcium ions to cross lipid bilayers) or inhibitors
of calcium pumps that sequester calcium in the ER. It was concluded by these authors
that the ER is therefore the most likely source of the calcium signal [Glushakova, Lizunov,
et al. 2013]. Consistent with this, a study of ookinete gliding (which requires PKG) found
PKG-dependent phosphorylation of enzymes involved in metabolism of IP3, a secondary
messenger, which is responsible for liberating calcium ions from the ER. The enzymes in-
cluded phospholipases which metabolise IP3. This led these authors to suggest that one
of the key roles of PKG is to regulate free cytosolic calcium levels through regulation of
phospholipases which metabolise IP3 [Brochet et al. 2014]. A recent phosphoproteomic
study on asexual blood stages has identified numerous substrates that become phospho-
rylated in a PKG-dependent manner [Alam et al. 2015]. These data should begin to shed
light on signalling pathways during blood stage egress.
The role(s) that calcium flux plays in egress remains unclear but at least one of its
functions may be to activate the calcium-dependent protein kinase 5 (CDPK5) which has
been shown to be essential for egress and so is a good candidate for the target of activa-
tion by the calcium flux [Dvorin et al. 2010]. The specific role of CDPK5 in egress is not
known however. It is not required for discharge of exonemes or micronemes which are
apparently central to egress/invasion as discussed below. How these signalling pathways
intersect remains quite unclear. Given the calcium dependent nature of CDPK5, it pre-
sumably functions downstream of PKG activation in view of the role of PKG in mediating
the calcium flux prior to egress. Plasmodium egress does not require motility [Fre´nal et al.
2017] so this cannot be the role of CDPK5 in achieving egress, although it is possible it
has a role in activating the actinomyosin motor for invasion. It has been suggested that
CDPK5 regulates the activity of factors involved in egress that might include proteases,
pore forming proteins and lipases. These would presumably have to be discharged from
secretory organelles though and given that exoneme and microneme discharge occur
following PKG activation, independently of CDPK5 [C. R. Collins, S. Das, et al. 2013], it
seems unlikely this is the case. It is possible that the functional diversity of these secretory
organelles is greater than we currently appreciate and there may be subsets of exonemes
and micronemes which do require CDPK5 activity for their secretion, parallel to those ex-
onemes and micronemes, containing SUB1 and AMA1 respectively, that are secreted in
the absence of CDPK5. Somehow though CDPK5 delivers an essential signal, separate
to that of the SUB1/SERA5/SERA6 putative proteolytic pathway that is the focus of this
PhD project and discussed below.
In summary, PKG is clearly essential for triggering egress and appears to be involved
in invasion as well. Its role in invasion is less obvious however, as the labile nature of P
falciparum merozoites makes dissecting true secondary effects on invasion, away from
general defects resulting from a primary effect on egress, difficult. PKG is clearly involved
in secretion of exonemes and micronemes and is likely involved in mobilising a calcium
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flux from internal stores (probably the ER) which may activate an additional parallel egress
signal through CDPK5.
Asexual blood stage egress is a protease dependent process
For many years it has been known that egress is a protease dependent process [Black-
man 2008; Blackman and Carruthers 2013]. Early studies showed that broad spectrum
protease inhibitors targeting cysteine and serine type proteases interrupted the parasite
lifecycle, trapping mature parasites in ‘clusters’ and blocking the infection of fresh erythro-
cytes [Lyon and Haynes 1986]. A global proteomic study found that over 180 Plasmodium
proteins are cleaved during the 6 h leading to egress [Bowyer et al. 2011]. Host calpain-1
in the erythrocyte cytosol has been demonstrated to facilitate egress; merozoite release
was found to be deficient in calpain-1 immuno-depleted erythrocytes [Chandramohanadas
et al. 2009]. Calpain-1 is the most abundant cysteine protease in erythrocytes and cal-
pains become activated by elevated levels of calcium and associate with membranes [Goll,
Thompson, and Li 2003]. Whether a calcium flux in the erythrocyte does activate calpain-
1, and how this is achieved is unknown. Zinc-dependent metalloproteases have also
been implicated in egress/exflagellation of microgametes with inhibitors of this class of
proteases preventing exflagellation [Sologub et al. 2011].
The parasite subtilisin like serine protease SUB1 has also been suggested to play a
role in egress, conjectured to act by triggering a proteolytic pathway when discharged
from exonemes into the PV following PKG activation [Yeoh et al. 2007]. SUB1 is con-
served across all Plasmodium species [Withers-Martinez, Strath, et al. 2014]. Studies in
P. berghei have demonstrated that SUB1 is required for rupture of the PVM during liver
stage infection [Tawk et al. 2013; Suarez et al. 2013]. During the asexual blood stage
cycle, SUB1 is maximally expressed late in schizont development and was found to be
refractory to non-conditional gene disruption, suggesting an essential role [Yeoh et al.
2007]. Pharmacological blockade of P. falciparum SUB1 (PfSUB1) activity was found to
block egress [Yeoh et al. 2007]. PfSUB1 is expressed as an 82 kDa zymogen form pos-
sessing a prodomain [Blackman, Fujioka, et al. 1998]. Following cleavage of the signal
sequence within the endoplasmic reticulum, PfSUB1 undergoes autocatalytic processing
which separates the 28 kDa N-terminal prodomain from the remaining C-terminal segment
(called p54) which contains the catalytic domain. The prodomain initially remains tightly
associated with p54 [Blackman, Fujioka, et al. 1998; Sajid, Withers-Martinez, and Black-
man 2000]. The p54 form in association with its prodomain is then trafficked to exonemes
via the Golgi. At some point during this trafficking, the prodomain dissociates from the p54
form and a further autocatalytic processing step occurs resulting in a final 47 kDa product
that accumulates in exonemes in highly mature schizonts [Sajid, Withers-Martinez, and
Blackman 2000; Yeoh et al. 2007].
Upon its PKG-regulated release from exonemes into the PV, PfSUB1 is known to
cleave an abundant merozoite surface protein called MSP1 [Koussis et al. 2009], as well
as PfSERA5 and PfSERA6 [Yeoh et al. 2007; Ruecker et al. 2012] which are members of
the multi-gene serine repeat antigen (SERA) family of putative papain like cysteine pro-
teases (see Section 1.14.2). A diverse range of additional potential PfSUB1 substrates
has also been identified which includes proteins in various compartments including the
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PV, rhoptries and the erythrocyte [Silmon de Monerri et al. 2011].
Another protease, a dipeptidyl aminopeptidase (DPAP), called PfDPAP3, was previ-
ously implicated in playing a role during egress [Arastu-Kapur et al. 2008]. This study
found that specific inhibition of PfDPAP3 blocked the PfSUB1-mediated processing of
PfSERA5. The authors proposed a model in which PfDPAP3 directly or indirectly reg-
ulates the proteolytic maturation of PfSUB1. However recent work (as yet unpublished)
has demonstrated this not to be the case, and that DPAP3 appears to be important for
efficient RBC invasion instead (personal communication Christine Lehmann). Another
P. falciparum DPAP, DPAP2 has been found to be expressed only in gametocyte stages
[Tanaka2013]. A more recent study found that DPAP2 resides in secretory organelles
called osmiophilic bodies and disruption of DPAP2 was found to decrease gamete egress
[Suarez-Cortes2016].
1.14.2 Members of the serine repeat antigen (SERA) family are putative
proteases implicated in playing roles during egress
The SERA family is a multi-gene family found in a tandem cluster in all Plasmodium
species as well as the closely related genus Theileria (Figure 1.6) [Arisue et al. 2011]
(Figure 1.6). The number of SERA genes varies between species, from just two in the
avian parasite P. gallinaceum to 12 in P. vivax [Arisue et al. 2011]. P. falciparum possesses
nine SERA genes with SERAs 1-8 on chromosome 2 and SERA9 on chromosome 9. The
SERA genes all possess a central papain-like cysteine protease domain and reside within
the PV [Aoki et al. 2002; Delplace et al. 1987; Debrabant et al. 1992]. The SERAs are
classified as ’Cys-type’ or ’Ser-type’ depending on the residue present in the active site
nucleophile position of the papain domain. Canonical cysteine proteases possess a Cys
residue in this position as it mediates protein hydrolysis by nucleophilic attack [Hodder et
al. 2009; Rosenthal 2011; Deu, Verdoes, and Bogyo 2012]. It is therefore intriguing that
some members of the SERA family have substituted this Cys with a Ser residue. This Cys
to Ser substitution is expected to abolish protease activity in a cysteine protease scaffold.
Corroborating this, no phenotypic consequences arose from substitution of the PfSERA5
active site Ser with an Ala residue, which is expected to abolish protease activity of a
cysteine protease as it cannot function as a nucleophile [Stallmach et al. 2015]. It is in-
ferred from the fact that Theileria possesses one SERA gene of the Cys-type that this is
the ancestral form of the SERA family [Arisue et al. 2011]. Furthermore, P. gallinaceum
which represents an out-group to the mammalian-infecting species possesses only Cys-
type SERAs. The mammal-infecting Plasmodium species possess Ser-type SERAs in
varying numbers, leading to the hypothesis that a gene duplication event and Cys to Ser
substitution took place in the common ancestor of all mammalian-infecting parasites, with
subsequent gene duplications, deletions and mutations to pseudogenes leading to vari-
able numbers of Ser-type genes present in the parasite species that infect mammals. All
mammal infecting Plasmodium species possess three Cys-type SERA genes that show
clear orthology across species. As such they can be classified into three groups [Arisue
et al. 2011]. PfSERA8 and orthologs form group I, PfSERA7 and orthologs form group II
and PfSERA6 and orthologs form group III. The Ser-type genes do not form clear ortholo-
gous relationships across species but together form a distinct monophyletic group called
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group IV. Interestingly the duplication of Ser-type genes has been particularly extensive in
primate infecting Plasmodium species, the significance of which is unclear [Arisue et al.
2011]. The group I SERAs, including PfSERA8, stand apart in the SERA family as they
are the only members whose expression is confined to the insect stages [Aly and Ma-
tuschewski 2005]; they also lack apparent SUB1 processing sites [Yeoh et al. 2007]. Work
on P. berghei SERA5 (also referred to as ECP1), the ortholog of P. falciparum SERA8,
has shown it is expressed exclusively in mature oocysts and is necessary for sporozoite
egress [Aly and Matuschewski 2005]. The same study also showed that oocysts lacking
the PbSERA5 gene cannot be permeabilised by saponin to allow IFA staining of circum-
sporozoite protein (CSP). The authors therefore suggested that in wild-type parasites,
PbSERA5 mediates proteolytic degradation of the oocyst wall. Work in P. falciparum and
P. berghei has shown that the group II, group III and group IV SERAs localise to the PV
in late trophozoite and schizont stages [S. K. Miller et al. 2002; Putrianti et al. 2010] and
that they are SUB1 substrates [Yeoh et al. 2007; Ruecker et al. 2012]. In P. falciparum,
gene deletion studies found that only PfSERA5 and PfSERA6 could not be disrupted in
the asexual blood stage cycle through non-conditional approaches, suggesting that they
have important roles [Ruecker et al. 2012; S. K. Miller et al. 2002; McCoubrie et al. 2007].
The cleavage of PfSERA5 and PfSERA6 following PKG mediated discharge of SUB1 has
implicated them in playing roles in this process. Conditional disruption of PfSERA5 has
now demonstrated that it plays a role in regulating the kinetics of egress with merozoite
release occurring prematurely (by ∼3 min) and inefficiently; merozoites remain bound by
residual erythrocyte membrane [C. R. Collins, Hackett, et al. 2017]. This results in a no-
ticeable replication defect but PfSERA5 is dispensable under standard in vitro conditions.
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Figure 1.5: A model of how PKG might signal for egress to occur. Elevated levels of
cGMP activate PKG which delivers signals required for the release of exonemes and mi-
cronemes. PKG is also believed to mediate a calcium flux in the cytosol which may be the
mechanism by which CDPK5 (which is also required for egress) is activated. The endoge-
nous egress signal which causes elevated levels of cGMP is unknown but is hypothesised
to act by inhibiting the activity of one or more cGMP degrading PDEs, or upregulating the
activity of GCs that metabolise cGMP.
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Figure 1.6: Schematic of the SERA multi-gene family in various species of Plasmod-
ium. Clear homology and synteny exists across the group I, II and III Cys-type SERAs
in all species examined other than P. gallinaceum. The group IV Ser-type SERAs exist in
varying numbers in the different species. From [Arisue et al. 2011].
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1.15 PfSERA6 may be an essential protease involved in egress
PfSERA6, with its active site Cys644, possesses the hallmark features of a cysteine pro-
tease (Figure 1.7). The failure to disrupt the PfSERA6 gene by targeted homologous
recombination [S. K. Miller et al. 2002] or to substitute the active site Cys644 with an Ala
residue [Ruecker et al. 2012], suggest that PfSERA6 plays an essential proteolytic role
during the asexual blood stage cycle. Furthermore, studies of the P. berghei ortholog of
PfSERA6, PbSERA3, showed that it appeared to possess an autocatalytic protease ac-
tivity in vitro, [Ruecker et al. 2012]. The activity of PbSERA3 was found be sensitive to
E64, an epoxide based irreversible inhibitor of cysteine proteases and a compound known
to inhibit merozoite release [Blackman 2008; Blackman and Carruthers 2013]. PfSUB1
was shown to process PfSERA6 either side of the papain domain just prior to erythrocyte
rupture, suggesting that PfSERA6 may be expressed as a precursor zymogen before con-
version to an active enzyme within the final minutes before merozoite release [Ruecker
et al. 2012]. As mentioned, various studies have found that E64 prevents parasite egress
and so these findings raised the possibility that PfSERA6 is the physiologically relevant
target of E64 in inhibiting egress.
Figure 1.7: Schematic representation of the primary structure of PfSERA6. This
figure shows a representation of the primary sequence of PfSERA6, showing the signal
sequence (solid black), papain like domain (shaded grey), and the sites at which SUB1
cleaves the protein either side of the papain domain. The amino acid sequence of the
SUB1 cleavage sites are shown, and the amino acid residue numbers of certain features
are shown below, with protein size in kilo Daltons.
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1.16 The reversible PKG inhibitors compound 1 and compound
2 and the irreversible cysteine protease inhibitor E64 have
become invaluable tools for investigating blood stage egress
The study of egress has greatly benefited from the ability to selectively arrest two different
stages in the pathway of egress. The reversible inhibition of PKG activity with C1/C2
has been particularly useful as it allows the preparation of highly synchronous cultures of
mature schizonts that are stalled approximately 10-15 minutes before egress (Figure 1.8)
[C. R. Collins, Hackett, et al. 2017]. Wash-off of C1/C2 reverses this inhibition of PKG and
allows egress to proceed. This allows high proportions of a population to undergo egress
within a very short space of time, greatly facilitating microscopic and biochemical studies
of this process. E64, as discussed, is an irreversible inhibitor of cysteine proteases that
prevents egress. The wash-off of C1/C2 in the presence of E64 arrests parasite egress at
a point downstream of PKG activation when merozoites become readily discernible by DIC
microscopic imaging which is the point at which PVM rupture has occurred [Glushakova,
Humphrey, et al. 2010]. This later stage of arrest is also very useful as PKG activation has
occurred, allowing the effects of PKG activation to be examined, which would be difficult or
impossible if the egress pathway was allowed to proceed all the way to merozoite release.
This approach ensures that parasites are only exposed to E64 when highly mature and
less than 15 minutes away from merozoite release. This ensures that off-target effects of
E64 are limited.
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Figure 1.8: Diagrammatic representation of the physical and cellular events leading
to egress during the asexual blood stage. PKG triggers egress. PKG and therefore
egress can be reversibly inhibited with compound 1 or compound 2. Following PKG ac-
tivation the contents of exonemes (which contain SUB1) are discharged into the PV. The
contents of micronemes are also discharged which results in AMA1 relocalisation to the
merozoite surface. In the PV SUB1 cleaves multiple substrates including MSP1, SERA5
and SERA6. The PVM then ruptures, followed by the erythrocyte membrane leading to
merozoite release. At some point during this process the erythrocyte membrane becomes
permeable [Glushakova, Humphrey, et al. 2010]. E64 can be used to inhibit egress at a
point when the PVM has ruptured but erythrocyte membrane rupture has yet to occur. The
target of this protease inhibitor relevant for achieving a block in egress remains unknown.
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Chapter 2
Aims of this project
As discussed in the Introduction, the existing data at the outset of this project indicated that
both SUB1 and SERA6 play roles in mediating merozoite release from the erythrocyte.
The SUB1 processing of SERA6, a putative papain-like cysteine protease, resembled a
classical proteolytic activation step converting a zymogen form to an active protease form.
As such this project set out to address the following three outstanding questions regarding
asexual blood stage egress in P. falciparum:
• Is SUB1 required for egress?
• Is SERA6 required for egress?
• Is SERA6 a protease and does its function require SUB1 processing?
To address these questions a molecular genetics approach has been used, making use
of the DiCre system to conditionally silence the expression of SUB1 and SERA6, inde-
pendently, in order to examine the biochemistry and cell biology of these mutants.
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Chapter 3
Methods
3.1 Culture and transfection of P. falciparum and P. knowlesi
3.1.1 Maintenance and synchronisation of parasite cultures
P. falciparum (wild type clone 3D7, the DiCre-expressing clone 1G5DC [C. R. Collins, S.
Das, et al. 2013], MSP1:loxPint [S. Das et al. 2015; Jones et al. 2016] or clones and lines
generated in this study, which were produced on the 1G5DC genetic background) were
routinely cultured at 37°C in human erythrocytes at 1-4% haematocrit in RPMI 1640 (Life
Technologies) supplemented with 2.3 gL-1 sodium bicarbonate, 4 gL-1 dextrose, 5.957 gL-1
HEPES, 0.05 gL-1 hypoxanthine, 0.5% (w/v) Albumax II, 0.025 gL-1 gentamicin sulphate,
and 0.292 gL-1 L-glutamine (complete medium) in a 90% nitrogen, 5% carbon dioxide and
5% oxygen atmosphere as previously described [Trager and Jensen 1976; Yeoh et al.
2007]. Human blood was obtained from anonymised donors through the UK National
Blood Transfusion service and was used within 2 weeks of receipt. No ethical approval is
required for its use. Routine microscopic examination of parasite growth was performed
by fixing air-dried thin blood films with 100% methanol before staining with 10% Giemsa
stain (VWR international) in 6.7 mM phosphate buffer, pH 7.1. For routine microscopic
determination of parasitaemia, at least 1,000 erythrocytes were examined. Exact haema-
tocrit values were determined using a haemocytometer (Marienfeld; 0.1 mm depth and
0.0025 mm2 area).
For synchronisation of parasite cultures, mature schizont stage parasites were isolated
on cushions of 63% (v/v) Percoll (GE Healthcare Life Sciences) adjusted to isotonicity
as described previously [Kramer, Chow Kan, and Siddiqui 1982]. Schizonts were then
added to fresh suspensions of erythrocytes in complete medium and incubated at 37°C
with shaking (∼60 rpm) for 3-4 h to allow egress of merozoites and invasion of fresh
erythrocytes. Remaining schizonts were then removed from the culture by isolation on
percoll. Lysis of mature forms of the parasite that remained in the erythrocyte pellet was
performed by suspension of the pellet in 5% (w/v) D-sorbitol [Lambros and Vanderberg
1979]. The synchronous ring stage parasites were then cultured as standard.
Plasmodium knowlesi A1.H1 clone parasites were cultured as P. falciparum but com-
plete medium was supplemented with 10% (v/v) horse serum [Moon, J. Hall, et al. 2013;
Moon, Sharaf, et al. 2016], and human erythrocytes used in cultures were pooled from
three donors in case any one individual donor was Duffy negative which would prohibit P.
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knowlesi invasion [L. H. Miller, Mason, et al. 1975].
3.1.2 Transfection of P. falciparum
For transfection of DNA constructs, Percoll-enriched mature synchronous schizonts were
electroporated with 10 µg of sterile ethanol precipitated DNA per transfection using an
Amaxa P3 primary cell 4D Nucleofector X Kit L (Lonza) (pulse code FP158). The DNA
(resuspended in 10 µl) was mixed with 100 µl of P3 Primary cell solution from the Lonza
kit. Then 20 µl of packed schizonts (previously washed after isolation on percoll in RPMI
1640 without albumax or supplementary glutamine) were resuspended in the DNA/P3
Primary Cell Solution mix, before transferring to a cuvette and being electroporated. Af-
ter electroporation the contents of cuvettes were immediately added to 2 ml of complete
medium at 15% haematocrit and shaken gently at 37°C for 1 hour to encourage invasion
of single merozoites per erythrocyte, as for invasion during synchronisation. This was
then made up to 10 ml of culture with fresh complete medium and incubated as stan-
dard (stationary overnight). Growth medium was replaced ∼20 h post transfection with
fresh complete medium containing drug. Once drug-resistant parasites appeared and
displayed sustained growth (usually 2-3 weeks post-transfection, aliquots of culture were
cryopreserved (see Section 3.1.5). In cases where episomal constructs were expected to
integrate, cultures were subjected to repeated cycles of 3 weeks of culture without drug
followed by culturing with drug until parasite growth recovered to sustained levels (‘drug
cycling’). This enriches for parasites in which the DNA construct has integrated into the
genome. After each round of drug cycling the integration of the construct was assessed
by diagnostic PCR to examine the presence of the native, unmodified chromosomal lo-
cus and the modified, integrant locus. When clear evidence of integration was detected
parasites were cloned either by limiting dilution of cultures to ∼0.1-0.3 parasites per well
followed by dispensing into round-bottomed 96-well microplates and screening for para-
site growth by examination of Giemsa stained thin films, or by serial dilution of culture and
determination of clonal parasite growth by examination of plaques (see Section 3.1.4).
Plates were incubated in sealed gassed incubator chambers.
3.1.3 Reagents
The antifolate drug WR99210 (from Jacobus Pharmaceuticals (New Jersey, USA)) was
used at 2.5 nM. Blasticidin (used at 2 µg/ml) and rapamycin (used at 100 nM) were from
Sigma. Compound 2 was kindly provided by Dr Simon Osborne (MRC Technology, Steve-
nage Bioscience Catalyst Campus, UK) and used at 1 µM.
3.1.4 Imaging and documentation of plaque formation
To allow plaque formation, synchronous parasite cultures at ring stage were diluted to the
desired densities in complete medium with human erythrocytes at haematocrits between
0.5% and 1%, then dispensed into the central 60 wells of flat-bottomed 96 well microplates
(Costar 3596, Corning NY, USA; 0.32 cm2 growth area per well, diameter 6.38 mm) us-
ing 200 µl culture per well. Plates were incubated in sealed, gassed incubator chambers
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(Billups-Rothenberg, CA, USA). To limit evaporation, sterile phosphate buffered saline was
added to the outer wells of plates. Plaque formation was assessed routinely by micro-
scopic examination using a Nikon TMS inverted microscope (4x objective, 10x eyepieces,
40x total magnification). When desired, plaque formation was documented without open-
ing the plates using a Perfection V750 Pro scanner (Epson) in top-down transmission light
mode, saving images as 4,800 dpi RGB TIFF files. Up to 3 microplates were imaged si-
multaneously with the scanner. Plaque clarity and visibility was generally enhanced by
using the ’Split channels’ function of the Fiji distribution of ImageJ [Schindelin et al. 2012]
to split the RGB TIFF file into red, green and blue data channels, then using the green
channel image for quantification of plaque number and dimensions, since this provided
maximum contrast between plaques and the surrounding erythrocyte layer. Plaques were
counted by visual examination of the images and plaque size quantified using the Magic
Wand tool in Adobe Photoshop CS5 using a tolerance setting value of 32. This tool de-
lineates the perimeter of selected plaques and calculates plaque area in pixels. No area
value was recorded for apparent plaques that could not be delineated by the tool.
3.1.5 Cryopreservation of P. falciparum cultures
P. falciparum cultures were cryopreserved in liquid nitrogen. Parasite cultures of approxi-
mately 5% ring parasitaemia were centrifuged and the erythrocytes resuspended in 28%
(v/v) glycerol, 3% (w/v) sorbitol, (w/v) 0.65% sodium chloride in distilled water with 1 ml
added to each cryovial and then frozen. To thaw parasites, the cryovial was warmed to
37°C before the 1 ml of thawed culture was added to 5 ml of sterile thawing solution (3.5%
(w/v) NaCl). Cells were pelleted at 1,100 rpm for 3 min. The pelleted cells were washed
once more in the same volume of thawing solution and finally resuspended in 10 ml com-
plete medium and cultured as standard. Selective drug medium, if applicable was added
∼20 h later.
3.1.6 Rapamycin treatment of parasites
Synchronous cultures of ring stage parasites (∼4-14 h old) were divided equally and
treated with 100 nM rapamycin, or an equivalent volume of DMSO as a solvent-only con-
trol (referred to as ’mock-treatment’), for 4 h at 37°C. Cells were then pelleted and washed
once in Albumax II-free RPMI before culturing as standard in complete medium.
3.1.7 Parasitaemia counts by flow-cytometry
Parasites were fixed in 4% (v/v) paraformaldehyde (Sigma), 0.02% (v/v) glutaraldehyde
(Sigma) in PBS for 30 min at 37°C and then diluted five-fold in PBS. Samples were stored
at 4°C until required. Cells were stained with Hoechst 33342 (Thermo Fisher Scientific)
(1:10,000) in PBS for 30 min at 37°C. Parasitaemia was determined using a BD FACS
Aria flow cytometer. Plots of forward scatter area and side scatter area were used in order
to gate for human erythrocytes. Subsequently doublet discrimination was performed by
gating with plots of forward scatter width and forward scatter height. Another round of
doublet discrimination was performed by gating on plots of side scatter width and side
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scatter height. Finally infected erythrocytes were gated for as erythrocytes positive for
DNA stain by plotting forward scatter area against UV-A fluorescence using a 450/50 filter.
3.1.8 Extraction of genomic DNA from P. falciparum
Parasite enriched pellets were obtained by haemolysis of pelleted erythrocytes in at least
5 pellet volumes 0.15% (w/v) saponin (Sigma) in PBS followed by centrifugation at 13,000
rpm for 5 min in a microfuge. The haemoglobin rich supernatant was aspirated and dis-
carded and pelleted parasite material stored at -20°C until required. DNA was extracted
from pellets using a DNeasy Blood and Tissue Kit (Qiagen) as per manufacturer’s instruc-
tions, or using standard phenol chloroform extraction.
3.1.9 Preparation of protein lysates for SDS PAGE and western blot
For the solubilisation of proteins in pelleted parasite material or culture supernatants the
sample was dissolved in standard Laemmli buffer (4 x concentrate: 8% (w/v) SDS, 40%
(v/v) glycerol, 250 mM Tris-HCl, 400mM DTT, 0.008% (w/v) bromophenol blue) and im-
mediately heated at 95°C for 5 min to denature proteins and reduce disulphide bridges.
Residual solid material was then pelleted by centrifugation at 13,000 rpm for 3 min in a
microfuge. The supernatant containing solubilised proteins was then subjected to SDS
PAGE fractionation.
3.1.10 Diagnostic polymerase chain reaction (PCR)
Diagnostic PCR was performed using Kappa2G HotStart ReadyMix (Kappa Biosystems)
as per manufacturer’s instructions. Primers were used at 500 nM. PCR was carried out
in a thermocycler and products examined by agarose gel electrophoresis as standard.
Oligonucleotide primers were obtained from Sigma.
3.2 Molecular cloning techniques
3.2.1 PCR for molecular cloning applications
‘Colony PCR’ was performed with GoTaq Green Master Mix (Promega). PCR reactions
were inoculated with a small amount of bacteria from a single colony using a sterile pipette
tip. Primers were used at 400 nM. PCR for amplification of sequences to be used for
DNA transfection constructs was performed using Phusion High-Fidelity DNA Polymerase
(Thermo Fisher Scientific) as per manufacturer’s instructions. Primers were used at 500
nM. PCR was carried out in a thermocycler and products examined by agarose gel elec-
trophoresis as standard. Oligonucleotide primers were obtained from Sigma. Purification
of PCR products for molecular cloning applications was performed using a QIAquick PCR
Purification Kit (Qiagen) as per manufacturer’s instructions.
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3.2.2 Restriction enzymes
All restriction enzymes used were obtained from New England Biolabs and used according
to manufacturer’s instructions.
3.2.3 DNA ligation
Ligation of DNA was performed using a Rapid DNA Ligation Kit (Roche) as per manufac-
turer’s instructions.
3.2.4 Ligation independent cloning
For ligation independent cloning the InFusion HD Cloning Kit (Clontech) was used as per
the manufacturer’s instructions.
3.2.5 Plasmid DNA preps
Plasmid DNA purification from E. coli was performed using a QIAprep Spin Miniprep Kit
(Qiagen) or a HiSpeed Plasmid Maxi Kit (Qiagen) as per manufacturer’s instructions.
3.2.6 Extraction and purification of DNA from agarose gels
Extraction and purification of DNA from agarose gels after electrophoretic separation was
performed using a QIAquick Gel Extraction Kit.
3.2.7 E. coli and transformation
DH5αand One Shot OmniMAX 2 T1 Phage-Resistant E. coli cells were used for transfor-
mation with plasmids. E. coli was grown at 37°C in standard lysogeny broth.
3.2.8 Nucleotide sequencing
Sanger sequencing of DNA constructs to verify correct construction was performed by
Beckman Coulter Genomics or Source Biosciences.
3.3 Generation of plasmids
SUB1HA3:loxP and SERA6:loxP parasite clones were generated by single crossover
homologous recombination into the 1G5DC genome using integration plasmids called
pHH1_SUB1HA3_loxP and pHH1_SERA6_loxP respectively. In both cases, correct tran-
scriptional regulation of the modified gene was assured by placement of the 3' UTR of
the P. berghei dihydrofolate reductase thymidylate synthase gene (PbDT 3' UTR) down-
stream of the floxed coding sequence [C. R. Collins, S. Das, et al. 2013]. To target the
SUB1 gene, a chimeric gene fragment with a native 5' portion and a recodonised 3' por-
tion was constructed by first amplifying the 5' sequence from P. falciparum 3D7 gDNA us-
ing primers JT-S1endo-F and JT-S1CO-R [Table 3.1], whilst the recodonised region was
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amplified from plasmid pFastBac-sPfSUB1wt [Withers-Martinez, Saldanha, et al. 2002]
using primers JT-S1CO-F and JT-S1synth-R [Table 3.1]. The amplicons were then fused
in frame by means of overlapping extension PCR by inclusion of both products in a fresh
PCR reaction including primers JT-S1endo-F and JT-S1synth-R [Table 3.1], and the prod-
uct cloned into pGEM-T (Promega). A segment of this fragment was then excised using
HindIII and KpnI and replaced with a similarly-digested loxP-containing synthetic intron
(loxPint) (Geneart) [S. Das et al. 2015; Jones et al. 2016]. This intermediate vector was
digested with HpaI and Xho I to liberate the SUB1 sequence which was ligated into the
plasmid pHH1_SERA5_LoxP1 [C. R. Collins, S. Das, et al. 2013] digested with the same
enzymes to generate plasmid pHH1_SUB1HA3_loxP (Figure 5.4). Integration of this con-
struct into the 1G5DC SUB1 locus by homologous recombination was detected by diag-
nostic PCR with primers JT111-1p and JT111-2p [Table 3.1], and the floxed or excised
SUB1 locus was detected by PCR using primers JT111-1p and JT111-3p [Table 3.1].
To generate pHH1_SERA6_loxP, a chimeric SERA6 gene fragment was excised from
plasmid MWS36 (a kind gift of Michael Shea) by digestion with HpaI and NcoI. The
chimeric sequence was cloned into plasmid pHH1_SERA5_LoxP (Figure 5.5). This plas-
mid was digested with HindIII and then blunted before digesting with NcoI before being
ligated to the excised SERA6 fragment to produce pHH1_SERA6_loxP which contained a
single loxP site downstream of the SERA6 stop codon. The SERA6 chimeric sequence in
this plasmid consisted of 920 bp of native sequence starting within the first intron, fused to
synthetic recodonised sequence stretching to the stop codon. Integration of this construct
by homologous recombination into the 1G5DC genome (which already contains a single
genomic loxP site upstream of the SERA6 locus) was designed to introduce a second
loxP site downstream of the SERA6 stop codon floxing the entire SERA6 open reading
frame and promoter region. Correct integration was detected by diagnostic PCR using
primers SERA6-5'UTRb and SERA6-37 (Table 3.1), whilst the floxed or excised SERA6
locus was detected with primers S65'UTRb-2 and S6EndoEx2Rev (Table 3.1).
For generation of plasmid constructs designed for transgenic expression of SERA6, a
chimeric coding sequence and native promoter region was excised from plasmid MWS28
(a kind gift of Michale Shea) and ligated into plasmid pDC-mCherry-MCS (a modification of
pDC2-mCherry [C. R. Collins, Hackett, et al. 2017]) by digestion with SalI and NcoI, giving
rise to pDC2-wtSERA6 (WT SERA6). The sequence comprised 979 bp of putative pro-
moter sequence upstream of the native SERA6 ATG start codon, as well as 477 bp of the
5' segment of the coding sequence (including the first intron) fused in frame to a synthetic
recodonised SERA6 cDNA (Geneart) encoding the remainder of the ORF. Site-directed
mutagenesis and sub-cloning steps were then used as previously described [Ruecker et
al. 2012] to generate identical constructs containing di-leucine substitutions of the P1 and
P2 positions at the SUB1 processing sites 1 and 2 in SERA6, as well as a Cys644Ala sub-
stitution of the active site nucleophile, giving rise to plasmids pDC2-SERA6_uncleavable
(Uncleavable SERA6) and pDC2-SERA6_Alamut (Cys644Ala) respectively (Figure 5.15).
The 979 bp of native promoter region of SERA6 used to drive expression from these epi-
somal constructs consisted of approximately almost the entire 1028 bp region between
the SERA6 start codon and the stop codon of the upstream SERA5 gene.
For transgenic expression of WT SUB1 the pDC-mCherry-MCS plasmid was modified
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such that the blasticidin deaminase (BSD) drug selection cassette and mCherry reporter
gene were expressed from a single promoter by the use of the ribosomal T2A skip pep-
tide [J. H. Kim et al. 2011; Szymczak et al. 2004; Wagner et al. 2013]. To do this, the
BSD cassette was excised from pDC2-mCherry_MCS with ApaI and SacI and the back-
bone re-ligated. The mCherry ORF was then excised by digestion with AvrII and XhoI
and replaced with a synthetic gBlock (IDT) comprising the mCherry and BSD ORFs sep-
arated by the T2A sequence. This resulted in construct pDC2-mCherryT2ABSD_MCS
in which these ORFs remained under control of the constitutive P. falciparum calmod-
ulin (CAM) promoter (which remained from the original mCherry expression cassette).
This vector was then linearised with SnaBI. The P. falciparum SUB1 promoter sequence
(1000 bp immediately upstream of the SUB1 start codon) was amplified from P. falciparum
3D7 gDNA using primers PfSUB1_prom_for_infu and PfSUB1_prom_rev_infu (Table 3.1).
Primers PfSUB1_synth_for_infu and PfSUB1_synth_rev_infu were used to amplify the re-
codonised synthetic SUB1 ORF from pFastBac-sPfSUB1wt [Withers-Martinez, Saldanha,
et al. 2002] and primers PbDT3UTR-for_infu and PbDT3UTR-for_infu were used to am-
plify the PbDT 3'UTR from pDC2-mCherry_MCS. Primers included complementary over-
hangs such that all 3 fragments could then be finally assembled into the linearised pDC2-
mCherryT2ABSD_MCS backbone in a single step using an InFusion HD Cloning Kit (Clon-
tech), generating pDC2-mCherryT2ABSD_wtSUB1 (WT SUB1) (Figure 5.14). The 1000
bp of native promoter region of SUB1 used to drive expression from this episomal con-
struct consisted of approximately 1/3 of the ∼3000 bp of sequence between the SUB1
start codon and the start codon of the putative upstream gene which is transcribed in the
opposite direction.
For episomal expression of an EXP1mCherry fusion protein (to fluorescently label the
PVM), a synthetic cDNA fragment encoding mCherry fused to the C-terminus of the P.
falciparum EXP1 gene (PlasmoDB IDPF3D7_1121600) via a polyglycine-alanine linker
(GAGGGGGGGGA) was obtained from Geneart. This was subcloned into vector pCR-
Blunt using the ZeroBlunt PCR cloning kit (Invitrogen). The resulting plasmid was digested
with AvrII and XhoI before ligating the EXP1mCherry fragment into pDC-mCherry-MCS,
digested with the same enzymes, in the place of the mCherry ORF, generating plasmid
pDC2-EXP1-mCherry.
3.4 Immunochemical techniques
3.4.1 SDS PAGE
Proteins were fractionated by electrophoresis on 4-15% Mini-PROTEAN TGX Precast pro-
tein gels at 200V in Tris/Glycine/SDS buffer (25 mM Tris, 190mM glycine, 0.1% (w/v) SDS).
3.4.2 Western blot analysis
SDS PAGE fractionated protein lysates were blotted onto nitrocellulose membranes in a
wet-transfer apparatus overnight using western blot transfer buffer (25 mM Tris, 190 mM
glycine, 20% (v/v) methanol). Membranes were blocked in 5% (w/v) milk powder (Sigma)
solution in 0.05% (V/V) Tween20 in PBS (PBST) for 1 h. Membranes were washed three
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times for 5 min in PBST before being probed with primary antibodies at 1:1,000 dilution in
1% (w/v) bovine serum albumin (BSA) (Sigma) in PBST (BSA/PBST) for 1 h. Membranes
were washed three times for 5 min in PBST before probing with horseradish peroxidase
(HRP) conjugated secondary antibodies specific for human, rabbit or mouse IgG (Invitro-
gen) at 1:10,000 dilution in BSA/PBST 1 h. For detection of triple HA-tagged SUB1, the
rat monoclonal anti-HA antibody 3F10 (Sigma) was used at a 1:1,000 dilution, followed
by biotin-conjugated anti-rat antibody (Roche) at 1:8,000 dilution, then HRP conjugated
streptavidin (Sigma) at 1:2,000 with three washes for 5 min in PBST in-between each step
as above. Immobilon Western Chemiluminescent HRP Substrate (Millipore) was used
according to the manufacturer’s instructions, and blots were visualised and documented
using a ChemiDoc Imager (Bio-Rad) with Image Lab software (BioRad).
3.4.3 Stripping nitrocellulose membranes of antibody and re-probing with
antibody
To strip nitrocellulose western blot membranes of bound antibody in order to re-probe
them with fresh antibody, blots were washed three times for 5 min in 5% (v/v) acetic acid
in distilled water. Blots were then washed three times for 5 min in PBS before re-blocking
in milk powder solution and re-probing with antibody as above.
3.4.4 Immunofluorescence analysis (IFA)
For IFA, air-dried thin films of parasite cultures were fixed in fresh 4% (v/v) paraformalde-
hyde in PBS for 30 min. Slides were washed twice for 5 min in PBS before cell membranes
were permeabilised in 0.1% (v/v) triton X100 (Sigma) in PBS for 10 min. Slides were then
washed twice for 5 in PBS and then blocked in blocking solution (3% (w/v) BSA (Sigma) in
PBS) for 1 h before being probed with relevant primary antibodies at 1:500 dilution in block-
ing solution for 1 h. Slides were washed three times for 5 min in PBS before secondary
Alexafluor 488-, 594- or 624-conjugated antibodies specific for human, rabbit or mouse
IgG (Invitrogen) at 1:1,000. For detection of triple HA tagged SUB1 a three step protocol
was used: rat monoclonal anti-HA antibody 3F10 (Sigma) was used at a 1:500 dilution,
followed by biotin-conjugated anti-rat antibody (Roche) at 1:500 dilution, then streptavidin
conjugated Alexafluor 594 (Sigma) at 1:1,000 with three washes in between each step as
above. Slides were washed three times for 5 min before being mounted in Vectashield
antifade mounting medium with DAPI (Vector Laboratories). Images were acquired using
a Nikon Eclipse Ni-E widefield upright microscope fitted with a Hamamatsu C11440 digital
camera and Nikon N Plan Apo λ100x/1.45NA oil immersion objective (Nikon, Japan) and
NIS Elements software (Nikon), using identical exposure conditions for each wavelength
for all samples being compared.
3.4.5 Reagents and antibodies
Monoclonal antibody (mAb) SB-SP1 specific for human erythrocytic spectrin was from
Sigma, whilst mAb 89.1, which recognises P. falciparum MSP1, has been described pre-
viously [Holder and Freeman, 1982], as have rabbit polyclonal antisera against P. falci-
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parum SERA5 [C. R. Collins, Hackett, et al. 2017], SERA6 [Ruecker et al. 2012; Withers-
Martinez, Saldanha, et al. 2002] and AMA1 [C. R. Collins, Withers-martinez, et al. 2009].
3.5 Timelapse videomicroscopy
Viewing chambers (internal volume ∼80 µl) for observation of live schizonts were con-
structed as described [C. R. Collins, S. Das, et al. 2013; S. Das et al. 2015] by adhering
22 x 64 mm borosilicate glass coverslips to microscope slides with strips of double-sided
tape, leaving 2 ∼2 mm gaps at diagonally opposite ends. Mature Percoll enriched sch-
izonts were incubated for 4-6 h at 37°C in complete medium supplemented with compound
2 (1 µM). Then ∼5 x 107 schizonts were rapidly washed twice in 1 ml of gassed pre-
warmed complete medium lacking compound 2, pelleting at 1,800 x g for 1 min. The cells
were then suspended in 50 µl of complete medium and introduced into the pre-warmed
viewing chamber on a temperature-controlled microscope stage held at 37° C on a Nikon
Eclipse Ni-E widefield upright microscope fitted with a Hamamatsu C11440 digital cam-
era and Nikon N Plan Apo λ100x/1.45NA oil immersion objective. Images (DIC alone or
simultaneous DIC and fluorescence) were taken at 5-10 s intervals over a total of 20-30
min, then annotated and exported as TIFFs or .mov files using the Fiji distribution of Im-
ageJ [Schindelin et al. 2012]. Alexa Fluor 488 phalloidin and Alexa Fluor 647-conjugated
wheat germ agglutinin were from Thermofisher. Phalloidin (Thermo Fisher) was used at
132 nM and wheat germ agglutinin (Thermo Fisher) at 1 µg/ml.
3.6 Electron microscopy
3.6.1 Scanning electron microscopy
Scanning electron microscopy (SEM) was carried out in collaboration with Gema Vizcay
(laboratory of Roland Fleck). Schizonts were fixed in 2.5% glutaraldehyde at room tem-
perature, washed in PBS, osmicated (1% OsO4 for 16 hours), dehydrated, critical point
dried and sputter coated with 5 nm gold for scanning EM. Images were collected on a
JEOL JSM 7610F with 2.6 kV accelerating voltage.
3.6.2 Transmission electron microscopy
Transmission electron microscopy (TEM) was carried out in collaboration with Victoria
Hale, Claudine Bisson and Trishant Umrekar (laboratory of Helen Saibil). Schizonts were
pelleted by centrifugation, mixed with 20% (w/v) dextran in complete medium contain-
ing baker’s yeast, then frozen using a HPM100 high-pressure freezer (Leica). Vitrified
cells were freeze-substituted using a EM AFS2 (Leica) into Lowicryl HM20 resin (EMS)
with 0.2% (w/v) uranyl acetate and cut into 120 nm sections using a UC7 microtome (Le-
ica). Sections were placed on glow-discharged carbon-coated copper London Finder grids
(EMS) with 10 nm Protein A-Au fiducials (EMS) and post-stained with 0.2% (w/v) uranyl
acetate 4% (w/v) lead citrate. Images and tomograms were recorded using a Model 2040
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dual-axis tomography holder (Fischione Instruments) on a Tecnai F20 200 kV field emis-
sion gun electron microscope (FEI), equipped with a DE20 camera (Direct Electron). Dual-
axis tilt series were acquired at 4.07 A˚/pixel from -60 to +60 with an increment of 2 using
SerialEM32 and processed using IMOD33 with nonlinear anisotropic diffusion filtering.
3.7 Statistical analysis
Linear regression analysis by analysis of covariance and t-tests were performed using
GraphPad Prism 7 software (CA, USA). Χ2 tests were performed manually in Excel (Mi-
crosoft). For Χ2 tests, where expected values were less than 5, data from that category
was pooled with the adjacent category to avoid confounding results with large percent-
age differences that arise when numbers are small. A p-value of <0.05 was considered
statistically significant.
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Table 3.1: List of oligonucleotide primer sequences used in this study. Numbers
in brackets are primer code numbers of primers used for diagnostic PCR referred to in
figures throughout this thesis
Name Nucleotide sequence
JT111-1p (1) GATTGTTAGCGAATTACGATTCCTAG
JT111-3p (2) GATGACTACAATTACTTGCAGATAC
JT111-2p (3) GAACAGTTCGACGCAGACACGAAGAAC
S65'UTRb-2 (4) CAGAAAAAGTAAAAGACCAAATGATA
S6EndoEx2Rev (5) CTTCAGAACATTTATTTTGAAGTTCC
SERA6-5'UTRb (6) AAAAGTAAAAGACCAAATGATA
SERA6-37 (7) AAGTAGGAGTCGGACTTAGAA
+27 (8) CAATATCATTTGAATCAAACAGTGGT
-25 (9) CCATTGGACTAGAACCTTCAT
-11 (10) CTTTGCCATCCAGGCTGTTC
JT111-6p (11) GAGTACCTGCAAAGAAAGGGTATCTTG
JTPbDT3'R (12) TTACAGTTATAAATACAATCAATTGG
JTS5synthF (13) GAATGCTATTTCTGCTACGTG
SERA6-34 (14) GTCCTGGAAGAAGAACGTTGCCGCCGCGAGACACAACACTGACTTCATG
hsp863'R1 (15) GACTTTACTGAGACATG
JTPrA1 (16) GGTTACGGGATCATGTGGG
S6synthRev2 (17) GTTCAAAACGTTGTGAGTGATG
S65UTRb-2 CAGAAAAAGTAAAAGACCAAATGATA
S6EndoEx2Rev CTTCAGAACATTTATTTTGAAGTTCC
SERA6-37 AAGTAGGAGTCGGACTTAGAA
JT-S1CO-F GAATATAGTGGTATTTTTAATTCTTCTGTCGAGTACCTGCAAAGAAAGGG
JT-S1syth-R AGTCTAACTAGTCTCGAGGTGCAGGTATCTGGACTTCTTCTT
JT-S1endo-F TAAGTTCCATGGGTTAACAACATAGGAGGGAATGAGGTAGATGC
JT-S1CO-R CCCTTTCTTTGCAGGTACTCGACAGAAGAATTAAAAATACCACTATATTC
PfSUB1-synth-for-infu CGGCTAGCCGATTACTGCATGGCCATATAAATGTTACAAATTC
PfSUB1-synth-rev-infu GGCATCTACCTCATTCCCTCCTATG
PbDT3UTR-for_infu GAGGGATATGGCAGCTTAATGTTC
PbDT3UTR-rev_infu CCCCCGGGTCGATACGCCTACCCTGAAGAAGAAAAGTCC
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Chapter 4
Results I: A simple and robust
plaque assay can be used to assess
growth of P. falciparum at the clonal
level.
As outlined in the Introduction, plaque assays can greatly facilitate the analysis of the
effects of drugs, gene modifications and antibodies on the proliferation of intracellular
pathogens. The work presented in this chapter describes the optimisation and application
of a simple plaque assay that is likely to become an attractive and widely used addition to
the available repertoire of malaria research tools. This work was borne out of a personal
observation of Arnault Graindorge which was communicated to members of the labora-
tory of Michael Blackman by Paco Pino (laboratory of Dominique Soldati): that zones of
clearance are sometimes seen in erythrocyte layers in cultures of P. falciparum. It was
serendipitous that this approach proved such a useful tool during attempts to characterise
the phenotype of SERA6 null mutants presented in Chapter 5. Herein is presented the
work I performed to develop, optimise and apply the plaque assay. The results were pub-
lished in the journal PLoS One [Thomas et al. 2016].
4.1 Growth of P. falciparum in static erythrocyte cultures in
microplate wells produces plaques.
Initially, work was conducted to determine whether asexual blood stage cultures of P. falci-
parum reliably produce plaques in static conditions in microplate wells. To this end, para-
site cultures were dispensed in complete medium into the central 60 wells of flat bottomed
96-well microplates (200 µl per well). These were incubated at 37°C in gassed chambers,
without disturbing the erythrocyte layers or replacing the medium, and examined period-
ically over the course of several days using an inverted light microscope. This revealed
the gradual appearance and expansion of roughly circular clearances in the otherwise
homogenous erythrocyte layers coating the bottom of each well (Figure 4.1). These dis-
continuities in the erythrocyte layers are referred to as plaques. Henceforth, all work in
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this chapter was performed on P. falciparum unless otherwise stated (P. knowlesi was also
used) and all work was performed in flat-bottomed 96-well microplates, simply referred to
as microplates.
Initial attempts to document these plaques using inverted microscopes with cameras
proved cumbersome as only proportions of the plates, or even only proportions of indi-
vidual wells could be documented per image. In the search for a more convenient and
higher throughput means of documenting plaques microplates were scanned using an
Epson Perfection V750 Pro high-resolution scanner in transmission light mode at 4,800
dpi as has been described previously [Sullivan et al. 2012]. It was found that plaques were
readily observable in scans of plates. The extremely wide field of view of a scanner is a
great benefit as it obviates the need for laborious microscopic examination of individual
wells and allows for simple documentation of up to three plates at a time. The cost of
a document scanner is also considerably less than an inverted microscope, facilitating
the implementation and use of this method, especially in resource poor settings. The cell
counter plugin of the free open source software Fiji (https://imagej.net/Fiji/Downloads) was
used to count plaques on scanned images. It was found that the green channels of the
images (obtained by separating the colour channels in Fiji using the ‘split channels’ tool)
provided the greatest contrast between plaques and the erythrocyte layer. The red chan-
nel provided the least contrast, with plaques practically undetectable. The clarity of the
green channel presumably results from absorbance of green wavelengths of light by the
haemoglobin of the erythrocyte layer, while it is transmitted through the area of clearance
of erythrocytes that constitutes plaques.
To formally demonstrate that plaque formation was a result of parasite replication,
highly synchronous ring stage parasite cultures (approximately 10% parasitaemia, 0.75%
haematocrit) were serially diluted (10-fold) into a suspension of uninfected erythrocytes
(0.75% haematocrit) in complete medium. Aliquots of each dilution were dispensed across
multiple wells of a microplate. Examination of plaques in each well revealed that mean
plaque number per well at any given dilution correlated linearly with starting parasitaemia,
with no plaques forming in the absence of parasites (Figure 4.2). Similar data was col-
lected from a further two independent experiments, this time with two-fold serial dilutions,
with identical results (Figure 4.3). This demonstrated that under the correct conditions par-
asite growth was capable of producing plaques in erythrocyte layers. These presumably
result from sequential rounds of egress and preferential invasion of fresh erythrocytes
immediately adjacent to the infected cells such that a ‘wave’ of erythrocyte destruction
emanates outwards from the focus of infection.
To optimise conditions for plaque formation and detection, plaque formation was ex-
amined in microplate wells seeded with cultures of a range of haematocrit values: 0.5%,
0.75% and 1%. This revealed that a haematocrit of 0.75% resulted in optimal plaque clar-
ity (Figure 4.4). Interestingly, and unexpectedly, it was noticed that erythrocyte longevity
under the conditions used for this assay was also haematocrit dependent. Signs of ery-
throcyte lysis were observed as early as 10 days in cultures of 0.5% haematocrit, with free
haemoglobin appearing in the culture medium and changes in the appearance and ho-
mogeneity of the erythrocyte layers. This resulted in plaques with reduced clarity and less
distinct perimeters. In contrast, at higher haematocrits erythrocytes were reproducibly
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stable for at least two weeks. As the optimum clarity and stability of plaques was found to
be achieved when using a haematocrit of 0.75%, this was used for all subsequent work. It
is important to note that haematocrits being discussed here depend on dispensing 200 µl
of culture into each well as it is the absolute number of erythrocytes dispensed into a well
that determines the thickness of the layer formed at the bottom of a well. Haematocrits
were counted precisely using a haemocytometer and were found to be 1.42 x 108 / ml for
0.75% haematocrit cultures. Therefore the number of erythrocyte per well was 2.84 x 107.
Should a smaller volume be dispensed into wells the haematocrit of the culture dispensed
must increase accordingly to maintain the same number of erythrocytes in each well.
Plaques typically reached a diameter of 0.1 mm before eventual complete lysis of
all erythrocytes between 16-21 days. This was not due to excessive parasitaemia in the
microwell cultures; microscopic examination of Giemsa-stained thin smears of cultures
recovered from wells containing 30 plaques at 14 days revealed parasitaemia values to
be ∼0.06% (1 parasite in 1,600 erythrocytes examined), well below what is routinely
achieved in standard conditions in flasks.
Figure 4.1: Time-dependency of plaque formation in a static culture of asexual blood
stage P. falciparum in a microplate well. Scanned images (RGB channels) of a single
microplate well (diameter 6.38 mm) taken at the indicated days following the introduction
of a low parasitaemia P. falciparum 3D7 clone culture (200 µl per well, 0.75% haematocrit,
starting parasitaemia 0.00004%, corresponding to∼ 6 infected cells per well) showing the
time-dependent evolution of plaques. Plaques first became detectable by light microscopy
or high-resolution scanning at day 8.
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Figure 4.2: Plaque frequency correlates linearly with starting parasitaemia. A) Mi-
croplate wells containing 10-fold serial dilutions (dilution of starting culture indicated) of
parasite culture (0.75% haematocrit, starting parasitaemia ∼13%). Plates were imaged
on day 13 following the introduction of the culture into the plate. By this point, at the highest
parasite densities (neat and 10-1 dilution) the erythrocyte layer was completely destroyed,
whilst discrete plaques were visible at the lower parasite densities. B) A plot showing the
mean plaque number per well across 6 replicate wells on a single plate containing 10-fold
serially diluted parasite culture. Plaques were only enumerated in wells containing culture
diluted between 10-3 and 10-8 as well as in those containing no parasites (none). The
wells containing culture at 10-2 possessed too many plaques to confidently discern dis-
crete plaques. Total plaque numbers across replicate wells were: 2,034 (10-3), 245 (10-4),
26 (10-5), 4 (10-6), and 0 plaques (10-7 and 10-8). No plaques were detected in wells con-
taining cultures lacking parasites (none). A plot of the observed plaque frequency against
dilution (blue) from the experiment is shown alongside a plot of the plaque frequencies
expected if there is a linear inverse correlation between mean plaque number and di-
lution (red). Linear regression by analysis of covariance (ANCOVA) indicated a strong
linear inverse correlation between dilution and observed mean plaque density in the wells
containing the 10-3-10-6 dilutions. These are not significantly different from the expected
values. Values of the statistical data (R2, F statistic, number of degrees of freedom (d.f.)
and p-value) are shown.
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Figure 4.3: Replicate experiments demonstrate that plaque frequency correlates
linearly with parasite number. Depicted are plaque assay data from two independent
experiments (A and B) carried out on different days in which, similarly to the experiment
depicted in Figure 4.2, a parasite culture was serially diluted (2-fold) across a microplate.
Plaques were enumerated at 14 days. Plots of the observed plaque frequency against
dilution (blue) are shown alongside a plot of the plaque frequencies expected if there is
a linear inverse correlation between plaque number and dilution (red). Linear regression
by analysis of covariance (ANCOVA) indicated strong linear inverse correlations between
dilution and observed mean plaque densities in both cases. These are not significantly
different from the expected values. Values of the statistical data (R2, F statistic, number
of degrees of freedom (d.f.) and p-value) are shown.
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Figure 4.4: Optimisation of culture haematocrit for plaque formation. Microplate wells
containing cultures at ∼0.00004% parasitaemia at the indicated haematocrits, imaged on
day 15. Whilst plaque formation was easily detected in the 0.75% haematocrit wells, they
were much more difficult to detect at 1% haematocrit, whilst at lower haematocrit values
the plaques were typically more diffuse and signs of erythrocyte lysis were observed.
Inset, zoomed region of the 0.75% haematocrit erythrocyte layer, showing the discrete
nature of the plaques.
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4.2 EachP. falciparum infected erythrocyte in the starting pop-
ulation forms one plaque.
During parasite growth under static conditions in a microplate well it is possible that dif-
fusive movement of free merozoites, or even infected erythrocytes, might result in the
formation of multiple plaques from a single parental infected cell. To investigate whether
this is the case, or whether each infected cell results in only one plaque, a synchronous
ring-stage culture was diluted into a suspension of fresh erythrocytes at 0.75% haema-
tocrit to obtain a theoretical density of <5 infected erythrocytes per ml of culture. This
culture was then dispensed into the central 60 wells of four microplates (200 µl per well,
240 wells total), and the plaques per well were enumerated 15 days later. If the para-
sitised cells assort randomly, and if each infected erythrocyte results in a single discreet
plaque, the distribution of plaques across the wells should follow Poisson statistics. The
experimentally determined frequency of plaques per well was compared to the theoretical,
expected frequency, according to a Poisson distribution with the same mean frequency
of plaques per well (0.388) as observed in this experiment (Figure 4.5). A Χ2 goodness-
of-fit test showed that the observed and expected distributions of plaque frequency were
not significantly different from each other (see Figure 4.5). Similar data were obtained
from three additional, independent experiments, with widely varying mean frequencies of
plaques per well (Figure 4.6); in every case the observed frequency closely matched the
expected frequency of plaques per well. Chi-squared tests showed that the observed and
expected distributions were not significantly different from each other.
Together with the observation that plaque number correlates linearly with parasite di-
lution, these results convincingly confirmed that, at least under limiting dilution conditions
where plaque number can be accurately determined, each plaque usually derives from a
single precursor parasite infected erythrocyte, and that multiple plaques do not frequently
arise from a single infected erythrocyte.
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Figure 4.5: The experimentally observed frequency distribution of plaques per well
follows a Poisson distribution. A parasite culture was dispensed into the central 60
wells of four microplates at a limiting dilution. Plaques were enumerated at 14 days.
The experimentally determined mean number of plaques per well (λ) was 0.388. Ex-
perimentally observed plaque frequency values are shown (blue) alongside the expected
frequency values of a Poisson distribution with a mean of 0.388 (red). A Χ2 goodness-
of-fit test showed no significant deviation of the observed distribution from the expected
distribution. Χ2 value, number of degrees of freedom (d.f.) and p-value are indicated.
For the purpose of statistical analysis, the 3 plaques/well category was pooled with the 2
plaques/well category as the expected frequency value for 3 plaques per well (2), is less
than 5. This is to avoid skewing the analysis with large percentage differences that occur
by chance between small numbers.
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Figure 4.6: Replicate experiments confirm that the experimentally observed fre-
quency distributions of plaques per well follows a Poisson distribution. Depicted are
data from three independent experiments (A, B and C) carried out as in Figure 4.5 on dif-
ferent days in which a parasite culture was dispensed into microplates. Plaques were enu-
merated at 14 days and mean number of plaques per well (λ) calculated. Experimentally
observed plaque frequency values are shown (blue) alongside the expected frequency
values of Poisson distributions with the same mean (red). Chi-squared goodness-of-fit
tests showed no significant deviation of observed distributions from the expected distribu-
tions. Χ2 values, degrees of freedom (d.f.) and p-values are indicated in each case. Note
that for the purpose of statistical analysis, those categories where expected frequency
values were less than 5 were pooled to create a single category in order not to skew the
analysis with large percentage differences that occur by chance between small numbers.
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4.3 Use of the plaque assay for phenotypic analysis of a replication-
defective P. falciparum mutant.
To explore the broader utility of the plaque assay it was applied to the phenotypic char-
acterisation of a genetically modified clone of P. falciparum known to display a partially
defined growth defect. Plasmodium merozoites are uniformly coated in the GPI-anchored
protein MSP1. It has been shown previously that conditional genetic truncation of the
MSP1 gene in P. falciparum, such that the C-terminal membrane anchoring domain is re-
moved, results in merozoites lacking surface-bound MSP1 [S. Das et al. 2015]. These
mutant parasite egress inefficiently from the host erythrocyte, which results in a replica-
tion defect under static growth conditions in vitro. The replication rate of parasites lacking
surface-bound MSP1 was reduced more than two-fold compared to control parasites [S.
Das et al. 2015]. It was predicted that this growth defect should manifest in the plaque
assay as a reduction in the number as well as size of plaques. To test this hypothesis, a
culture of highly synchronous ring-stage P. falciparum MSP1:loxPint parasites [S. Das et
al. 2015; Jones et al. 2016] which possess a floxed 3' portion of the MSP1 gene, and con-
stitutively express the DiCre fragments [C. R. Collins, S. Das, et al. 2013], was divided into
two and mock-treated or RAP-treated (to induce DiCre mediated gene excision and thus
disruption of MSP1 function). These cultures were then diluted identically to a theoretical
density of ∼75 parasitised erythrocytes per ml (15 parasites per well, 0.75 haematocrit)
and dispensed into microplate wells. The resulting plaques were documented and quan-
tified 14 days later with the pixel area of individual plaques determined using the Magic
Wand tool of Adobe Photoshop CS5. Plaques that formed in RAP-treated cultures were
smaller and approximately five times less numerous (mean plaque area (pixels) = 199.3,
SD = 9.2, n = 54) than those in the mock-treated cultures (mean plaque area (pixels) =
329.1, s.d. = 6.7, n = 205) with a two-tailed independent t-test revealing this difference
to be highly significant (t = 9.290, d.f. = 257, p<0.0001) (Figure 4.7). The differences in
mean plaque area values indicate a fitness defect associated with truncation of MSP1,
consistent with the previously observed ∼2-fold slower replication rate displayed by RAP-
treated MSP1:loxPint parasites, compared to mock-treated controls in standard parasite
replication assays [S. Das et al. 2015]. These results showed that the plaque assay can
be used as a simple means of assaying and characterising even rather subtle effects on
parasite fitness resulting from mutagenesis.
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Figure 4.7: Phenotypic characterisation of a replication-defective MSP1 mutant us-
ing the plaque assay. Scatter plots showing the distribution of plaque areas (pixels)
obtained following mock- or RAP-treatment of MSP1:loxPint parasites. Plaque numbers
were n = 205 for mock-treated samples and n = 54 for RAP-treated samples. Plaque ar-
eas were quantified using the Magic Wand tool of Photoshop CS5 (Adobe). Horizontal
bars indicate mean plaque area ±1 standard deviation
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4.4 Rapid phenotypic analysis of a conditional lethalPlasmod-
ium falciparum mutant.
To further examine the utility of the plaque assay it was used to characterise the replication
defect of another P. falciparum mutant deriving from work presented in this thesis. As pre-
sented in Chapter 5, a transgenic clone of P. falciparum was produced called SERA6:loxP
in which the entire SERA6 open reading frame and promoter region were flanked by loxP
sites. As is presented in Section 5.3, RAP-mediated excision of the SERA6 gene results
in a lethal phenotype. It was predicted that this should result in a significant decrease
in plaque formation. A highly synchronous ring-stage culture was divided into two and
mock- or RAP-treated as described in Section 5.3. The cultures were then diluted equiv-
alently to a theoretical density of ∼75 parasites per ml (15 parasites per well) in a 0.75%
haematocrit erythrocyte suspension, dispensed into microplates and plaques quantified
14 days later. The results showed that RAP-mediated SERA6 gene disruption resulted
in a substantial reduction in plaques compared to mock-treated samples (Figure 5.10);
only a single plaque was seen following RAP-treatment. Whilst RAP-mediated excision
in the P. falciparum DiCre system is highly regulated and efficient, it is rarely complete
[S. Das et al. 2015; C. R. Collins, S. Das, et al. 2013]. This results in heterogeneity in
the RAP-treated population, with a small proportion of parasites failing to undergo exci-
sion following RAP-treatment. It was therefore predicted that the single plaque that was
observed in the RAP-treated culture was produced by a non-excised parasite. To test
this hypothesis parasites recovered from the plaque-positive well were expanded in cul-
ture and analysed by diagnostic PCR (see Section 5.3.2). This demonstrated that, as
predicted, these parasites possessed an intact, non-excised SERA6 locus (Figure 5.13).
The use of the plaque assay therefore allowed the visualisation of parasite fitness at the
level of individual parasites. This has allowed an unambiguous assessment of the essen-
tiality of SERA6 which would not be possible if assays could only be performed on mixed
populations containing both excised and non-excised parasites.
4.5 The culture-adapted P. knowlesi clone A1.H1 produces ir-
regularly shaped and indistinct plaques.
Until recently it has only been possible to culture P. knowlesi in vitro using cynomolgus
macaque erythrocytes which, given the difficulty in obtaining a regular supply of cynomol-
gus blood, precludes most laboratories from culturing P. knowlesi. The A1.H1 strain of
P. knowlesi has recently been adapted to grow in human erythrocytes in vitro [Moon, J.
Hall, et al. 2013]. To determine whether the plaque assay is applicable to examining the
growth of P. knowlesi in vitro, as has been demonstrated for P. falciparum, a culture of P.
knowlesi A1.H1 clone (∼5% parasitaemia, 0.75% haematocrit) was serially diluted (10-
fold) into erythrocyte suspensions across a microplate. Microplates wells were examined
for plaques every day between 12 and 20 days after dispensation into plates, without
changes of culture medium. Plaque formation was observed, correlating linearly with di-
lution. However these plaques lacked clarity compared to those resulting from growth of
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P. falciparum (Figure 4.8). They were also noticeably less round and regular in shape
making assessment of number more difficult.
Figure 4.8: P. knowlesi asexual blood stage cultures form plaques that lack clar-
ity and regularity compared to those in cultures of P. falciparum. A) a culture of
P. knowlesi A1.H1 clone (∼5% parasitaemia, 0.75% haematocrit) was serially diluted
(10-fold) a across a microplate. Depicted are wells of culture at the indicated dilutions.
Scanned images were taken 20 days after dispensing of culture. Inset, zoomed region of
a well showing 4 plaques. Only the green channel has been depicted for maximum clarity,
and brightness and contrast have been significantly altered for the purposes of depiction.
89
4.6 Conclusions
There has long been a need for a simple and robust plaque assay suitable for use with
P. falciparum. Here such as system has been developed, using the simple approach of
culturing the parasite under static, limiting dilution conditions in human erythrocytes in flat-
bottomed microplates. Visualisation of plaque formation was haematocrit-dependent, but
it was found that plaques were easily detectable within ∼2 weeks under optimised condi-
tions (0.75% haematocrit). This method with a thicker layer of erythrocytes likely allows
productive parasite proliferation and plaque growth in 3 dimensions, as opposed to the
two-dimensional plaque expansion allowed by the adherent erythrocyte monolayers used
in previously-described P. falciparum plaque assays [Bruce et al. 1990; Inselburg 1983;
Williams 1999]. The plaques, which presumably consist predominantly of haemoglobin-
free erythrocyte ghosts, cell debris and haemozoin pigment, are completely stable under
conditions of regular manual plate transferral to and from incubators, even without the
use of semi-solid medium, probably because the small volumes and surface areas of the
liquid columns in each microplate well limit liquid movement and consequent disturbance
of the erythrocyte layer. Use of larger wells or flasks would probably destabilise plaques,
which may explain why the formation of these structures has not previously been de-
scribed. Plaque integrity and stability was further ensured in the assay by not replacing
the medium during the 2-3 week period of the assay. Although this may have the ef-
fect of limiting parasite growth rates, it was found that up to a plaque density of at least
340 plaques per well, plaque frequency correlated with starting parasite density, implying
that, at least within this parasitaemia range, plaque formation is not adversely affected
by plaque density. Plaques produced by clonal parasite populations were not completely
homogeneous in size or shape, but this is a feature of many plaques, including those
produced by Toxoplasma. The P. falciparum plaques are easily visible using an inverted
light microscope and, similar to viral plaques [Sullivan et al. 2012], can be rapidly imaged
with minimal disturbance using an inexpensive, commercially available document scanner,
avoiding the need for laborious photographic imaging of individual wells. Indeed, using
a high resolution (4,800 dpi) flat-bed scanner in transmission light mode, it was possible
to scan and document up to 3 plates simultaneously in a single TIFF image, allowing for
rapid documentation of multiple plates. The availability, low cost and lack of user training
required to use a flat-bed scanner makes this a highly accessible, medium-throughput
means of documenting the results of assays.
The P. falciparum plaque assay has important advantages compared to those com-
monly used for viruses and other intracellular pathogens such as Toxoplasma. Mature
erythrocytes do not replicate, so there is no need to take into account changes in host
cell confluency over the course of the assay. Furthermore, there is no requirement to fix
and stain the cells before plaque analysis. The ability to easily visualise parasite clonal
growth has other advantages. The plaque assay is now regularly used in the laboratories
of Michael Blackman, Moritz Treeck and Edgar Deu for rapid limiting dilution cloning of P.
falciparum lines without the need for laborious determination of starting parasitaemia val-
ues, simply by performing serial dilutions of a parasite culture across a plate then picking
clones only from those wells that contain a single plaque. It is important to transfer these
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clones from the plaque assay plates into cultures containing fresh erythrocytes before the
plaque assay cultures begin to undergo generalised erythrocyte lysis, which was found
usually occurs between 16-21 days after initiating the plaque assay.
Reverse genetic technologies have become increasingly important in malarial research
over the past two decades. With the relatively recent introduction of Cas9-mediated mu-
tagenesis [Wagner et al. 2013; Ghorbal et al. 2014] and conditional gene modification
technologies in P. falciparum discussed in Section 1.11 the development of simple as-
says such as that described here is particularly timely. The plaque assay has multiple
applications; it can be used to rapidly phenotype genetic mutants without the need for
complex equipment or facilities (e.g. flow cytometry), but it will also be invaluable for the
calculation of kill-curves with anti-parasite drugs and antibodies, for the selection of drug-
resistant or fast-growing mutants, for facile comparison of parasite fitness under a range
of growth conditions (e.g. in different defined media) and numerous other uses. Differ-
ences in parasite growth rate are determined over the course of the 4-7 cycles required to
produce visible plaques, providing some advantages over traditional growth assays in that
the cultures do not need to be passaged or fed. Importantly, the assay complements other
widely used approaches for quantification of parasite growth, including light microscopy,
flow cytometry and assays based on expression of parasite proteins or enzymes [Makler
and Hinrichs 1993; Noedl, Wernsdorfer, et al. 2002], incorporation of fluorescent dyes
[Ndiaye et al. 2010; J. D. Johnson et al. 2007] or radioactive hypoxanthine [Desjardins
et al. 1979]. Although not explored here, the assay may be suitable for scaling up to high
throughput image based screens using high content microscopy. Indeed, colleagues in
the laboratories of Edgar Deu, and Moritz Treeck now routinely use independently devel-
oped Fiji based semi-automated methods of plaque counting to increase the throughput
of plaque assay analysis (personal communication, Sophie Ridewood and Hugo Belda).
The plaque assay may be applicable to the study of other Plasmodium species that
can be cultivated in vitro. Adaptations to the protocol by Robert Moon and colleagues
have already achieved significant improvements on the results shown here for detection of
plaques formed in cultures of P. knowlesi (personal communication Robert Moon). It was
found that gently aspirating half of the culture medium in each well (100 µl) and replacing
it with fresh medium regularly (every 3 days) significantly improved the clarity of plaques
compared to when medium was unchanged (as was performed in the study presented
here) despite resulting in some disturbance to some areas of the erythrocyte layers. The
improvement in plaque clarity that results from medium changes is likely due to enhanced
parasite replication rates. P. knowlesi appears to be more sensitive to toxic components
of the culture medium that result from nutrient degradation compared to parasite clones
derived from P. falciparum 3D7 clone (personal communication, Robert Moon). One such
source of toxic components is L-glutamine, an essential amino acid present in many culture
medium formulations. It is important for parasite growth but its instability at physiological
pH causes it to breakdown to form pyroglutamate and ammonium, the latter of which is
toxic. The extended period that P. falciparum 3D7 clone has been cultured in vitro (years,
or even decades in some cases) (personal communication Christine Collins) has likely
resulted in it becoming highly adapted to such conditions of in vitro culture, compared to
the P. knowlesi A1.H1 clone which was culture adapted only recently. It is possible that, in
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the P. knowlesi assays performed in the study presented here, parasite replication rates
declined over the course of the assay as a result of toxin accumulation. No attempt was
made to recover and expand parasite cultures from the wells, or to examine them for the
presence of live parasites by Giemsa stained thin smear and so it is possible that the
parasites may have died completely by the end of the assay. The use of glutaMAX, a
stabilised form of L-glutamine, could help reduce or even eliminate the need for medium
changes when performing plaque assay analysis on P. knowlesi. Even with the improve-
ments achieved in plaque clarity, P. knowlesi plaques appear to still be irregular in shape
(personal communication Rob Moon). This may result from the well documented greater
extracellular motility and longevity of free P. knowlesi merozoites [Bannister et al. 1975;
J. Johnson et al. 1980] which may allow dispersal of released merozoites over greater
distances within the wells than occurs with P. falciparum, and consequently a less con-
strained plaque perimeter.
One shortcoming of the plaque assay seems to be its relatively low dynamic range
or ‘sensitivity’ in measuring parasite growth. As has been demonstrated [S. Das et al.
2015], RAP-induced disruption of the MSP1 gene of MSP1:loxPint clone parasites results
in an approximately 2-fold slower replication rate. In the plaque assay performed in this
study this defect manifested as an approximately five-fold reduction in plaque number. As
such the plaque assay might be said to be relatively insensitive in reporting the growth
of all parasites; presumably, stochastically, some grow too slowly over the course of a
plaque assay to visualise plaques such that the readout from the plaque assay ‘over-
exaggerates’ the growth defect. For detailed phenotypic analyses, the plaque assay is
therefore unlikely to replace standard flow cytometry-based replication assays. However,
it will complement such approaches. Given the ease with which it can be performed, the
low degree of expertise required and the lack of any requirement for expensive equipment,
the plaque assay will likely prove a valuable addition to the experimental tools available
for studying this important pathogen, especially at a time when CRISPR/Cas and Cre
recombinase technologies are changing the scope of questions can be addressed with
regards to Plasmodium biology.
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Chapter 5
Results II: SUB1 and SERA6 are
members of an essential proteolytic
cascade that regulates blood stage
egress.
As outlined in the Introduction, SUB1 and SERA6 are hypothesised to play roles in egress
during the asexual blood stage cycle of P. falciparum. Several previous studies have led
to the hypothesis that SUB1 acts as a central regulator of egress, cleaving various sub-
strates in the PV following its release from exonemes shortly before egress. SUB1 has
been proposed to both prime merozoites for invasion by cleaving MSP1 on the mero-
zoite surface and achieve their release from the erythrocyte [Yeoh et al. 2007; Koussis
et al. 2009]. One of the substrates of SUB1 is the putative papain like cysteine protease
SERA6, and previous work has suggested that its cleavage activates a proteolytic function
[Ruecker2012a,]. The timing of this makes involvement of SERA6 in egress or invasion
likely. In this chapter the work conducted during this PhD project that adds to our under-
standing of SUB1 and SERA6 function, as well as egress more generally, will be outlined.
Work presented in this chapter has recently been published in combination with work of
Michele Ser Ying Tan as an advanced online publication in Nature Microbiology (DOI:
10.1038/s41564-018-0111-0).
5.1 DiCre mediated excision of crucial catalytic residues of
SUB1 or the entire SERA6 coding region results in effi-
cient silencing of gene expression.
All previous attempts to disrupt the SUB1 [Yeoh et al. 2007] and SERA6 [S. K. Miller et al.
2002; McCoubrie et al. 2007] genes in P. falciparum by integration of episomal constructs
by single crossover homologous recombination have proved unsuccessful, suggesting
that both are essential for the viability of the asexual blood stage cycle in vitro. This
approach does not definitively confirm essentiality of a gene however, which requires a
conditional system of disruption. With the advent of the DiCre system there existed an
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opportunity to disrupt both of these genes for the first time, using a conditional system, to
investigate their roles and unambiguously determine their essentiality. Indeed, a recent
study has demonstrated that SERA5, which could not be disrupted by a non-conditional
approach, is in fact not essential when this conditional system is used [C. R. Collins,
Hackett, et al. 2017].
To this end, the DiCre system was used to conditionally excise a portion of the SUB1
gene encoding crucial catalytic residues (Figure 5.1), or the entire SERA6 coding se-
quence and promoter (Figure 5.2). To achieve this, loxP sites were introduced into the
loci in the 1G5DC clone [C. R. Collins, S. Das, et al. 2013] through single crossover ho-
mologous recombination of episomal constructs. In the case of SUB1, a loxP containing
heterologous intron (loxPint) [Jones et al. 2016; S. Das et al. 2015] was inserted within the
catalytic domain, as well as a loxP site downstream of the stop codon, such that a portion
of the catalytic domain including the active site nucleophile Ser606 and the oxyanion hole
residue Asn520 were flanked with loxP sites (‘floxed’) (Figure 5.4). In the process, SUB1
was fused to a C-terminal triple HA tag and the endogenous SUB1 3' UTR was replaced
with the PbDT 3'UTR to regulate gene expression. RAP-induced excision of the sequence
between the loxP sites was therefore expected to truncate the catalytic domain which in
turn was expected to ablate SUB1 protease activity. In the case of SERA6, a single loxP
site already existed on chromosome 2, upstream of SERA6 (immediately downstream of
the SERA5 stop codon), in the 1G5DC clone such that integration of a single loxP site
downstream of the SERA6 stop codon, was sufficient to flox the entire gene (Figure 5.5).
Again, the endogenous 3' UTR was replaced with the PbDT 3' UTR.
The integration constructs pHH1_SUB1HA3_loxP and pHH1_SERA6_loxP, for floxing
of the SUB1 and SERA6 genes respectively, were transfected into 1G5DC clone para-
sites and ‘drug cycling’ of cultures performed to enrich for parasites in which integration
into the chromosome had occurred. Following three rounds of drug cycling parasite clones
were obtained by serial dilution for each gene knockout. The SUB1 conditional knockout
clones were called SUB1HA3:loxP clone 3E4 and 5E11, whilst the SERA6 conditional
knockout clones were called SERA6:loxP clone C4 and D2. Following isolation of these
clones gDNA was extracted from cultures and PCR analysis performed to confirm inte-
gration of the pHH1_SUB1HA3_loxP (Figure 5.1) and pHH1_SERA6_loxP (Figure 5.2)
constructs. The presence of the DiCre expression cassette was also confirmed by PCR
analysis in each of the four clones (Figure 5.3) as this locus is liable to revert to a wild-type
locus in the 1G5DC clone resulting in loss of expression of the DiCre fragments (personal
communication Christine Collins and Sujaan Das).
To determine whether silencing of SUB1 expression could be achieved following RAP-
induced excision, synchronised ring-stage SUB1HA3:loxP clone 3E4 and clone 5E11 par-
asites (<14 h old) were mock- or RAP-treated for 4 h before being washed and cultured
as standard. PCR analysis of gDNA extracted from mature parasites (∼48 h old) demon-
strated that highly efficient excision had taken place at the SUB1 locus (Figure 5.6). West-
ern blots of SDS-PAGE fractionated protein lysates (collected in parallel with gDNA sam-
ples) were probed with the α-HA monoclonal antibody (mAb) 3F10. The almost complete
lack of western blot signal demonstrated that the excision of the SUB1 locus had resulted
in silencing of expression of full length SUB1by 48 h (Figure 5.6). Analysis of blots with
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an α-SUB1 polyclonal rabbit serum [Withers-Martinez, Saldanha, et al. 2002] corrobo-
rated this. This antibody revealed a weak ∼75 kDa band (full length SUB1 is 82 kDa) that
likely corresponds to a product expressed from the truncated SUB1 gene that fails to fold
properly, preventing the co-translational auto-proteolytic processing that normally results
in the dominant processed form of SUB1 in mature schizonts [Sajid, Withers-Martinez,
and Blackman 2000]. Note that this p47 form often runs as an apparently larger species
on SDS PAGE gels. IFA analysis of mock- and RAP-treated 3E4 clone parasites using
mAb 3F10 further confirmed the loss of SUB1 expression from the parasite population.
88.2% of mock-treated 3E4 clone schizonts (total of 493 mature schizonts examined) were
positive for the mAb 3F10 signal (Figure 5.6). In contrast, in samples of RAP-treated 3E4
clone parasites only 0.2% (10 out of 5,056) mature schizonts examined were positive for
3F10 staining. This suggests that the rate of excision following RAP-treatment in this clone
was approximately 99.8%.
SERA6:loxP clone C4 ring-stage parasites were mock- or RAP-treated and cultured
as standard. PCR analysis demonstrated excision of the SERA6 locus by the end of
this erythrocytic growth cycle (cycle 0, ∼48 h) (Figure 5.7). Interestingly, the SERA6 null
(ΔSERA6) parasites displayed no phenotype until ∼96 h post RAP-treatment (i.e. the end
of erythrocytic cycle 1) (see Section 5.7), so parasite culture was continued and gDNA was
extracted from ∼96 h old parasites. PCR performed on gDNA extracted at this later time
point (end of cycle 1) demonstrated that excision of the SERA6 locus was readily apparent
with little evidence of the non-excised locus. In addition to interrogating the chromosomal
architecture of the SERA6 locus following mock- or RAP-treatment, PCR was also used to
assess the presence of the circular DNA plasmid which is expected to be excised from the
chromosome following DiCre-mediated excision (Figure 5.5 and Figure 5.7). This revealed
that the excised plasmid is readily detectable at 48 h, but by 96 h it is almost undetectable
in the population (Figure 5.7). In D2 clone parasites excision of the SERA6 locus by PCR
was performed only at the end of cycle 1 (∼96 h old), following mock- or RAP-treatment
(Figure 5.7). Again, as is evident from the presence of a band corresponding to the excised
locus after RAP-treatment, efficient RAP-induced DiCre mediated excision of the SERA6
locus had occurred.
Southern blot analysis is often performed to confirm integration of episomal constructs
into the genome. Given that RAP treatment of SUB1HA3:loxP clones 3E4 and 5E11 and
SERA6:loxP clones C4 and D2 clearly resulted in loss of protein expression, as expected,
alongside the predicted PCR products, southern blot analysis was not deemed necessary
in this study. It is possible that PCR analysis that might not reveal some aberrant integra-
tion of episomal constructs. For example concatemerisation of episomal constructs might
occur followed by integration into the locus of interest as occurred in a study of AMA1
[Yap et al. 2014]. Was this to occur in the case of the SUB1 or SERA6 loci, RAP induced
excision would still excise the intervening DNA between the most extreme loxP sites such
that the chromosomal architectures of the SUB1 or SERA6 loci would be the same follow-
ing RAP treatment as if only a single copy of the plasmid had integrated - resulting in a
knockout. Furthermore Integration of the plasmids elsewhere into the genome for either
of the integration plasmids would not result in expression of the SUB1 or SERA6 genes
as the sequences in the episomal constructs are lacking the extreme 5' regions of the
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ORFs including the start codons and signal sequences. Again, the western blot analy-
sis and IFA confirm that expression, including with antibodies raised against the proteins
themselves, not just epitope tags, is lost following RAP-induced excision. The genetic
complementation outlined in Section 5.4 further confirms that the phenotypes that are ob-
served following loss of SUB1 or SERA6 expression presented herein result from loss of
these genes rather than any other alteration of the genome.
To examine SERA6 expression at the end of cycle 0 and cycle 1, western blots of
SDS-PAGE fractionated protein lysates from mock- and RAP-treated SERA6:loxP clone
C4 and clone D2 were probed with either an α-SERA6 mAb specific for the N-terminus of
the protein (3F12.1C9) or a rabbit serum raised against the SERA6 putative papain like
domain (S6C1). In both cases it was evident that SERA6 expression was silenced by the
end of cycle 1 (∼96 h old) (Figure 5.7). A faint band corresponding to full length SERA6
was detected at 48 h with the S6C1 rabbit serum, suggesting expression was severely di-
minished but not completely absent at this time point. This likely explains why the ΔSERA6
parasites were apparently phenotypically indistinguishable from control parasites until 96
h (see Section 5.7). The expression observed up to the end of cycle 0 likely results from
the excised plasmid which was shown to be present at 48 h and contains the SERA6 ORF
under control of its native promoter. Indeed it is well documented that continued expres-
sion of even low amounts of enzymes can be sufficient to sustain WT phenotypes due to
their extreme catalytic efficiencies [Me´thot et al. 2007; Methot et al. 2008]. The plasmid,
of which there is presumably only one copy per schizont at 48 h, as RAP-treatment was
performed on ring-stage parasites which possess only a single copy of the genome, is
presumably not replicated and acquired by no more than one daughter merozoite at the
end of cycle 0. Following proliferation of the population only a minority of parasites would
be predicted to possess this plasmid during cycle 1. It may also be lost due to instability
diminishing the number of parasites possessing this plasmid during cycle 1 still further.
To assess this possibility, IFA analysis was performed on SERA6:loxP clone C4 parasites
using both of the α-SERA6 antibodies, however a low signal to noise ratio made it difficult
to reliably determine whether individual parasites were positive or negative for staining.
As such the rate of excision could not be determined for the SERA6:loxP clones.
Together, these data clearly demonstrate that DiCre mediated gene excision of the
SUB1 and SERA6 loci occurs rapidly and efficiently following RAP-treatment and in the
vast majority of the transgenic parasite population. This resulted in silencing of SUB1 and
SERA6 expression by the ends of erythrocytic cycle 0 and cycle 1 respectively.
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Figure 5.1: Integration of episomal construct pHH1 SUB1HA3 loxP floxes a portion
of the SUB1 gene containing crucial catalytic residues. A) Schematic showing archi-
tecture of the SUB1 locus (chromosome 5) in P. falciparum 1G5DC clone prior to integra-
tion of construct pHH1 SUB1HA3 loxP and as expected following construct integration.
This construct is designed to integrate by single-crossover homologous recombination
and contains an artificial loxP site (arrowheads) containing intron (loxPint) within a re-
codonised portion of SUB1 (hatched) and a loxP site downstream of the SUB1 stop codon
such that integration will flox a portion of the gene containing crucial catalytic residues.
Following integration, a triple-HA tag (HA3) is fused to the C terminus of SUB1 (dark grey)
and the PbDT 3' UTR is placed downstream of SUB1 to regulate gene expression. Hu-
man DHFR (hDHFR) drug resistance marker is shown. Catalytic residues of SUB1 are
indicated (single letter amino acid code): Asp, D; His, H and Ser S. Oxyanion hole reside
is indicated: Asn, N. B) PCRs to detect endogenous SUB1 locus (Endog. locus) and
the locus following integration of construct pHH1 SUB1HA3 loxP (Integ. locus) in clones
3E4 and 5E11. The parental 1G5DC clone is included for comparison. Primers used for
diagnostic PCR to assess integration are shown (half-arrows) (see Table 3.1 for primer
sequences). The endogenous locus is expected to produce a product of 1440 bp, the
integrant locus is expected to produce a product of 1445 bp.
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Figure 5.2: Integration of construct pHH1 SERA6 loxP floxes the entire SERA6 ORF.
Schematic showing architecture of the SERA6 locus (chromosome 2) in P. falciparum
1G5DC clone prior to integration of construct pHH1 SERA6 loxP and as expected fol-
lowing construct integration. This construct is designed to integrate by single-crossover
homologous recombination and introduces a single loxP site (arrowhead) downstream of
the SERA6 stop codon such that integration will flox the entire SERA6 ORF given the prior
existence of a single loxP site upstream of SERA6 in the 1G5DC clone. Following inte-
gration the PbDT 3' UTR is placed downstream of SERA6 to regulate gene expression.
The upstream SERA5 gene, human DHFR (hDHFR) drug resistance marker and DiCre
expression cassette are shown. The recodonised portion of SERA6 is shown (hatched).
Predicted conserved catalytic triad residues of SERA6 are indicated (single letter amino
acid code); Cys, C; His, H; Asn, N. B) PCRs to detect endogenous SERA6 locus (Endog.
locus) and the locus following integration of construct pHH1 SERA6 loxP (Integ. locus) in
clones C4 and D2. The parental 1G5DC clone is included for comparison. A positive con-
trol is also included (Ctl). This control consisted of gDNA extracted from a P. falciparum
clone (‘clone 1’) which had the pHH1-SERA6chim plasmid integrated into the SERA6 lo-
cus, referred to in [Ruecker et al. 2012]. The pHH1-SERA6chim plasmid used the same
endogenous targeting and recodonised region of SERA6 as the pHH1 SERA6 loxP plas-
mid used in this study. Primers used for diagnostic PCR to assess integration are shown
(half-arrows) (see Table 3.1 for primer sequences). The endogenous locus is expected
to produce a product of 1125 bp, the integrant locus is expected to produce a product of
1923 bp.
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Figure 5.3: The DiCre cassette is present in clones SUB1HA3:loxP clones 3E4 and
5E11 and SERA6:loxP clones C4 and D2. A) Schematic showing architecture of the
DiCre locus (chromosome 2) in P. falciparum 1G5DC clone (non-revertant DiCre locus),
and following reversion of the locus to a wild-type locus (reverted locus). B) Left panel;
PCR analysis demonstrating the presence of the DiCre cassette in SUB1HA3:loxP clones
3E4 and 5E11 clones as well as the parental 1G5DC clone. Right panel; PCR analysis
showing the lack of DiCre cassette, i.e. wild-type locus, in 3D7 clone P. falciparum. C)
PCR analysis demonstrating the presence of the DiCre cassette in SERA6:loxP clones
C4 and D2 as well as the parental 1G5DC clone. Primers used for diagnostic PCR to
assess integration are shown (half-arrows) (see Table 3.1 and [C. R. Collins, S. Das, et
al. 2013] for primer sequences). Detection of the non-revertant DiCre locus with primers
8 and 10 was expected to produce a PCR product of 1914 bp. Detection of the reverted,
i.e. wild-type locus, with primers 8 and 9 was expected to produce a product of 1737 bp.
No product is expected from primers 8 and 9 from the non-revertant locus due to its size
(>10 kbp) under the PCR conditions used.
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Figure 5.4: Expected SUB1 locus architecture following RAP-induced excision in
SUB1HA3:loxP clones 3E4 and 5E11. Schematic showing architecture of the SUB1
locus (chromosome 5) in P. falciparum 1G5DC clone prior to integration of construct
pHH1 SUB1HA3 loxP, as expected following construct integration, and following DiCre-
mediated excision. This construct is designed to integrate by single-crossover homol-
ogous recombination and contains an artificial loxP site (arrowheads) containing intron
(loxPint) within a recodonised portion of SUB1 (hatched) and a loxP site downstream of
the SUB1 stop codon such that integration will flox a portion of the gene containing crucial
catalytic residues. Following integration, a triple-HA tag (HA3) is fused to the C terminus
of SUB1 (dark grey) and the PbDT 3' UTR is placed downstream of SUB1 to regulate gene
expression. Human DHFR (hDHFR) drug resistance marker is shown. Catalytic residues
of SUB1 are indicated (single letter amino acid code): Asp, D; His, H and Ser S. Oxyanion
hole reside is indicated: Asn, N. Primers used for diagnostic PCR to assess excision are
shown (half-arrows) (see Table 3.1 for primer sequences). The expected episome de-
riving from DiCre-mediated excision following RAP-treatment, which truncates the SUB1
gene and removes the HA3 tag, is shown.
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Figure 5.5: Expected SERA6 locus architecture following RAP-induced excision
in SERA6:loxP clones C4 and D2. Schematic showing architecture of the SERA6
locus (chromosome 2) in P. falciparum 1G5DC clone prior to integration of construct
pHH1 SERA6 loxP, as expected following construct integration and following DiCre-
mediated excision. This construct is designed to integrate by single-crossover homol-
ogous recombination and introduces a single loxP site (arrowhead) downstream of the
SERA6 stop codon such that integration will flox the entire SERA6 ORF given the prior
existence of a single loxP site upstream of SERA6 in the 1G5DC clone. Following inte-
gration the PbDT 3' UTR is placed downstream of SERA6 to regulate gene expression.
The upstream SERA5 gene, human DHFR (hDHFR) drug resistance marker and DiCre
expression cassette are shown. The recodonised portion of SERA6 is shown (hatched).
Predicted conserved catalytic triad residues of SERA6 are indicated (single letter amino
acid code); Cys, C; His, H; Asn, N. Primers used for diagnostic PCR to assess excision
are shown (half-arrows) (see Table 3.1 for primer sequences). The expected episome
deriving from DiCre-mediated excision following RAP-treatment, which excises the entire
SERA6 ORF and its native promoter is shown.
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Figure 5.6: RAP-treatment of SUB1HA3:loxP clones 3E4 and 5E11 results in rapid
and efficient truncation of theSUB1 and silencing of expression. A) Diagnostic PCRs
performed on gDNA extracted from mature schizonts at the end of cycle 0 (∼48h old)
confirm that rapid and efficient DiCre-mediated truncation of SUB1 occurs within a single
cycle following RAP-treatment. Primers are indicated (half arrows) (refer to Figure 5.4
and Table 3.1). B) western blots probed with α-HA mAb 3F10 or polyclonal rabbit α-SUB1
demonstrate silencing of SUB1 expression at the end of cycle 0, following RAP-treatment.
The faint∼75 kDa band detected by the rabbit α-SUB1 likely results from expression of the
truncated SUB1 gene. This product likely does not fold properly and therefore does not
undergo the co-translational auto-processing event that converts full length 82 kDa SUB1
to the ∼47 kDa species (this runs higher than expected on SDS PAGE gels and appears
as a ∼60 kDa band). As a control a blot was stripped and reprobed with with α-spectrin
mAb SB-SP1. C) Representative IFA images demonstrating loss of SUB1 expression
following RAP-treatment. In RAP-treated SUB1HA3:loxP clone 3E4 samples only 0.2%
of parasites were scored positive for the presence of the punctate mAb 3F10 α-HA staining
(10 positive parasites in 5,056 infected erythrocytes examined). In mock-treated samples
88.2% of parasites scored positive (435 positive parasites in 493 infected erythrocytes
examined). Parasites were co-stained with the 89.1 α-MSP1 mAb and DAPI (DNA stain).
102
Figure 5.7: RAP-treatment of SERA6:loxP clones C4 and D2 results in rapid and effi-
cient excision of SERA6 and silencing of expression. A) Diagnostic PCRs performed
on gDNA extracted from mature schizonts at the end of cycle 0 (∼48 h old) confirm rapid
and efficient DiCre-mediated excision of SERA6 following RAP-treatment of SERA6:loxP
clone C4 parasites. The same pattern was recapitulated by PCR on gDNA samples col-
lected at the end of cycle 1 (∼96 h old). PCR on these same gDNA samples demonstrated
that the episome which is expected to result from DiCre-mediated excision is detectable
at the end of cycle 0 but not at the end of cycle 1. PCRs on clone D2 parasites also
demonstrated efficient excision by the end of cycle 1 following RAP-treatment. Primers
are indicated (half arrows) (refer to Figure 5.5 and Table 3.1). B) Western blots probed
with α-SERA6 3F12.1C9 mAb and S6C1 α-SERA6 rabbit polyclonal serum demonstrate
almost complete loss of SERA6 expression by the end of cycle 0 and no discernible ex-
pression by the end of cycle 1 following RAP-treatment. Western blots of protein lysates
from clone D2 probed with 3F12.1C9 mAb demonstrated complete loss of protein expres-
sion by the end of cycle 1. Loading control blots probed with α-spectrin SB-SP1 mAb or
α-SERA5 polyclonal rabbit serum.
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5.2 Silencing of SUB1 expression ablates proteolytic process-
ing of known SUB1 substrates.
It has been well documented that a number of proteins resident in the PV, as well as on
the merozoite surface are proteolytically processed by SUB1 following its discharge from
exonemes into the PV lumen [Silmon de Monerri et al. 2011]. These include SERA5,
SERA6 and MSP1. In order to confirm that silencing of SUB1 expression results in the
expected loss of SUB1-mediated proteolytic processing of SERA5, SERA6 and MSP1,
protein extracts of mock- and RAP-treated SUB1HA3:loxP clone 3E4 parasites were ex-
amined for the presence of processed forms of these substrates. Mature mock- and RAP-
treated parasites were Percoll purified and incubated in the presence of the reversible
PKG inhibitor Compound 2 (C2) for ∼4-5h as standard. C2 was then washed off and the
parasites rapidly resuspended into Albumax II-free medium in the presence of fresh C2,
E64 in the absence of C2 (which arrests egress downstream of C2 arrest and does not
inhibit SUB1), or no drug. The parasites were then incubated for a further 30 min before
parasite pellets and culture supernatants were collected. SDS-PAGE fractionated protein
extracts of all three samples were then examined by western blot. This revealed that fol-
lowing wash-off of C2, either in the presence of E64 or no drug, the expected processing
events occurred normally for all substrates in the mock-treated samples (Figure 5.8 and
Figure 5.9). This was observed as a decrease in the intensity of each full-length band as
well as the appearance of smaller molecular weight bands. Interestingly, in the case of
SERA5, it was found that the majority of the processed p50 form was found in the cul-
ture supernatant, suggesting that it had ‘leaked’ from the parasitised cells. In contrast,
no, or little evidence of processing could be detected for any of the SUB1 substrates in
the RAP-treated samples. This confirmed that following silencing of SUB1 expression its
substrates remained unprocessed. This confirmed that the degree to which expression
of SUB1 was decreased in these clones was sufficient to ablate known SUB1 processes;
it also suggested that no redundancy of function exists i.e. these substrates cannot be
processed by other proteases. These data confirm that SUB1 process these substrates
within the parasite. Previous studies made use of recombinant protein or an inhibitor of
SUB1 that was not highly potent, which may not have reflected the reality of the situation
in the parasite. Together the data from this study, together with in vitro data from previous
studies, confirm the role of SUB1 in cleaving these substrates in the parasite.
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Figure 5.8: Silencing of SUB1 expression results in loss of processing of the SUB1
substrates SERA5, SERA6 and MSP1. Western blots of pelleted parasite material and
culture supernatants from mature Percoll-purified schizonts probed with α-SERA5 rabbit
polyclonal serum, α-SERA6 rabbit polyclonal serum S6C1 and the α-MSP1 mAb 89.1.
C2-arrested schizonts at the end of cycle 0 following mock-treatment (- RAP) or RAP-
treatment (+ RAP) were washed into Albumax II-free medium containing fresh C2, E64
in the absence of C2 (E64), or no drugs (n.d.). Cleaved forms that result from SUB1
processing in mock-treated cultures can be seen and are indicated by arrows. Processed
forms are not readily detectable in RAP-treated samples. The processed p50 form of
SERA5 had leaked from the parasitised cells into the culture supernatant following reversal
of C2 arrest in the absence of E64 or no drug. A control blot was probed with the α-spectrin
mAb SB-SP1.
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Figure 5.9: SUB1 processing of SERA5, SERA6 and MSP1. A schematic showing the
processing SUB1 mediated events of SERA5 [Stallmach et al. 2015], SERA6 [Ruecker
et al. 2012] and MSP1[S. Das et al. 2015] and the major products that result, as well as
the ’protease X’ mediated cleavage that occurs to SERA5. Intermediate products are not
represented. The products shown in red correspond to the major observable products
detected by western blot in Figure 5.8 and indicated with red arrows.
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5.3 SUB1 and SERA6 are essential for the viability of the asex-
ual blood stage cycle of P. falciparum in vitro.
5.3.1 Conditional silencing of SUB1 or SERA6 results in a severely dimin-
ished replication rate.
In order to assess whether SUB1 and SERA6 are essential for the viability of asexual
blood stage cycle parasites, standard flow-cytometry based replication assays were per-
formed on mock- and RAP-treated cultures of SUB1HA3:loxP clones 3E4 and 5E11 as
well as SERA6:loxP clones C4 and D2. In the case of clones 3E4 and 5E11, cultures
were diluted to the desired densities during cycle 0, the same cycle in which they were
mock/RAP-treated. It was previously discovered that RAP-treated SERA6:loxP clone C4
parasites proliferated at the end of cycle 0 as efficiently as those that were mock-treated;
parasitaemia counts (by examination of Giemsa stained thin films) of mock- and RAP-
treated cultures during cycle 1 were 10.6% and 10.4% respectively. As such clone C4 and
clone D2 cultures were established during cycle 1 for the purposes of the replication assay.
Parasitaemias were measured at the onset of the assay and over the ensuing two cycles
by flow cytometry. The results demonstrated dramatic reductions in parasite replication
rate resulting from RAP-mediated silencing of SUB1 or SERA6 expression (Figure 5.10).
The flow-cytometry based replication assay only assesses parasite replication over a
relatively short period. In order to assay viability over a longer period of time, mock- and
RAP-treated cultures of SUB1HA3:loxP clone 3E4 and SERA6:loxP clone C4 were pas-
saged for up to 20 days, such that parasitaemia never exceeded 5%. To evaluate the fate
of the excised parasites and the initially small fraction of co-existing non-excised parasites,
gDNA was periodically extracted from both mock- and RAP-treated cultures in parallel to
assess the prevalence of excised and non-excised loci by PCR. This revealed that in both
cases the initially minor populations of non-excised parasites gradually out-grew the ex-
cised (ΔSUB1 or ΔSERA6) parasites, which were undetectable by PCR by the end of
the assay (Figure 5.11). This qualitative approach confirmed the results of the short-term
replication assay in showing that disruption of the SUB1 or SERA6 genes results in se-
vere growth defects. Furthermore, it suggested that even over extended periods ΔSUB1
and ΔSERA6 parasites are unable to replicate productively. PCR product corresponding
to excised parasites persisted following RAP-treatment of both SUB1HA3:loxP clone 3E4
and SERA6:loxP clone C4 for up to 8 and 4 cycles respectively. This likely results from
excised DNA of dead parasites present in the culture supernatant. This is because the
precipitous decline in parasitaemia in the RAP-treated cultures meant the cultures could
not be passaged for some time. In contrast, in mock-treated cultures parasitaemia in-
creased exponentially as normal and cultures had to be passaged to avoid parasite death
due to nutrient starvation and toxic buildup. The excised DNA of dead parasites in the
RAP-treated culture likely remains in solution which can be detected by PCR. Eventually
the outgrowth of the initially minor population of non-excised parasites in the RAP-treated
culture allowed the passage of these cultures which would dilute this DNA such that PCR
product was no longer readily amplified from it.
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5.3.2 Examination of parasite growth by plaque assay demonstrates that
disruption of SUB1 or SERA6 abolishes parasite replication.
The flow-cytometry based replication assays presented above assess parasite replication
rate at the population level for only a few erythrocytic growth cycles. The use of diagnos-
tic PCR to assess the relative prevalence of non-excised and excised parasites was an
attempt to examine parasite growth over a longer period of time and to examine the geno-
types present in the population, given that DiCre mediated gene excision is never complete
and results in a genetically heterogeneous population containing some non-excised, ef-
fectively wild-type, parasites. This still only examines the population level however and is
by no means quantitative. To assess the impact of gene disruption on parasite viability at
the clonal level, parasite growth was examined using the plaque assay presented in Chap-
ter 4. This method assays the ability for individual parasite clones that are dispensed into
a microplate well to undergo successive rounds of invasion, replication and egress. The
readout of the plaque assay is the presence or absence of individual plaques which result
from single parasites. Combined with the fact that it is performed at close to limiting dilu-
tion, with parasitaemias never exceeding a level where they need passaging, the ability for
the original initiating parasite clones to proliferate is examined, in effect, in isolation from
other parasites. The plaque assay therefore overcomes the ambiguity which can result
from the previously presented methods that provide a readout at the population level. To
this end, cultures were diluted equivalently to densities of between 1-50 parasites per well
following mock- and RAP-treatment and dispensed into 96-well flat-bottomed microplates.
Plaques were quantified 14 days later. For each individual experiment the number of
plaques forming in wells containing RAP-treated culture was calculated as a percentage
of those forming in an equivalent number of wells containing mock-treated cultures: this
ratio was termed the relative plaque forming ability (RPFA). Dramatic reductions in RPFA
were seen as a result of RAP-mediated disruption of either SUB1 or SERA6. In the case
of SUB1HA3:loxP clone 3E4 the average RPFA of RAP-treated cultures was 2.6% (mean
= 2.6%, SD = 1.4, n = 2) (Figure 5.12). In other words, for every 100 plaques formed in
wells containing mock-treated culture only 2.6 plaques formed in an equivalent number
of wells containing RAP-treated culture. The same experiment performed on clone 5E11
revealed a similar effect, generating a RPFA value of 1.4% (mean = 1.4%, SD = 0.4, n =
2) (Figure 5.12). A number of wells containing single plaques produced by RAP-treated
clone 3E4, were expanded. gDNA was extracted from these cultures and analysed by
PCR. In all cases, evidence of the non-excised locus was detected by PCR (Figure 5.13).
The significant reductions in RPFA following RAP-treatment, along with this demonstra-
tion that only viable non-excised, i.e. effectively wild-type parasites, could be isolated,
provides further evidence that ΔSUB1 parasites are not viable in in vitro culture. Similar
results were obtained upon analysis of the ΔSERA6 phenotype. The RPFA of RAP-treated
SERA6:loxP clones C4 and D2 was found to be 0.6% (mean = 0.6, SD = 0.7, n = 2) and
0.8% (mean = 0.8, SD = 0.4, n = 2) respectively (Figure 5.12). Similarly, from a single
experiment performed on clone C4, a single well contained a single plaque following-RAP
treatment. This culture was expanded and gDNA extracted and analysed by PCR. This
revealed this parasite clone to be non-excised (Figure 5.13). Similarly therefore, dramatic
reductions in RPFA were seen following RAP-induced silencing of SERA6 expression and
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only non-excised parasites could be isolated. Together, the data from these various as-
says convincingly demonstrates that SUB1 and SERA6 are both essential for viability of
the asexual blood stage of P. falciparum in in vitro culture.
Figure 5.10: Silencing of SUB1 or SERA6 expression results in dramatic reductions
in parasite replication rates. Plots showing growth curves (parasitaemias counted by
flow-cytometry) of SUB1HA3:loxP clones 3E4 and 5E11 and SERA6:loxP clones C4 and
D2 following mock-treatment (-RAP) or RAP-treatment (+ RAP) of synchronous ring-stage
cultures. Cultures of clones 3E4 and 5E11 were established ∼24 h post treatment (cycle
0) and cultures of clones C4 and D2 were established ∼72 h post treatment (cycle 1) to
account for the delayed phenotype resulting from SERA6 disruption. Solid lines represent
mock-treated samples, dashed lines represent RAP-treated samples error bars indicate
mean ± 1 standard deviation from two replicate experiments performed using blood from
different donors.
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Figure 5.11: PCR analysis of passaged RAP-treated cultures demonstrates that
ΔSUB1 and ΔSERA6 parasites cannot proliferate. A) Diagnostic PCR analysis of para-
site gDNA extracted from mock- or RAP-treated cultures of SUB1HA3:loxP clone 3E4. Sig-
nals corresponding to PCR amplicons demonstrating the presence of the excised SUB1
locus become less intense with time, as PCR amplicons demonstrating presence of non-
excised locus appear and become more intense. Primers 1 and 2 were used for the de-
tection of excised and non-excised locus (refer to Figure 5.4, Figure 5.6 and Table 3.1). B)
Diagnostic PCR analysis of parasite gDNA extracted from mock- or RAP-treated cultures
of SERA6:loxP clone C4. Signals corresponding to PCR amplicons demonstrating the
presence of the excised SERA6 locus become less intense with time, as PCR amplicons
demonstrating presence of non-excised locus appear and become more intense. Sepa-
rate primer pairs are used to examine for non-excised and excised SERA6 loci: Excised
(E) primers 3 and 2; Non-excised (NE) primers 4 and 2 (refer to Figure 5.5, Figure 5.7 and
Table 3.1).
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Figure 5.12: Silencing of SUB1 or SERA6 results in dramatic reductions in relative
plaque forming ability. Plots showing RPFAs of SUB1HA3:loxP clones 3E4 and 5E11
and SERA6:loxP clones C4 and D2 following RAP-treatment. Cultures were mock- or
RAP-treated and dispensed into microplates at equivalent parasite densities. Plaques
were enumerated after 14 days of incubation and the RPFA of RAP-treated cultures was
calculated as the number of plaques forming in wells containing RAP-treated cultures as
a percentage of those formed in wells containing mock-treated cultures. Error bars show
± 1 standard deviation from two replicate experiments using blood from different donors.
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Figure 5.13: Genotyping of clones isolated following RAP-treatment of
SUB1HA3:loxP clone 3E4 and SERA6:loxP clone C4 reveals them to be non-
excised. A) Diagnostic PCR analysis examining the presence of excised or non-excised
loci of starting bulk cultures of mock- (- RAP) or RAP-treated (+ RAP) SUB1HA3:loxP
clone 3E4 prior to dispensing in microplate wells (left) and clones isolated from wells
containing RAP-treated culture following plaque assay (right). A single PCR detects both
excised and non-excised loci, primers used are indicated (half arrows) (refer to Figure 5.4,
Figure 5.6 and Table 3.1). No isolated RAP-treated clones were found to have undergone
excision corroborating the conclusion that SUB1 is essential and knockouts are not
viable. B) Diagnostic PCR analysis examining the presence of excised or non-excised
locus of starting bulk cultures of mock- (- RAP) or RAP-treated (+ RAP) SERA6:loxP
clone C4 prior to dispensing in microplates (left) and a single clone (called D8) isolated
from a well containing RAP-treated culture (right). Primers used are indicated (refer to
Figure 5.5, Figure 5.7 and Table 3.1). No isolated RAP-treated clones were excised
corroborating the conclusion that SERA6 is essential and knockouts cannot be isolated.
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5.4 Transgenic expression of wild-type copies ofSUB1 orSERA6
is able to complement the respective growth defects re-
sulting from disruption of the chromosomal copies of these
genes.
To confirm that loss of viability of ΔSUB1 and ΔSERA6 parasites results specifically from
silencing of these genes and not from unintended chromosomal alterations associated
with Cre recombinase activity, rescue of the growth defects was attempted by genetic com-
plementation. To do this, episomal constructs were designed for transgenic expression of
wild-type SUB1 in SUB1HA3:loxP clone 3E4 and WT SERA6 in SERA6:loxP clone C4.
Clones 3E4 and C4 were also transfected with identical constructs lacking the expression
cassettes for SUB1 or SERA6, referred to as ‘empty vectors’, as controls. Following trans-
fection of the episomal constructs and drug selection with blasticidin-S, disruption of the
chromosomal genes was induced by RAP-treatment and growth of the lines was assessed
by plaque assay. This demonstrated that a significant increase in RPFA was achieved in
RAP-treated lines harbouring the episomal wild-type genes, compared to RAP-treated
lines harbouring empty vectors. In the case of SUB1HA3:loxP clone 3E4 harbouring the
episomal WT SUB1 vector, the relative plaque forming ability was 13.5 (mean = 13.5, SD
= 1.0, n = 2) compared to an RPFA of only 2.8 (mean = 2.8, SD = 1.7, n = 2) for those
parasites harbouring the empty vector (Figure 5.14). An unpaired two-sample t-test con-
firmed this difference to be significant (t = 7.702, d.f. = 2, p = 0.0164). For clone C4
parasites harbouring the episomal WT SERA6 gene the figure was 88.1% (mean = 88.1,
SD = 6.3, n = 2) compared to an RPFA of only 0.4% (mean = 0.4, SD = 0.5, n = 2) for
those harbouring the empty control vector (Figure 5.15). An unpaired two-sample t-test
confirmed this difference to be significant (t = 19.65, d.f. = 2, p = 0.0026). In a similar
approach to that outlined in Section 5.3.2, for both clones, those wells which contained
RAP-treated culture and in which plaques were observed, were expanded and parasite
gDNA examined by PCR to assess the genotypes of these lines (they were not necessar-
ily clonal). It was found that in every case examined, parasite lines had undergone gene
excision as expected (Figure 5.16). For SUB1HA3:loxP clone 3E4 the complementing
episomal construct was detected by PCR using the same primers (Figure 5.16).
The isolation of parasite lines which had excised the chromosomal SUB1 or SERA6
genes but that possessed episomal gene copies acted as further evidence that expression
of these genes from episomal constructs was sufficient to rescue the otherwise lethal
defect resulting from chromosomal gene silencing. The complementation data confirmed
that the loss of viability seen from silencing of these genes is indeed due to loss of SUB1
or SERA6 expression and not unintended chromosomal changes that might occur upon
activation of Cre recombinase activity.
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Figure 5.14: Genetic complementation confirms SUB1 essentiality. SUB1HA3:loxP
clone 3E4 harbouring the WT SUB1 complementation construct (WT SUB1) displayed
a significant increase in RPFA following RAP-treatment (mean = 2.8%, SD = 1.7, n =
2) compared to clone 3E4 harbouring an empty control vector (Empty) (t=7.702, d.f.=2,
p=0.0164). Statistical significance was determined by unpaired two-tailed t-test: Empty vs
WT (mean = 13.5%, SD = 1.0, n = 2). Error bars show ± 1 standard deviation. Bars show
means of two repetitions in blood from different donors. Schematics of complementation
constructs are shown. The recodonised SUB1 gene is shown shaded grey/hashed, under
control of its native promoter.
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Figure 5.15: Genetic complementation confirms SERA6 essentiality, and an indis-
pensable enzymatic role for SERA6, as well as the requirement for SUB1-mediated
processing to activate SERA6 function. SERA6:loxP clone C4 parasites harbouring
the wild-type SERA6 complementation construct (WT SERA6) displayed a significant in-
crease in RPFA following RAP-treatment (mean = 88.1%, SD = 6.3, n = 2) compared to
clone C4 harbouring an empty control vector (Empty(SERA6)) (mean = 0.4%, SD = 0.5, n
= 2). The same clone harbouring a construct designed for episomal expression of a mutant
form of SERA6, possessing a Cys644Ala substitution, which is expected to ablate enzy-
matic activity, did not significantly restore the RPFA of parasites following RAP-treatment
(mean = 1.4%, SD = 0.9, n = 4). Similarly, a construct with an ‘uncleavable’ mutant of
SERA6 that cannot be proteolytically processed by SUB1, by virtue of di-leucine substitu-
tions in the P1 and P2 positions of the cleavage sites, fails to restore the RPFA of parasites
(mean = 6.3%, SD = 7, n = 4). Error bars show ± 1 standard deviation. Bars show means
of between two and four repetitions in blood from different donors. Statistical significance
was determined by two-tailed unpaired t-tests: Empty vs WT SERA6 (t = 19.65, d.f. = 2,
p = 0.0026); WT vs Cys644Ala (t = 30.96, d.f. = 4, p < 0.0001); WT vs Uncleavable (t =
13.8, d.f. = 4, p = 0.0002); Empty vs Cys644Ala (t = 1.557, d.f. = 4, p = 0.1944); Empty
vs Uncleavable (t = 1.136, d.f. = 4, p = 0.3195). Significance levels indicated: p < 0.001,
***; p ≤ 0.01, **; p ≤ 0.05, *. Schematics of complementation constructs are shown. The
SERA6 gene is shown shaded grey (recodonised portions are hashed) under control of
its native promoter.
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Figure 5.16: Genotyping of clones obtained following RAP-treatment confirms ge-
netic complementation. A) Diagnostic PCR analysis examining the presence of excised
or non-excised loci of clones isolated from wells containing RAP-treated SUB1HA3:loxP
clone 3E4 harbouring the WT SUB1 complementation vector. Primers used are indicated
(refer to Figure 5.4, Figure 5.6 and Table 3.1). B) Diagnostic PCR analysis examining
the presence of excised or non-excised locus of clones isolated from wells containing
RAP-treated SERA6:loxP clone C4 harbouring the WT SERA6 complementation vector.
In addition, a third PCR strategy was employed which is specific for the chromosomal
SERA6 gene, but not the complementing copy (which has a more extensive recodonised
portion). This confirmed that the chromosomal copy of SERA6 is not present. A schematic
is shown indicating difference in size of recodonised portions of the chromosomal SERA6
and the episomal WT complementing SERA6 (bottom). Primers used are indicated (refer
to Figure 5.5, Figure 5.7 and Table 3.1). In both A )and B) all isolated clones were excised
at the chromosomal loci.
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5.5 Failure to genetically complement ΔSERA6 parasites with
mutant forms of SERA6 demonstrates that SERA6 plays
an enzymatic role and that processing by SUB1 is required
for function.
Having established genetic complementation of ΔSERA6 parasites with an episomal copy
of WT SERA6, gene function was further interrogated by complementation with mutant
forms of SERA6. Previous work from the laboratory of Michael Blackman [Ruecker et al.
2012] has indicated that SERA6 Cys644 corresponds to the canonical active site nucle-
ophilic Cys residue required for catalytic activity of all papain-like cysteine proteases. The
same study produced evidence that SUB1-mediated processing of SERA6 is important
for parasite viability. To build on these data using the complementation system, a mutant
form of SERA6 which contained a Cys644Ala substitution (expected to ablate proteolytic
activity) as well as a form in which the SUB1 processing sites had been disrupted by
di-leucine substitutions in the P1 and P2 positions of the two cleavage sites (shown to
disrupt SUB1 cleavage [Yeoh et al. 2007]), were transfected into SERA6:loxP clone C4.
Plaque assays revealed that the RPFA of RAP-treated parasites harbouring the episomal
Cys644Ala mutant (mean = 1.4, SD = 0.9, n = 4) did not differ significantly from that of
similarly RAP-treated parasites harbouring the empty control vector (Figure 5.15) as de-
termined by two-tailed unpaired t-test (t = 1.557, d.f. = 4, p = 0.1944). This finding that
the Cys644Ala mutant cannot reverse the lethal growth defect resulting from disruption of
the chromosomal gene strongly suggests that SERA6 plays an essential enzymatic role in
maintaining viability of asexual blood stage parasites. In the case of parasites harbouring
the episomal uncleavable mutant of SERA6 the RPFA of RAP-treated parasites was also
found to be not significantly different from that of RAP-treated parasites harbouring the
empty control vector (mean = 6.3, SD = 7.0, n = 4) as determined by two-tailed unpaired
t-test (t = 1.136, d.f. = 4, p = 0.3195) (Figure 5.15). This is in accord with the model that
processing of SERA6 by SUB1 is required for SERA6 function. These data are consistent
with SERA6 playing a proteolytic role in the parasite, and being expressed as a zymogen
form which requires processing to activate this function.
5.6 SUB1 is required for rupture of the PVM and for all of the
morphological changes that occur downstream of PKG ac-
tivation.
Having established that SUB1 is clearly essential for parasite viability, the effect of SUB1
disruption specifically on egress was then assessed. Live time-lapse microscopy was
used to examine egress of mock- and RAP-treated SUB1HA3:loxP clone 3E4 parasites at
the end of the cycle in which they were treated (cycle 0). For this, mature Percoll enriched
schizonts were incubated in the presence of C2 for∼4.5-6 h, then washed, followed by im-
mediate examination by time-lapse DIC microscopy. The ΔSUB1 parasites were clearly
deficient in egress with no release of merozoites seen. Of particular interest, the PVM
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apparently did not rupture in ΔSUB1 parasites as determined by the lack of discernible
merozoites within the erythrocyte in the DIC imaging, (Figure 5.17) and rounding up was
also not observed. In fact, the phenotype exhibited was indiscernible from that produced
by continued inhibition of PKG by C2 (not shown). Conversely, in mock-treated parasites
there comes a point where merozoites suddenly become discernible at the same time that
rounding-up of the parasitised erythrocyte occurs prior to erythrocyte membrane rupture
and merozoite release (Figure 5.17). To quantify the defect, the percentage of parasites
in which PVM rupture was observed in mock- and RAP-treated cultures was scored for.
PVM rupture deemed to have occurred when individual merozoites became readily dis-
cernible. The raw percentage of PVM rupture events for each video was normalised, with
the highest percentage of PVM rupture from any single video within a single experiment
(invariably a mock-treated sample) being treated as 100%. This was to control for the
differences in parasite maturity, and therefore egress rate, between replicate experiments
conducted on different days, using different parasite samples. As shown in Figure 5.17,
normalised PVM rupture was significantly higher in mock-treated cultures (mean = 90.8%,
SD = 12.72, n = 5) than in RAP-treated cultures (mean = 4.1%, SD = 6.7, n = 5). An un-
paired two-sample t-test revealed this difference to be highly significant (t = 13.49, d.f. =
8, p < 0.0001). Similar time-lapse examination of a clone derived from RAP-treatment
of SUB1HA3:loxP clone 3E4 harbouring the WT SUB1 complementation construct which
was confirmed to be excised at the chromosomal SUB1 locus (see Section 5.4) revealed
that normal PVM rupture and egress had been restored to these parasites (Figure 5.18),
confirming the role of SUB1 as an effector of these morphological changes.
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Figure 5.17: Silencing of SUB1 expression ablates all the morphological changes
that follow PKG activation. Left-hand side, DIC images from time-lapse microscopy
of mature SUB1HA3:loxP clone 3E4 schizonts. Parasites were mock- (- RAP) or RAP-
treated (+ RAP) at ring-stage then Percoll purified at the end of cycle 0 and C2 arrested.
C2 arrest was reversed by washing of parasites to allow egress to proceed with para-
sites immediately examined microscopically for 30 min. Time from commencement of
microscopy is indicated. Scale bar, 10 µm. In mock-treated parasites merozoite release
is clearly discernible, in contrast to RAP-treated parasites which undergo none of the mor-
phological changes that are usually visible in time-lapse analysis, including rounding up,
PVM rupture which allows increased visibility and movement of merozoites, and final rup-
ture of the erythrocyte membrane to allow merozoite release. Right-hand side, quantifica-
tion revealed that significantly fewer RAP-treated parasites underwent PVM rupture (mean
= 4.1, SD = 6.7, n = 5) compared to mock-treated parasites (mean = 90.8, SD = 12.7, n
= 5). Data were collected from 5 videos each of mock- and RAP-treated parasites from
2 replicate experiments (total number of observed PVM rupture events in mock-treated
parasites, 226). Percentage PVM rupture of each replicate within a single experiment
was normalised with the replicate that demonstrated the greatest percentage egress in a
single experiment treated as 100%. Statistical significance was determined by two-tailed
unpaired t-test: -RAP vs +RAP (t=13.49, d.f.=8, p=0.0001). Error bars show ± 1 standard
deviation.
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Figure 5.18: Episomal expression of WT SUB1 restores normal PVM rupture and
merozoite release following disruption of the chromosomal SUB1 locus. Still images
from time-lapse DIC and fluorescence microscopic analysis of a clone harbouring the WT
SUB1 complementation vector, isolated after RAP-induced disruption of the chromosomal
gene in SUB1HA3:loxP clone 3E4 parasites. As can be seen, normal PVM rupture and
merozoite release occurs. Presence of the episomal construct is indicated by expression
of mCherry marker protein (red). Time from commencement of microscopic examination
is shown. Scale bar, 10 µm.
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5.7 SERA6 is not required for rupture of the PVM but is re-
quired for rupture of the erythrocyte membrane to achieve
merozoite release.
To assess the importance of SERA6 for schizont egress, live time-lapse microscopy was
used to examine the egress of SERA6:loxP clones C4 and D2 at the end of cycle 1 fol-
lowing mock- or RAP-treatment of synchronous ring-stage parasites. This revealed very
little merozoite release in the RAP-treated parasites, suggesting that SERA6 is required
for egress. In contrast to the ΔSUB1 parasites, however, the ΔSERA6 parasites were ob-
served to successfully undergo rounding up and PVM rupture, as evidenced by the change
in shape of the bounding erythrocyte membrane and increased visibility and motility of
merozoites (Figure 5.19). This was interpreted as demonstrating that SERA6 is required
specifically for erythrocyte membrane rupture. To quantify this effect, erythrocyte mem-
brane rupture and consequent merozoite release was scored and normalised in a similar
fashion as for PVM rupture following SUB1 disruption. This revealed that erythrocyte
membrane rupture and merozoite egress was significantly higher in mock-treated para-
sites (mean = 89.8%, SD = 13.5, n = 10) compared to RAP-treated parasites (mean =
1.0%, SD = 2.3, n = 10). An unpaired two-sample t-test confirmed this difference to be
highly significant (t = 20.5, d.f. = 18, p < 0.0001). Examination of a clone that was isolated
following the RAP-treatment of SERA6:loxP clone C4 harbouring the WT SERA6 comple-
mentation construct (confirmed to be excised at the chromosomal SERA6 locus) revealed
that normal egress had been restored to these parasites (Figure 5.20), confirming the role
of SERA6 in erythrocyte membrane rupture.
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Figure 5.19: Silencing of SERA6 expression prevents erythrocyte membrane rup-
ture. Left-hand side, DIC images from time-lapse microscopy of mature SERA6:loxP
clone schizonts. Parasites were mock- (- RAP) or RAP-treated (+ RAP) at ring-stage then
Percoll purified at the end of cycle 1 and C2 arrested. C2 arrest was reversed by wash-
ing to allow egress to proceed and parasites immediately examined microscopically for
30 min. Time from commencement of microscopy is indicated. Scale bar, 10 µm. In
mock-treated samples merozoite release is clearly discernible, in contrast to RAP-treated
parasites which undergo all of the usual morphological changes apart from erythrocyte
membrane rupture and merozoite release. Right-hand side, quantification of erythrocyte
membrane rupture and merozoite release revealed that significantly fewer RAP-treated
SERA6:loxP parasites underwent merozoite release (mean = 1.0, SD 2.3, n = 10) com-
pared to mock-treated parasites (mean = 89.8, SD = 13.5, n = 10). Data are collated from
10 videos each of mock- and RAP-treated parasites from 4 independent experiments (total
number of observed egress events in mock-treated parasites, 356). Percentage egress of
each replicate within a single experiment was normalised with the replicate that demon-
strated the greatest percentage egress in a single experiment (100%). Statistical signifi-
cance was determined by two-tailed unpaired t-test: -RAP vs +RAP (t = 20.46, d.f. = 18,
p < 0.0001). Error bars show ± 1 standard deviation.
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Figure 5.20: Episomal expression of WT SERA6 restores normal erythrocyte mem-
brane rupture and merozoite release following disruption of the chromosomal
SERA6 locus. Still images from time-lapse DIC and fluorescence microscopic analysis of
a clone harbouring the WT SERA6 complementation vector, isolated after RAP-induced
disruption of the chromosomal gene in SERA6:loxP clone C4. As can be seen, normal
merozoite release occurs. Presence of the episomal construct is indicated by expression
of mCherry marker protein (red). Time from commencement of microscopic examination
is shown. Scale bar, 10 µm.
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5.8 Fluorescent tagging of the PVM protein EXP1 confirms that
PVM rupture and erythrocyte membrane poration occur in
ΔSERA6, but not ΔSUB1 parasites.
The DIC imaging presented above provided insights into the physico-mechanical pro-
cesses that take place following disruption of SUB1 or SERA6. A particularly interesting
step in the egress pathway is that at which the intracellular merozoites suddenly become
more easily discernible (associated with loss of different interference contrast of the im-
ages) and mobile. In agreement with previous work from this group [C. R. Collins, Hack-
ett, et al. 2017] , this was observed to occur concomitantly with erythrocyte rounding-up
and was initially interpreted to represent the point at which the PVM ruptures, leaving
free merozoites bound only by the erythrocyte membrane. To unambiguously ascertain
whether PVM rupture occurs in ΔSERA6 but not ΔSUB1 schizonts, and whether this
change in DIC imaging indeed corresponds to PVM rupture, SUB1HA3:loxP clone 3E4
and SERA6:loxP clone C4 were transfected with an episomal construct designed to ex-
press the PVM resident protein EXP1, fused at the C-terminus to the fluorescent reporter
protein mCherry [Graewe et al. 2011]. Time-lapse microscopy of these lines in the pres-
ence of fluorescent wheat germ agglutinin which binds to glycoproteins on the exterior
surface of the erythrocyte membrane allowed discrimination of the two membranes by flu-
orescence microscopy. As described in the Introduction, shortly before erythrocyte mem-
brane rupture and merozoite release, the erythrocyte membrane becomes permeable.
This can be visualised using the F-actin binding peptide phalloidin, which binds the short
actin filaments that are integral to the erythrocyte cytoskeleton. It has been shown that
fluorescently labelled phalloidin is only able to traverse the erythrocyte membrane when
it becomes permeabilised. When it does so it binds to the F-actin in the cytoskeleton
producing a local high concentration of phalloidin around the internal periphery of the ery-
throcyte which can be visualised microscopically [Glushakova, Humphrey, et al. 2010].
Time-lapse combined DIC and fluorescent microscopic imaging of the EXP1:mCherry
tagged parasite lines in the presence of fluorescently labelled wheat germ agglutinin and
fluorescently labelled phalloidin clearly confirmed that rounding up, PVM rupture and ery-
throcyte membrane poration occurred normally in ΔSERA6 parasites as in mock-treated
control parasites, but that none of these events occurred in ΔSUB1 parasites (Figure 5.21).
This experiment demonstrated that erythrocyte membrane poration occurs only after PVM
rupture. Raising the possibility that the factor responsible for poration is released from the
PV lumen or PVM when the PVM ruptures. It also confirmed that the point at which mero-
zoites become readily discernible by DIC imaging is indeed the point at which PVM rupture
has occurred.
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5.9 Transmission and scanning electron microscopy confirm
that rounding up of the parasitised erythrocyte and PVM
rupture occurs following disruption of SERA6, but not fol-
lowing disruption of SUB1.
To corroborate the above findings, transmission and scanning electron microscopy (EM)
was used to examine the internal and external morphology of mock- and RAP-treated
SUB1HA3:loxP clone 3E4 and SERA6:loxP clone C4 schizonts. Transmission EM demon-
strated that the PVM of ΔSUB1 parasites was intact, as in C2 arrested parasites (Fig-
ure 5.22). Scanning EM demonstrated rounding up of ΔSERA6 parasites following C2
release (Figure 5.22). Transmission EM demonstrated PVM rupture had occurred in
ΔSERA6 parasites, mimicking E64 arrest following C2 wash-off (Figure 5.22). The single
bounding membrane that could be seen surrounding ΔSERA6 and E64 arrested para-
sites contained knob structures demonstrating it to be the erythrocyte membrane. These
findings corroborate what was seen by light microscopy, presented in Section 5.8.
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Figure 5.21: Rounding up, PVM rupture and erythrocyte membrane poration occur
normally in ΔSERA6 schizonts but not ΔSUB1 schizonts. Images from simultane-
ous time-lapse DIC and fluorescence microscopic examination of control (mock-treated
SERA6:loxP), ΔSUB1 and ΔSERA6 schizonts harbouring an episomal construct to ex-
press an EXP1:mCherry fusion to delineate the PVM. Schizonts were examined in the
presence of fluorescently labelled phalloidin, which indicates the point at which erythro-
cyte membrane poration occurs by binding to F-actin in the host cell cytoskeleton, and
wheat germ agglutinin (WGA) which binds to and delineates the outer surface of the ery-
throcyte membrane. Times following wash-off of the egress inhibitor C2 are shown. PVM
swelling and rupture as well as erythrocyte membrane poration occurs in ΔSERA6 par-
asites but not in ΔSUB1 parasites, whilst erythrocyte membrane rupture and merozoite
release occurs in neither mutant.
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Figure 5.22: Electron microscopy confirms that PVM rupture and morphological
changes associated with egress other than erythrocyte membrane rupture do oc-
cur in ΔSERA6 parasites but not in ΔSUB1parasites A) Transmission EM confirms that
ΔSUB1 parasites (ΔSUB1) are bound by an intact PVM. This is also the case with para-
sites in which egress is inhibited by C2 treatment (C2 arrested WT). Scale bar, 1 µm. B)
Scanning EM demonstrates that ΔSERA6 parasites have undergone rounding up follow-
ing wash-off of C2. Scale bar, 10 µm. C) Transmission EM confirms that PVM rupture,
as seen by the increased spacing of merozoites and the lack of an intact PVM occurs
in ΔSERA6 parasites (ΔSERA6) as in E64 arrested parasites (E64 arrested WT). Scan-
ning electron microscopy was carried out in collaboration with Gema Vizcay-Barrena in
the laboratory of Roland Fleck, and transmission electron microscopy was carried out in
collaboration with Victoria Hale, Claudine Bisson and Trishant Umrekar in the laboratory
of Helen Saibil.
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5.10 Surrogate markers of maturation reveal that ΔSUB1 and
ΔSERA6 parasites develop normally following PKG acti-
vation.
5.10.1 AMA1 discharge and re-localisation from micronemes to the mero-
zoite surface in ΔSUB1 parasites confirms that merozoites progress
normally following PKG activation despite not rupturing the PVM.
As presented, the phenotype of ΔSUB1 schizonts was indistinguishable from that ob-
served in C2 arrested schizonts, with no signs of rounding up or rupture of either bounding
membrane. To assess what cellular processes might be occurring in the ΔSUB1 parasites,
localisation of the micronemal protein AMA1 was examined by IFA following C2 wash off.
AMA1 is known to be rapidly discharged from micronemes onto the merozoite surface
following PKG activation [C. R. Collins, S. Das, et al. 2013], an event that is easily visu-
alised by IFA as the staining pattern transforms from a punctate (micronemal) signal to a
circumferential, merozoite surface pattern similar to that of the GPI-anchored merozoite
surface protein MSP1. Such a transformation was seen in ΔSUB1 parasites following re-
versal of C2 arrest by wash-off, indicating that microneme discharge occurred normally
(Figure 5.23). This demonstrates that mature ΔSUB1 parasites are biochemically active
and not merely developmentally arrested in some other fashion. It also demonstrates that
microneme discharge alone is insufficient for PVM or erythrocyte membrane rupture to
occur. No markers of exonemes other than SUB1 are known and so it was not possible
to directly assess whether exonemes are discharged normally in ΔSUB1 parasites. How-
ever, given that micronemes are clearly discharged normally following reversal of PKG
inhibition, and that SUB1 is known to be discharged from exonemes concomitantly with
AMA1 discharge from micronemes [C. R. Collins, S. Das, et al. 2013] it is reasonable to
assume that exoneme discharge also occurs normally in ΔSUB1 parasites.
5.10.2 AMA1 discharge and re-localisation from micronemes to the mero-
zoite surface, as well as normal SUB1-mediated processing of MSP1
and SERA5 confirms that ΔSERA6 parasites mature normally follow-
ing activation of PKG.
In a similar fashion to that outlined above, the maturation of ΔSERA6 parasites was as-
sessed by a combination of IFA to examine whether microneme discharge occurred, and
western blot analysis to examine whether SUB1-mediated proteolytic processing of MSP1
and SERA5 occurred. Microneme discharge was apparent from the re-localisation of
AMA1 following C2 wash off (Figure 5.24). To examine SERA5 and MSP1 processing,
mock- or RAP-treated schizonts of SERA6:loxP clone C4 were arrested with C2. The sch-
izonts were then washed into Albumax II-free medium containing either fresh C2, E64 in
the absence of C2, or no drugs and incubated for 30 min. Pelleted parasite material and
culture supernatants were then harvested and fractionated by SDS-PAGE. Western blot
analysis demonstrated clear SUB1-mediated processing of MSP1 and SERA5, demon-
strating that the maturation of merozoites that normally occurs in preparation for their
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release from the erythrocyte proceeds in the absence of SERA6.
Figure 5.23: Microneme discharge takes place in arrested ΔSUB1 parasites.
IFA demonstrating that normal discharge of micronemes occurred in RAP-treated
SUB1HA3:loxP clone 3E4 as apparent from visualisation of AMA1 re-localisation to the
surface of trapped intracellular merozoites. Parasites were mock (- RAP) or RAP-treated
(+ RAP) at ring-stage then Percoll purified at the end of cycle 0 and C2 arrested. C2 ar-
rest was reversed to allow egress to proceed by wash-off and parasites incubated for 5
min before thin films were made on glass slides. Staining was performed with α-AMA1
polyclonal rabbit serum and the MSP1-specific mAb X509. DNA was stained with DAPI.
Scale bar, 10 µm.
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Figure 5.24: Normal microneme discharge and SUB1 activity in arrested ΔSERA6
parasites. A) IFA analysis demonstrating that normal discharge of micronemes occurs in
RAP-treated SERA6:loxP clone C4 as apparent from visualisation of AMA1 re-localisation
to the surface of trapped merozoites. Parasites were mock- (- RAP) or RAP-treated (+
RAP) at ring-stage then Percoll purified at the end of cycle 1 and C2 arrested. C2 arrest
was reversed to allow egress to proceed by wash-off and parasites incubated for 5 min
before thin films were made on glass slides. Staining was performed with α-AMA1 poly-
clonal rabbit serum and counterstaining with the α-MSP1 mAb X509. DNA was stained
with DAPI. Scale bar, 10 µm. B) Western blot analysis of extracts from parasites. Mature
C2 arrested schizonts as described in A) were washed in and re-suspended into Albumax
II-free medium containing fresh C2, E64 in the absence of C2, or no drugs (n.d.), and
incubated for 30 min. Pelleted parasite material and culture supernatants were then har-
vested and examined by western blot, probed with an α-SERA5 polyclonal rabbit serum
or the α-MSP1 mAb 89.1. Blots of the same samples were also probed with the α-spectrin
mAb SB-SP1 as a control. Processed forms of SERA5 and MSP1 (indicated by arrows)
were detected in mock- and RAP-treated samples.
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5.11 SERA6 is not responsible for the additional, SUB1 inde-
pendent processing that converts the p56 form of SERA5
to a p50 form.
As discussed in the Introduction, the SERA proteins expressed during the asexual blood
stage cycle are processed by SUB1 either side of the papain-like domain. In the case of
SERA5 this converts full length SERA5 (p120) to a p56 form. SERA5 has been found
to undergo additional non-SUB1-mediated processing which then converts the p56 to a
p50 form. The biological significance of this is unclear as is the identity of the protease
that mediates this cleavage event. This unknown protease is referred to as ‘protease
X’ and appears to be a cysteine protease due to its sensitivity to E64 [Debrabant et al.
1992; Stallmach et al. 2015]. This raised the intriguing possibility that SERA6 might be
protease X and that at least one way in which SERA6 might act is via processing of SERA5.
A subset of the samples presented in Figure 5.24 were fractionated on a single SDS-
PAGE gel to compare the migration of the various SERA5 species. This confirmed that
the p50 form of SERA5 was highly abundant in culture supernatants of both mock- and
RAP-treated SERA6:loxP clone C4 schizonts that were incubated following reversal of
C2 arrest by washing (Figure 5.25). The presence of the SERA5 p50 form in the culture
supernatants of ΔSERA6 parasites clearly demonstrates that SERA6 is not responsible
for the protease X activity that processes SERA5.
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Figure 5.25: SERA6 is not responsible for the protease X activity that processes
SERA5 p56 to its p50 form. Percoll purified schizonts of mock- (-RAP) and RAP-treated
(+ RAP) cultures were arrested with C2 at the end of cycle 1. Schizonts were washed
into Albumax II-free medium containing either fresh C2 (C2), E64 in the absence of C2,
or no drugs (n.d.) followed by incubation for 30 min before pelleted parasite material
and culture supernatants (sup’s) were harvested and analysed by Western blot. Some
samples have been loaded multiple times to aid comparison of fragment sizes. Different
processed forms of SERA5 are indicated. A second blot of pelleted parasite material was
probed with the α-spectrin mAb SB-SP1 as a loading control.
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5.12 Shaking culture does not reverse the egress defects of
ΔSUB1 or ΔSERA6 parasites.
Having observed the egress defects that manifest following disruption of SUB1 or SERA6,
it was natural to ask whether these defects might be overcome by mechanical liberation
of merozoites. This was particularly the case for ΔSERA6 parasites as anecdotal evi-
dence suggests that these, like parasites arrested with E64 following C2 wash-off, are
relatively fragile compared to C2 arrested or ΔSUB1 parasites; when making thin smears
for Giemsa staining it was noticed that both E64 arrested schizonts and ΔSERA6 parasites
would often rupture, resulting in a spread of merozoites not contained within a bounding
membrane, whereas C2 arrested and ΔSUB1 parasites reliably remained intact. In light
of this, and the fact that disruption of either of these genes does not appear to inhibit
normal maturation of merozoites it was reasoned that mechanical rupture of mature sch-
izonts to liberate free merozoites might overcome the growth defects that act via blocks
in egress. Mechanical liberation of free merozoites by syringe lysis [Dvorin et al. 2010]
and by filtration [Boyle et al. 2010] has been described previously. Attempts were there-
fore made in preliminary experiments to liberate merozoites by passing mature schizonts
mixed with fresh erythrocytes through a 28G needle. The invasion achieved through such
approaches was found to be inefficient and inconsistent however, which prohibited this
method from being used in a quantitative manner to compare invasion rates across differ-
ent cultures. Instead a different approach was turned to. Normally P. falciparum is cultured
under static conditions but gentle shaking is also routinely used during egress of mature
schizonts in the presence of fresh erythrocytes, in order to obtain highly synchronous ring
stage cultures with infected erythrocytes predominantly infected by single parasites. It was
reasoned that shear forces generated by vigorous shaking might be sufficient to liberate
invasive merozoites from arrested ΔSUB1 or ΔSERA6 schizonts. This was considered
a particularly important issue because during natural infection parasitised erythrocytes
are continuously exposed to the shear forces generated by passage through the circula-
tion or (in the case of sequestered schizonts in the deep vasculature) impingement from
passing uninfected erythrocytes. To test this notion, cultures containing mature schizonts
(∼1% parasitaemia) of mock- or RAP-treated SUB1HA3:loxP clone 3E4 and SERA6:loxP
clone C4 parasites were incubated either under standard stationary conditions, or with
vigorous shaking (225 rpm) overnight, sampling both at the beginning of the experiment
and the next day to count parasitaemias by flow-cytometry. The results demonstrated
that for mock-treated parasites, shaking produced an approximately two-fold increase in
parasite proliferation rate compared to stationary culture conditions, presumably due to
more effective dispersal of merozoites (Figure 5.26). However, shaking conditions failed
to significantly increase the poor proliferation rate of ΔSUB1 or ΔSERA6 parasites fol-
lowing overnight culture. While the exact magnitude of the shear forces created in this
experiment are unknown (as are the shear forces exerted on sequestered schizonts by
blood flow in vivo), this suggests that neither the ΔSUB1 nor ΔSERA6 defects would be
readily overcome in vivo.
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Figure 5.26: Shaking fails to significantly increase the proliferation of ΔSUB1 or
ΔSERA6 parasites. Plots showing fold-change in parasitaemia overnight under station-
ary or vigorous shaking conditions. Starting cultures were established at ∼1% (between
0.8% and 1.7%) following mock- (- RAP) or RAP-treatment (+ RAP). SUB1HA3:loxP cul-
tures were established at the end of cycle 0, SERA6:loxP cultures at the end of cycle 1,
following mock- or RAP-treatment. Data displayed here are normalised such that starting
parasitaemia values are exactly 1% for each replicate experiment to allow comparison
across experiments. Four replicates were performed for each gene disruption using both
of the clones in each case. Two-sample t-tests were used to determine significance. T-
test statistics for SUB1HA3:loxP: - RAP stationary vs - RAP shaking (t = 5.233, d.f. = 5,
p = 0.0034) n=4. + RAP start vs + RAP stationary (t = 1.722, d.f. = 5, p = 0.1456) n=4. +
RAP stationary vs + RAP shaking (t = 0.4585, d.f. = 5, p = 0.6658) n=4. T-test statistics
for SERA6:loxP: - RAP stationary vs + RAP shaking (t = 5.674, d.f. = 4, p = 0.0048) n=4.
+ RAP start vs + RAP stationary (t = 2.741, d.f. = 4, p = 0.0518) n=4. + RAP stationary
vs + RAP shaking (t = 2.526, d.f. = 4, p = 0.0649) n=4. Error bars show ± 1 standard
deviation.
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5.13 Conclusions
Both SUB1 and SERA6 have been hypothesised to be involved in P. falciparum blood
stage egress for some time but the evidence for this has remained incomplete. Through
the use of the conditional DiCre system this study has conclusively demonstrated their
essentiality for the viability of asexual blood stage P. falciparum and elucidated the spe-
cific roles they play during egress. SUB1 is required for rupture of the PVM and all mor-
phological changes that occur downstream of PKG activation. Intriguingly microneme
discharge (and presumably exoneme discharge) occur normally. While SERA6 is not re-
quired for PVM rupture, rounding-up or erythrocyte membrane poration, it is required for
the final event of erythrocyte membrane rupture. The failure to complement ΔSEAR6
parasites with Cys644Ala mutant and uncleavable mutant forms of SERA6 demonstrates
that SERA6 functions as an enzyme and requires SUB1 processing. These data support
a model whereby a bifurcating pathway leads to egress, with SUB1 acting as a central
regulator of this process which mediates PVM rupture (directly or indirectly) and activates
SERA6 which mediates erythrocyte membrane rupture (Figure 6.1). Erythrocyte mem-
brane poration occurs immediately following PVM rupture and is independent of SERA6.
It is unknown what mediates PVM rupture or erythrocyte membrane poration. The occur-
rence of erythrocyte poration in the presence of cysteine protease inhibitors [Glushakova,
Humphrey, et al. 2010] demonstrates that calpain, or indeed other cysteine proteases, are
not responsible for mediating it. Both PVM rupture and erythrocyte membrane poration
are presumably mediated by either pore-forming proteins or phospholipases. It is possible
that the poration factor is liberated from the PV into the residual erythrocyte cytoplasm. It
is possible that it may be the same factor that mediates rupture of the PVM itself.
It has not been possible to determine whether exoneme biogenesis occurs normally
in ΔSUB1 parasites as the only known component of these organelles is SUB1 itself.
As such it is conceivable that exonemes contain one or more additional components re-
quired for PVM rupture. It is possible that in ΔSUB1 parasites exoneme biogenesis is
adversely affected such that these other putative components are not discharged appropri-
ately. However, this seems unlikely as microneme discharge, which occurs concomitantly
with exoneme discharge was found to occur normally. It is unclear whether exonemes
represent a truly distinct class of secretory organelles. Whilst they are clearly distinct
from micronemes containing AMA1 [C. R. Collins, S. Das, et al. 2013] they may represent
an additional sub-class of micronemes. In any case this study is the first to conclusively
demonstrate the requirement of SUB1 for egress, including for activation of SERA6. Al-
though prior evidence pointed to a role for SUB1 in egress [Yeoh et al. 2007] this relied on
pharmacological inhibition using an inhibitory compound with potency in the micro molar
range. As it was not possible in that study to determine the fine specificity of the inhibitor
(for example by introduction of gatekeeper mutations that exclude the inhibitor from the
enzyme in question), off-target effects may have been responsible for the phenotype ob-
served. All the results obtained here, however, confirm and extend the findings of Yeoh
and colleagues [Yeoh et al. 2007].
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Chapter 6
Discussion
At the outset of this PhD project the physical and mechanical events of P. falciparum blood-
stage egress were relatively well described. None of the molecular effectors responsible
for mediating any of these events were known however. Over many years the accumu-
lating genetic and biochemical evidence supported the hypothesis that both SUB1 and
SERA6 are required for egress. Biochemical studies had shown that SUB1 is a protease.
SUB1 was also shown to be secreted into the PV shortly before egress where it cleaves
various parasite proteins including the putative papain-like protease SERA6. SUB1 and
SERA6 were both found to be refractory to disruption and most significantly, pharmaco-
logical blockade of SUB1 was found to block egress, although the inhibitor used (with an
IC50 of 0.3 µM) was not highly potent and significant off-target effects could not be ex-
cluded [Yeoh et al. 2007]. Nevertheless, the combination of evidence pointed to a role in
egress for SUB1 and SERA6 and led to three hypotheses: 1) that SUB1 is required for
egress, 2) that SERA6 is required for egress and 3) that SERA6 functions as a protease,
requiring SUB1 processing for activation.
Egress is mediated by SUB1 and SERA6.
It was with these hypotheses in mind that this PhD project was embarked upon. With the
advent of the DiCre system for conditional gene modification in P. falciparum it was finally
possible to address the above three hypotheses using a robust molecular genetic ap-
proach. Broadly speaking these hypotheses have been corroborated by the data obtained
during this project. The data presented here demonstrate unambiguously that SUB1 and
SERA6 are essential for P. falciparum egress during the asexual blood stage cycle in
vitro. SUB1 is required to mediate both breakdown of the PVM and all of the morphological
changes that take place during egress following PKG activation (Figure 6.1). SERA6 is not
required for PVM rupture or any other morphological changes that occur during egress but
is required for rupture of the erythrocyte membrane. The failure to complement ΔSERA6
parasites with a catalytically dead mutant of SERA6 or a form that cannot be cleaved by
SUB1 confirms that SERA6 has an enzymatic role that depends on SUB1 processing. Vir-
tually all proteases are expressed as enzymatically inactive zymogen forms to prevent the
potentially catastrophic consequences of uncontrolled proteolysis within a cell [Coulombe
et al. 1996]. These findings are consistent with SERA6 possessing protease activity but it
cannot be said for certain, however, that it is a protease. The possibility that SERA6 is a
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non-peptidase protein with homology to the papain sub-family of cysteine proteases can-
not be excluded. Examples of such non-peptidase proteins that resemble papain include
pytochelatin synthase [Vivares, Arnoux, and Pignol 2005], arylamine N-acetyltransferase
[Boukouvala and Fakis 2005], silacteins [Shimizu et al. 1998] and coagulation factor XIII
transglutaminase [Makarova, Aravind, and Koonin 1999]. Definitive evidence that SERA6
is a protease, and that proteolytic activity is activated by SUB1 cleavage will likely require
an in vitro biochemical demonstration of protease activity of purified SERA6 expressed
recombinantly or pulled-down from the parasite. Such attempts are underway in the lab-
oratory of Michael Blackman. A common mechanism by which the zymogen forms of
proteases are kept inactive is by having an N-terminal prodomain, which is often required
for correct folding of the translated protein, interact with the active site in order to prevent
entry of any substrates, and thus their cleavage. This is the case for various protease of
the papain clan (CA) including cathepsin B [Podobnik et al. 1997], cathepsin S [Vasiljeva
et al. 2005] and papain itself [Roy et al. 2012]. Various proteases of clan CA cleave the
prodomain from the mature portion of the enzyme auto-catalytically in an intramolecular
fashion when activated by appropriate conditions (e.g. acidic pH) but others, such as
cathepsin C and cathepsin X, rely on other proteases to remove their prodomains [Turk
et al. 2012]. It is therefore likely that SERA6 is activated by SUB1 mediated cleavage of
a prodomain portion of SERA6 from the active portion of SERA6, causing it to dissociate
from the active site.
PVM rupture precedes rupture of the erythrocyte membrane.
The data presented here demonstrates that rupture of the PVM precedes rupture of the
erythrocyte membrane and corroborates previous studies [Wickham, Culvenor, and Cow-
man 2003; Glushakova, Humphrey, et al. 2010; Glushakova, Busse, et al. 2017]. This
has previously been a topic of some disagreement with an early study suggesting that
erythrocyte membrane rupture occurs first [Salmon, Oksman, and Goldberg 2001]. The
reason that Salmon and colleagues came to an opposing conclusion likely stems from the
general toxicity of treating relatively early stage parasites with E64 as was performed in
this study. This would likely be exacerbated if cultures were not highly synchronous. PVM
rupture has also been shown to precede host cell membrane rupture of both liver-stage
parasites [Burda, Caldelari, and Heussler 2017; Schmidt-Christensen et al. 2008; Putri-
anti et al. 2010; Graewe et al. 2011] and gametocytes [Sologub et al. 2011; Deligianni
et al. 2013; Wirth, Glushakova, et al. 2014]. Thus, it appears the order of membrane rup-
ture (PVM followed by erythrocyte membrane) is a consistent and universal feature of the
Plasmodium lifecycle.
How is the sequential rupture of the two bounding membranes achieved?
The mechanism by which SUB1 mediates PVM rupture is uncertain. Unlike the erythro-
cyte cytoskeleton, the PVM is not known to possess structural protein components [Atkin-
son1988]. It is therefore unlikely that this confirmed protease functions by cleaving struc-
tural protein components of the PVM or degrades lipid components of the PVM. It has
not been possible to determine whether exoneme biogenesis occurs normally in ΔSUB1
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parasites as the only known component of these organelles is SUB1 itself. It is conceiv-
able that exonemes contain one or more additional components that would be sufficient
for PVM rupture but that these fail to be secreted into the PV. However, this seems unlikely
as microneme discharge, which normally occurs concomitantly with exoneme discharge
was found to occur normally. It is unclear whether exonemes represent a truly distinct
class of secretory organelles. Whilst they are clearly distinct from micronemes containing
AMA1 [C. R. Collins, S. Das, et al. 2013] they may represent an additional sub-class of mi-
cronemes. In any case this study is the first to conclusively demonstrate the requirement
of SUB1 for egress, including for activation of SERA6.
Pore-forming proteins and phospholipases are used by various microbial pathogens
for their egress from host cells [Friedrich et al. 2012b] and P. berghei liver stage schizonts
have been shown to require a phospholipase, PbPL, for efficient PVM rupture [Burda,
Roelli, et al. 2015]. Mature liver-stage ΔPbPL parasites either did not rupture the PVM
or took significantly longer to do so. Intriguingly Burda and colleagues found that during
liver stage infection PbPL localises to the PVM well before PVM rupture occurs. They
suggested that PbPL is maintained at the PVM in an inactive state and requires activation
through phosphorylation by kinases or processing by proteases. In line with this hypoth-
esis it has been shown that a phospholipase C of Listeria monocytogenese is activated
by proteolytic cleavage [Marquis, Goldfine, and Portnoy 1997]. At the time of publication
Burda and colleagues [Burda, Roelli, et al. 2015] suggested that members of the SERA
family might be responsible for activating PbPL, but given that work from the same labora-
tory (laboratory of Volker Heusseler) has since shown that PbSUB1 is required for rupture
of the PVM during P. berghei liver stage infection [Burda, Caldelari, and Heussler 2017],
and in light of the findings presented in this thesis, SUB1 would seem a more likely can-
didate. It was found that more than 50% of PbPL null parasites did eventually rupture
the PVM however. This led the authors to suggest that redundancy of molecular effectors
of PVM rupture exists, with multiple phospholipases and potentially other types of effec-
tors, such as pore forming proteins, contributing to PVM rupture. Burda and colleagues
found no defect during the erythrocytic stage of infection of ΔPbPL parasites but the pos-
sibility that another phospholipase, or that redundancy of function exists in this stage as
well means the involvement of phospholipases in the rupture of the PVM during blood
stage egress cannot be ruled out. Five putative phospholipases exist in the P. falciparum
genome. One or more of these phospholipases, may be activated by SUB1-mediated
proteolytic processing to mediate rupture of the PVM during asexual blood stage egress.
Pore forming protein such as the PPLPs could also be involved with one or more of these
contributing to PVM rupture. This might be achieved through osmotic pressure resulting
from influx of water through a pore. TgPLP1, a perforin like protein, has been demon-
strated to be involved in rupture of the T. gondii PVM [Kafsack et al. 2007] and this has
been suggested to act by causing osmotic pressure which ruptures the PVM [Wade and
Tweten 2015]. As outlined in the Introduction the current picture of PPLP involvement in
egress is rather complex with studies carried out in different lifecycle stages and on or-
thologs in three different species. Further work will be required to determine the function
of both the perforin and phospholipase genes in the stage-specific egress of individual
species including P. falciparum blood stage egress. It is possible that these putative me-
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diators of PVM rupture, hypothesised to be activated by SUB1 cleavage, are located in the
micronemes/exonemes and discharged into the PV during egress, or they might already
reside in the PV lumen at the point of SUB1 discharge.
Underlying the erythrocyte membrane is the mesh-like network of the cytoskeleton.
This ‘chicken-wire’ like mesh is made up of α- and β-spectrin. Two heterodimers of en-
twined α- and β-spectrin associate to form a tetramer. Junctional complexes that con-
sist of many components including band 3, Ankyrin and 4.1R tether the ends of spectrin
tetramers into the membrane at either end with multiple spectrin tetramers attached to
each junctional complex [Mohandas and Gallagher 2008]. Typically six spectrin tetramers
are linked to each junctional complex which results in a hexagonal mesh. This cytoskeletal
network is responsible for the remarkable properties of the human erythrocyte which in-
clude: tremendous elasticity (100x greater than that of latex), rapid responses to applied
fluid stresses and a structural resistance greater than steel [Mohandas and Gallagher
2008]. This strength and resilience is required for the erythrocyte to withstand the con-
siderable forces exerted upon it during its ∼4 month existence in the bloodstream, with
repeated passage through narrow capillaries with a cross section one third of the diame-
ter of an erythrocyte and the fluctuations in pressure that this brings. In order for malaria
parasites to achieve erythrocyte membrane rupture the cytoskeleton must therefore be dis-
rupted in some fashion. This could involve the disruption of key protein-protein interactions
of cytoskeletal components by the competitive interaction of a parasite protein, phospho-
rylation of cytoskeleton components to disrupt their interactions or proteolytic processing
of cytoskeletal components to literally ‘snip’ components off one another. It has been
proposed that a progressive dismantlement of the erythrocyte cytoskeleton occurs during
parasite maturation [Millholland et al. 2011]. The findings presented herein and published
recently [Hale et al. 2017] suggest that contrary to this claim, the erythrocyte cytoskeleton
remains intact until very late in parasite development. Only following PKG activation which
signals egress does rounding up and a collapse of the cytoskeleton appear to take place
as seen by light microscopy and scanning electron microscopy.
Host calpain-1 in the erythrocyte has been implicated in mediating blood-stage egress
through studies on resealed immuno-depleted erythrocytes [Chandramohanadas et al.
2009]. This demonstration that calpain-1, a cysteine protease, is involved in egress raises
the question of whether it is responsible for mediating erythrocyte membrane rupture by
degradation of the cytoskeleton and the physiologically relevant target of protease in-
hibitors, including E64 used in this and previous studies, that prevent egress. The ge-
netic data presented here demonstrates that calpain-1 is not sufficient for egress and
that egress does require the action of at least one confirmed parasite protease, SUB1,
with SERA6 likely acting proteolytically as well. That the rodent malaria parasite P. yoelii
was found to be viable in calpain-/- mice also raises questions about the role of calpain-
1 [Hanspal et al. 2002]. These conflicting data may occur due to differences between
in vitro and in vivo egress, or biochemical differences between these two species. The
data from this project demonstrate that in all ways examined E64 treatment following PKG
activation mimics SERA6 knockout, consistent with the idea that SERA6 is the physiolog-
ical relevant target of E64. Importantly though, this does not preclude the possibility that
calpain-1 is indeed essential for egress and also a physiologically relevant target of E64
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in the prevention of egress. It is possible that both SERA6 and calpain-1 act in concert
to achieve erythrocyte membrane rupture and that E64 inhibition of either of these can
prevent egress.
Supporting the idea that disruption of the erythrocyte cytoskeleton only occurs once
egress is underway is as yet unpublished evidence from a colleague (Michele Ser Ying
Tan in the laboratory of Michael Blackman). It has been demonstrated that cleavage of
β-spectrin occurs following PKG activation, associated with egress. This discrete cleav-
age occurs between two calponin homology domains of β-spectrin. This is the region that
associates with the junctional complexes and is apparently the only region of either α-
or β-spectrin where cleavage would cause dissociation of the spectrin tetramers from the
junctional complexes. This is because α- and β-spectrin associate with each other along
the length of these molecules so discrete cleavage within these regions seems unlikely to
affect their association. At this point it is unclear whether this processing is performed by
SERA6 directly or by another protease but it is SERA6 dependent: cleavage of spectrin
is not seen in cultures of ΔSERA6 parasites. A manuscript presenting a combination of
data presented in this thesis with data outlining this spectrin cleavage has very recently
received favourable reviews and is expected to be published in Nature Microbiology fol-
lowing the acquisition of some additional data. This raises two questions: what is the
exact role of SERA6 in this process and is this cleavage sufficient for egress? With re-
gards to the latter, there is not yet formal proof that this β-spectrin cleavage is sufficient
for egress but it is highly likely that it is. Multiple hereditary human erythrocyte disorders
result from mutations in the genes encoding cytoskeletal components including α- and
β-spectrin. These disorders result in loss of erythrocyte membrane cohesion which leads
to loss of membrane surface area and mechanical stability and causes changes to the
shape of erythrocytes that defines various syndromes. They include: spherocytosis when
erythrocytes take on a spherical shape; elliptocytosis when erythrocyte become ellipsoid
in shape and pyropoikilocytosis where erythrocytes form in all shapes and sizes [Maillet
et al. 1996]. In the case of spectrin, mutations have been identified that prevent spec-
trin dimer self-association [S. C. Liu, Palek, and Prchal 1982]. This results in large areas
of the membrane being left free of spectrin coverage with the erythrocytes undergoing
fragmentation. The symptoms associated with these syndromes vary from asymptomatic
to severe and fatal haemolytic anaemia [Da Costa et al. 2013]. It is therefore entirely
plausible that cleavage of spectrin that causes its dissociation from the membrane bilayer
results in destabilisation of the erythrocyte membrane and its eventual rupture.
Given that cleavage of β-spectrin is SERA6 dependent one of two possibilities pre-
sumably occurs (assuming SERA6 is a protease): 1) SERA6 directly cleaves β-spectrin
or 2) SERA6 activates another effector through proteolytic cleavage that achieves spec-
trin cleavage. The question of whether SERA6 directly cleaves spectrin will require a
biochemical approach and will form the basis of further study in the laboratory of Michael
Blackman. If the latter situation is true, it begs the following questions: what is cleaved
by SERA6? Does the protein cleaved by SERA6 go on to cleave β-spectrin directly or
does it act indirectly to achieve β-spectrin cleavage as well? The identification of SERA6
substrates will require proteomic analysis of ΔSERA6 and control parasites and will also
be followed up in the laboratory of Michael Blackman. In any case this SERA6 dependent
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cleavage of β-spectrin is highly likely to be the mechanism, or at least part of the mecha-
nism, that achieves erythrocyte membrane rupture. Rupture of the erythrocyte membrane
might also require the activity of other proteases upon components of the cytoskeleton.
This might be the role that calpain-1 plays in achieving egress.
Regulated vesicle fusion, to achieve secretion of SUB1, is therefore central to Plas-
modium egress and an understanding of how this is achieved following PKG activation
is necessary for a complete understanding of egress. In Toxoplasma gondii TgDOC2.1
has been implicated in microneme secretion, resulting in both egress and invasion defects
[Farrell et al. 2012]. TgDOC2.1 contains two C2 domains which are membrane binding do-
mains found in a diverse range of eukaryotic proteins, most of which are involved in mem-
brane trafficking and fusion by binding lipids in a calcium dependent manner [Corbalan-
Garcia and Go´mez-Ferna´ndez 2014]. Knockdown of the PfDOC2.1, the ortholog in P.
falciparum, was found to result in an invasion defect concomitant with a decrease in the
release of EBA-175 into the supernatant[Farrell et al. 2012]. No egress defect was ob-
served suggesting that Plasmodium relies on microneme secretion for invasion but not for
egress, and that exoneme secretion is sufficient for egress but requires different factors
to those necessary for microneme secretion. As discussed in Section 1.13 calcium has
been implicated in Apicomplexan egress including microneme secretion [Carruthers and
L. D. Sibley 1999]. The identities of effectors that achieve exoneme secretion, and indeed
the other effector molecules that are presumably involved in microneme secretion remain
to be discovered.
The role of erythrocyte membrane poration during egress remains unknown.
It had been shown prior to this study, that shortly before merozoite release, the erythrocyte
membrane becomes porated. It has also been demonstrated that the membrane ‘sealing’
molecules Tetronic 90R4 and P1107 interfere with exflagellation during gametocyte egress
[Wirth, Glushakova, et al. 2014] and asexual blood stage egress [Glushakova, Humphrey,
et al. 2010] respectively. In neither of these studies was the effect of these sealants on
poration, or their general toxicity assessed however. The significance of this process re-
mains unclear therefore and an assessment of its essentiality for, and role, in egress will
require further work. Clearly poration alone is insufficient for egress to occur as porated
parasites (arrested with E64) have been shown to remain intact by time-lapse microscopy
[Glushakova, Humphrey, et al. 2010]. This has also been observed (not presented explic-
itly) during this study. The observation in this study that p50 SERA5 leaks from parasitised
erythrocytes following rupture of the PVM demonstrates that large proteins, not just small
molecules such as phalloidin, are able to traverse the erythrocyte membrane when pora-
tion occurs. It has also been observed (not presented here) that the p64 form of SUB1
leaks from E64 arrested parasites as well. Leakage of SERA6 has not been examined but
it is reasonable to assume that the p65 form of SERA6 would also leak from the erythro-
cyte as well. It was also noticed during this study that culture supernatants of parasites
treated with E64 following C2 wash-off were noticeably redder in colour compared to su-
pernatants of parasite cultures where C2 treatment was maintained. This presumably
results from the leaking of residual haemoglobin (64 kDa) from the parasitised cells. It is
intriguing that at the point of erythrocyte membrane poration large proteins including key
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molecular effectors of egress leak from the cell. They presumably cannot play any further
role in the parasite lifecycle after this point. Of course, the arrest of porated parasites with
E64 is an artificial situation and the leakage, indeed the poration itself, may merely be a
side-effect of egress as the erythrocyte’s rupture draws nearer. What causes erythrocyte
membrane poration is unknown but could, as is hypothesised for PVM rupture, be a pore
forming protein or phospholipase. Given that erythrocyte poration only occurs following
PVM rupture it is tempting to speculate that it might be caused by exactly the same factor,
or factors, that rupture the PVM and are then released into the confines of the erythrocyte.
A molecule of haemoglobin is ∼5 nm in width [Erickson 2009]. If a pore-forming protein is
responsible for erythrocyte membrane poration it would have to create pores large enough
to allow molecules of ∼5 nm diameter to pass through them. Pores resulting from pore-
forming proteins vary in diameter but have been described with diameters exceeding 5
nm so this is plausible [Parker2005]. Streptolysin-O forms pores that allow the passage
of molecules with diameters of ∼15 nm [Bhakdi and Sziegoleit 1985] and perfringolysin O
can form pores of 150 nm diameter [Hong et al. 2002]. Interestingly, equinatoxin II which
generally forms pores of 1-2 nm diameter has been shown to liberate haemoglobin from
P. falciparum infected erythrocytes [Jackson et al. 2007]. This likely results from hetero-
geneity of pore size with some large enough to allow haemoglobin release. The authors
report the existence of pores, as seen by scanning electron microscopy as large as 100
nm in diameter. Given what is understood of pore-forming proteins it is entirely plausible
that the PPLPs (discussed in the Introduction and in this section) could be responsible for
the poration of the erythrocyte membrane during egress.
What is the relevance of this work to real malaria infections?
During this project, I attempted to address the question of whether SUB1 and SERA6
would be required for egress during a natural infection. It might be hypothesised that in
vivo, shear stresses from blood flow might mechanically rupture the erythrocyte mem-
branes of ΔSUB1 and ΔSERA6 parasites, releasing viable merozoites that can success-
fully propagate. Previous studies have successfully achieved the release of viable in-
vasion competent merozoites following mechanical rupture of the bounding erythrocyte
membrane [Dvorin et al. 2010; Boyle et al. 2010]. In this study, however, these methods
were not found to be efficient and consistent enough to allow a quantitative assessment
of the viability of mature merozoites of mock- and RAP-treated cultures. It was therefore
not possible to tease apart secondary effects of SUB1 or SERA6 knockout on merozoite
invasion from the primary effects on egress, which almost certainly would affect invasion
through preventing these labile forms from escaping the confines of an erythrocyte in
a timely manner. The exposure of knockout parasites to the shear forces in vigorously
shaking culture did not significantly reverse the growth defects that result from these gene
knockouts. Of course, the shear forces that are exerted upon parasitised erythrocytes dur-
ing shaking culture are unknown, as are the shear forces exerted upon schizonts in blood
vessels. While the exact nature of a real infection cannot be mimicked it does suggest
these defects are not readily overcome. To more definitively address this question stud-
ies would either have to be performed in monkeys using the DiCre system in P. knowlesi,
which is currently being implemented (personal communication Robert Moon), or perhaps
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using a flow culture system which more closely approximates the flow conditions of the
bloodstream such as those used in studies of endothelial adhesion of infected erythro-
cytes [Ho et al. 1998; Cooke, Coppel, and Nash 2002]. Supporting the hypothesis that
both SUB1 and SERA6 are essential to the parasite’s viability during in vivo infection is the
fact that the homologs of both of these genes appear refractory to knockout in P. berghei.
Data from the PlasmoGEM project clearly demonstrates SUB1 essentiality [Gomes et al.
2015]. SERA6 knockout has yet to be performed in the PlasmoGEM system but knockout
has been attempted on an individual basis and it was found to be refractory (personal
communication Kai Matuschewski).
Further to this point, it is worth considering more generally what relevance the study
of the eruptive, spontaneous in vitro egress of P. falciparum has to a real infection with
non-laboratory strains of parasites. The fact that P. berghei does not undergo egress in
vitro is often put forward as evidence that the eruptive egress seen in laboratory strains of
P. falciparum might be an artefact of long-term in vitro culture. This feature of egress might
have been selected for to achieve efficient dispersal of merozoites in static cultures and
be unnecessary when parasites are present in the bloodstream which could rupture the
bounding erythrocyte membranes and disperse merozoites by shear forces from blood
flow. Supporting the idea that spontaneous eruptive egress is not an artefact of in vitro
culture, however, is the observation that various different species and strains of Plasmod-
ium appear to egress in this way including when freshly removed from an animal host. The
first published video-microscopic examination of Plasmodium egress was of P. knowlesi
which were freshly removed from a monkey and these were seen to egress spontaneously
[Dvorak et al. 1975]. Similarly two strains of P. yoelii maintained in mice have been shown
to egress in a similar fashion [Yahata et al. 2012]. Therefore spontaneous egress cannot
merely be an artefact of in vitro culture, and actually seems to be a general feature of
Plasmodium egress. It remains uncertain however whether egress of ΔSUB1 or ΔSERA6
parasites might nevertheless be achieved by mechanical rupture in vivo. It is unclear why
the rodent malaria model P. berghei does not egress spontaneously in vitro. It is possible
that it requires a host factor not present in in vitro culture or it might rely, to some extent,
on shear forces of blood flow.
The use of the DiCre system.
The DiCre system has continued to be developed since its establishment and significant
advances have been made since this PhD project was started. This means that were this
project to be started again, some things would almost certainly be done differently. In-
deed, the wide implementation of the DiCre system has both facilitated and necessitated
innovation in complementary techniques, approaches and tools. The implementation of
the loxPint by Jones and colleagues, and used in this project, was borne out of a desire to
utilise the DiCre system more fully and effectively [Jones et al. 2016; Sherling et al. 2017].
The loxPint has and will be particularly important in realising the full potential of the DiCre
system. It has allowed the floxing of gene fragments through the integration of single con-
structs, made integration of loxP sites more efficient by allowing targeting of integration
into relatively GC rich coding sequences and allows enzymatic inactivation of genes by
truncation, as was achieved for SUB1 in this project. Indeed the analysis of SERA6:loxP
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clones C4 and D2 in this study was made more difficult by the fact that the phenotype re-
sulting from SERA6 disruption only manifests after the completion of erythrocytic growth
cycle 0. The maintenance of synchronous cultures of mock-treated and RAP-treated par-
asites for four days before analysis (∼96 h post mock/RAP-treatment) is, if nothing else,
laborious. It would be preferable to integrate a loxPint within the SERA6 catalytic domain
such that truncation of this putative protease domain would occur upon RAP-treatment.
This would ablate the function of any residually expressed form of the gene on the resulting
excised episome. The fact that SERA6 was not truncated in this fashion and is present
on an episome under control of its promoter is presumably responsible for the delayed
ΔSERA6 phenotype. The loxPint is also allowing the implementation of allele switching
studies which are underway in the laboratories of Edgar Deu and Michael Blackman. The
use of the loxPint for an allele switching strategy is also a preferable approach for genetic
complementation compared to the episomal approach taken in this study. RAP-mediated
excision could be used to swap a gene to an allele possessing specific mutations, or to
reconstitute the wild-type gene. Chromosomal expression would likely achieve more sta-
ble and consistent expression of complementing alleles when ‘switched on’ compared to
expression from episomal constructs which may vary due to episomal copy number. Al-
though the SUB1 and SERA6 native promoter regions were used for episomal expression
in this study inefficient expression, or an inappropriate profile of expression may have
been responsible for the incomplete complementation seen. Allele switching would likely
achieve expression profiles more closely resembling that of the endogenous wild-type
gene in question as being in its normal genomic environment should place a comple-
menting gene under control of endogenous cis-acting factors that regulate expression.
The way in which the DiCre system is being implemented has also changed since this
project was embarked upon. The 1G5DC clone used in this study suffers from a significant
drawback in that the DiCre expressing locus can revert to a wild-type locus meaning the
parasite no longer expresses the DiCre fragments. This results from the fact that the Di-
Cre expression cassette was integrated by single-crossover homologous recombination,
creating a duplication of the targeting sequence. As this locus lacks a drug marker, fol-
lowing its excision from the genome [C. R. Collins, S. Das, et al. 2013], recombination can
occur between the two identical targeting sequences. Reversion of this locus to wild-type
likely cannot be undone and may be selected for if expression of the DiCre fragments are
slightly costly to the parasite’s fitness. Parasites not expressing the DiCre fragments will
of course fail to excise DNA between loxP sites. A high proportion of parasites not under-
going excision when RAP-treated can confound the interpretation of data. This mandated
the regular thawing of frozen parasite isolates. Even then, as reversion could ‘spread’
through the population in the culture either by selection or genetic drift after it had arisen,
it was unpredictable. This required the periodic assessment of the prevalence of reverted
parasites using PCR or an assay in which the phenotype was well established already.
This has been a significant hindrance in working with clones derived from the 1G5DC
clone. As such the DiCre fragment expressing locus of the 1G5DC clone has been mod-
ified using Cas9 genome editing technology to remove the displaced targeting sequence
and prevent reversion (personal communication Christine Collins, laboratory of Michael
Blackman). The DiCre fragment expressing locus in this new clone (B11DC) does appear
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stable over long periods of time. Another DiCre expressing clone has also been created
by integration of the DiCre expression cassette into the pfs47 locus which is not essential
during the asexual blood stage cycle [Knuepfer et al. 2017].
The plaque assay is a valuable addition to our suite of tools and technologies for
malaria research.
It is from the use of the DiCre system and a desire to assay parasite replication at the
level of individual parasites that created the impetus to develop the plaque assay pre-
sented herein. This was because, despite being highly efficient, the DiCre system results
in heterogeneous populations of parasites following RAP-treatment. A small proportion
of non-excised, effectively wild-type parasites, always remain and these replicate at ex-
ponential rates. This can confound the interpretation of results if analysis of RAP-treated
populations is extended beyond a few growth cycles. Hopefully the simplicity, lack of com-
plex and costly equipment and lack of expertise required to implement the plaque assay,
as well as its scalability will facilitate studies of Plasmodium species, including in resource
poor settings. The plaque assay is now routinely used in the laboratories of Michael Black-
man, Edgar Deu and Moritz Treeck as well as others around the world for the isolation of
parasite clones and assays of parasite growth in response to gene knockouts or inhibitor
treatments. Colleagues in the laboratories of Edgar Deu and Moritz Treeck have devel-
oped semi-automated systems of plaque counting using Fiji software. The plaque assay
has the potential to be scaled-up for medium or even high-throughput screens of parasite
growth and automation of plaque counting would be an important step in implementation
such projects. Furthermore, Robert Moon has and continues to develop a modified pro-
tocol to allow the plaque assay to be used for the assessment of P. knowlesi growth. It is
therefore likely that the plaque assay will become a routinely used tool in malaria research.
In the last five years we have seen the implementation of some powerful and reli-
able tools for the manipulation of the malaria parasite genome including the DiCre system
[C. R. Collins, S. Das, et al. 2013], Cas9 genome editing technology [Ghorbal et al. 2014],
selection linked integration [Birnbaum et al. 2017] and artificial introns [Jones et al. 2016].
Combined with the advent of the P. knowlesi A1.H1 clone with its various advantages in-
cluding high efficiency of genetic modification, larger merozoite dimensions and increased
duration of merozoite viability [Moon, J. Hall, et al. 2013; Moon, Sharaf, et al. 2016; Tarr et
al. 2014; Gru¨ring et al. 2014] now is a particularly exciting time to be involved in research
of the molecular and cellular biochemistry of the malaria parasite.
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Figure 6.1: Schematic model of the branching pathway leading to egress involving
SUB1 and SERA6. SUB1 is discharged from micronemes into the PV lumen following
PKG activation and is is required for PVM rupture, possibly by activating other effectors
which might be perforins or phospholipases (PL?). SUB1 processes SERA6 either side
of the papain-like domain and activates an enzymatic function. SERA6 is required for
erythrocyte membrane rupture, perhaps by cleaving components of the cytoskeleton in-
cluding β-spectrin, or activating other effectors through proteolytic processing which go on
to cleave cytoskeletal components. The poration of the erythrocyte that occurs to allow
phalloidin to enter the cell likely results from insertion of perforin molecules into the ery-
throcyte membrane. These putative perforins might be present in the PV and released into
the residual erythrocyte cytosol upon PVM rupture, or might be released from exonemes
or micronemes.
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Abstract
Malaria is caused by an obligate intracellular protozoan parasite that replicates within and
destroys erythrocytes. Asexual blood stages of the causative agent of the most virulent
form of human malaria, Plasmodium falciparum, can be cultivated indefinitely in vitro in
human erythrocytes, facilitating experimental analysis of parasite cell biology, biochemistry
and genetics. However, efforts to improve understanding of the basic biology of this impor-
tant pathogen and to develop urgently required new antimalarial drugs and vaccines, suffer
from a paucity of basic research tools. This includes a simple means of quantifying the
effects of drugs, antibodies and gene modifications on parasite fitness and replication rates.
Here we describe the development and validation of an extremely simple, robust plaque
assay that can be used to visualise parasite replication and resulting host erythrocyte
destruction at the level of clonal parasite populations. We demonstrate applications of the
plaque assay by using it for the phenotypic characterisation of two P. falciparum conditional
mutants displaying reduced fitness in vitro.
Introduction
As one of the most important human pathogens, much research on the human malaria parasite
Plasmodium falciparum focuses on the identification and characterisation of drug targets and/
or an improved understanding of how host immune responses interfere with parasite replica-
tion and associated pathology. During the clinically relevant asexual blood stage of the parasite
lifecycle, merozoites invade host erythrocytes where they divide within a parasitophorous vacu-
ole to produce 16–20 daughter merozoites. These are then released from the erythrocyte,
completely destroying it in the process. In certain regards the parasite blood-stage lifecycle
therefore mimics a viral lytic cycle, in that destruction of each host cell allows the release of
multiple invasive forms which go on to invade and destroy further host cells, amplifying the
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pathogen population. For many viruses, this lytic cell cycle has long been exploited in in vitro
assays in which the concentration of infectious viral particles in a sample can be determined by
microscopic visualisation of destruction of host cells following their infection by suitably
titrated aliquots of virus. First described for animal viruses by Dulbecco and Vogt in 1953 [1],
the assay protocol usually involves limiting diffusive dispersion of the released viral particles
through the use of semi-solid media in order to achieve discrete, highly localised regions of
host cell monolayer destruction called plaques. The cell monolayers are finally stained to visu-
alise the plaques. Because of their simplicity and broad applicability, plaque assays are amongst
the most valuable and widely-used tools in viral research, allowing facile quantitation of the
effects on viral replication of environmental conditions, drugs, antibodies and genetic manipu-
lation, and simplifying isolation of viral clones. Plaque assays have also been developed for
other intracellular pathogens, including several bacterial species [2] and even protozoan organ-
isms related to the malaria parasite, notably Toxoplasma gondii which readily infects most
nucleated mammalian cells and so can be cultured in adherent fibroblast monolayers [3]. In
contrast, blood stages of P. falciparum and other Plasmodium species pathogenic to humans
replicate exclusively in erythrocytes (or reticulocytes), which are not normally adherent. Plaque
assays developed for Plasmodium have therefore used monolayers of erythrocytes adhered to
the base of plastic tissue culture wells using concanavalin A [4, 5], Cell-Tak [6], or anti-Rhesus
D antibodies plus protein L [7], with plaque formation being visualised using either Giemsa
staining of fixed monolayers or immunofluorescence. Such assays were key to the success of
elegant pioneering experiments demonstrating the phenomenon in which all the merozoite off-
spring of a single infected erythrocyte are committed to either continuation of the asexual life
cycle or transformation into either male or female forms of the sexual stages (gametocytes)
responsible for transmission to the mosquito vector [4, 5, 7]. However, due to the single-cell-
thick nature of the adherent erythrocyte monolayers produced by these methods and the need
for fixation and staining to visualise the plaques, the assays are unsuitable for routine quantita-
tion of malaria parasite growth rates. Here we describe the optimisation and application of an
extremely simple plaque assay that we expect will become an attractive and widely used addi-
tion to the available repertoire of malaria research tools.
Results
P. falciparumGrowth in Static Erythrocyte Cultures Produces Plaques
In initial work, asexual blood-stage cultures of P. falciparum (clone 3D7) were dispensed in
complete medium into the central 60 wells of flat-bottomed 96-well microplates and incubated
undisturbed (without replacing the medium or disturbing the erythrocyte layers) at 37°C in
sealed, humidified gassed chambers, monitoring by daily examination with an inverted light
microscope. This revealed the gradual appearance and expansion of translucent, roughly circu-
lar discontinuities or apparent zones of clearance in the otherwise homogeneous erythrocyte
layer coating the base of each well (Fig 1A). These discontinuities are henceforth referred to as
plaques. Importantly, plaque formation was easily detected and recorded without opening the
plates using a high resolution flatbed digital scanner (top-down transmission light mode, 4,800
dpi), avoiding the need for frequent and laborious microscopic examination of individual wells
and also allowing simple recording and documentation of the plate images. To formally estab-
lish whether plaque formation was a result of parasite replication, synchronous parasite cul-
tures (~10% parasitaemia, 0.75% haematocrit) were serially diluted into a suspension of fresh
uninfected erythrocytes (0.75% haematocrit) in complete medium and aliquots of each dilution
dispensed across a microplate. Monitoring of plaque formation in these plates showed that the
mean frequency of plaques at any given dilution correlated linearly with the starting
Malaria Parasite Plaque Assay
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parasitaemia in each well (Fig 1B and 1C and S1 Fig). No plaques formed in the absence of par-
asites. These results suggested that, so long as the erythrocyte cultures remained static and
undisturbed, parasite growth with concomitant host cell lysis was capable of producing
restricted, microscopically discernible zones of erythrocyte destruction. The discrete nature of
the plaques was presumably a result of repeated cycles of preferential invasion and lysis of
immediately adjacent host cells upon completion of each erythrocytic growth cycle. To opti-
mise conditions for plaque formation and detection, further assays were performed using a
range of haematocrit values. This revealed that a haematocrit of 0.75% (~7.5 x 107 erythrocytes
per ml, or ~1.5 x 107 cells per well) resulted in optimal plaque morphology and clarity (Fig
1D). Interestingly, erythrocyte longevity under the conditions of the assay was also haemato-
crit-dependent, with clear signs of generalised erythrocyte lysis (i.e. appearance of free haemo-
globin in the medium) typically evident as early as 10 days at a 0.5% haematocrit, whilst at
higher haematocrits the cells were reproducibly completely stable for at least 2 weeks. All sub-
sequent work therefore used a haematocrit of 0.75%. Typically, plaques attained a maximum
diameter of ~0.1 mm before eventual complete lysis of all the erythrocytes between 16–21 days.
Note that this was not due to excessive parasitaemia in the microwell cultures; microscopic
examination of Giemsa-stained cultures recovered from wells containing 30 plaques at 14 days
revealed parasitaemia values of only ~0.06% (~1 parasite in 1600 erythrocytes examined).
Each P. falciparum-Infected Erythrocyte in the Starting Population
Forms One Plaque
We reasoned that during parasite growth in the environment of a microplate well, even under
the static conditions described above, diffusive movement of free merozoites or even infected
erythrocytes might allow multiple plaques to form from a single parental infected cell. To
investigate this possibility, a synchronous parasite culture at ring-stage was diluted into a sus-
pension of fresh erythrocytes at 0.75% haematocrit in order to obtain a theoretical density of
<5 parasitised erythrocytes per ml of culture. The suspension was dispensed into the central
wells of 4 flat-bottomed plates (200 μl/well, 240 wells total), then the resulting plaques enumer-
ated 15 days later. If the parasitised cells assort randomly and if each parasite-infected cell pro-
duces only a single discrete plaque, the numerical distribution of plaques across the wells is
expected to follow Poisson statistics. A key indicator of this is that the experimentally deter-
mined (observed) mean average number of plaques per well is sufficient to allow a prediction
Fig 1. Formation of plaques in static P. falciparum asexual blood stage microplate cultures. (A) Time-dependent
evolution of plaques. Scanned images (RGB) of a single microplate well (diameter 6.38 mm) taken at the indicated times
following the introduction of a low parasitaemia P. falciparum 3D7 culture (200 μl per well, 0.75% haematocrit, starting
parasitaemia ~0.00004%, corresponding to ~6 infected cells per well). Plaques first became detectable by light microscopy
or high resolution scanning at day 8. (B) Plaque density correlates with starting parasitaemia. Shown are microplate wells
containing 10-fold serial dilutions (indicated) of a P. falciparum culture (0.75% haematocrit, starting parasitaemia 13%). The
wells were imaged on day 13 following initiation of the culture. By this point, at the highest parasite densities (neat and 10−1
dilution) the erythrocyte layer was completely destroyed, whilst discrete plaques were visible at the lower parasite
densities. Total numbers of plaques in each set of 6 replicate wells of the 10−3–10−8 dilutions (replicate wells are not shown)
was 2,034 (10−3), 245 (10−4), 26 (10−5), 4 (10−6), and 0 plaques (10−7 and 10−8). No plaques were ever detected in the
complete absence of parasites (none). (C) Linear regression by analysis of covariance (ANCOVA) indicating a strong linear
inverse correlation between dilution and plaque density in the wells containing the 10−3–10−6 parasite dilutions. A plot of
observed mean plaque frequency against dilution (blue) from the experiment shown in (B) is shown alongside a plot of the
plaque frequencies expected if there is a linear inverse correlation between plaque number and dilution (red). Values of the
statistical data (R2, F statistic, number of degrees of freedom and p value) are shown. (D) Optimisation of haematocrit
conditions. Microplate wells containing cultures at ~0.00004% parasitaemia at the indicated haematocrits, imaged on day
15. Whilst plaque formation was easily detected in the 0.75% haematocrit wells, they were much more difficult to detect at
higher haematocrit, whilst at lower haematocrit values the plaques were typically more diffuse with signs of erythrocyte
lysis. Inset, zoomed region of the 0.75% haematocrit erythrocyte layer, showing the discrete nature of the plaques.
doi:10.1371/journal.pone.0157873.g001
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of the probability distribution of plaque numbers across all the wells. In the experiment
depicted in Table 1, the observed frequency distribution of plaques per well was compared to
the theoretical Poisson distribution with the same mean number of plaques per well as
observed in this experiment (0.388). A chi-squared test of goodness-of-fit showed that the
observed distribution of plaques per well was not significantly different from the expected Pois-
son distribution. Similar data were obtained from three additional independent plaque assays
with widely varying mean values of plaque numbers per well; in each case, the observed distri-
bution showed a good match with the expected Poisson distribution (S2 Fig). Together with
the observed linear relationship between plaque number and parasite dilution, these results
convincingly confirm that–at least under limiting dilution conditions where plaque numbers
can be accurately counted–each plaque usually or always derives from a single precursor para-
site-infected erythrocyte and multiple plaques do not frequently arise from a single infected
cell.
Use of the Plaque Assay for Phenotypic Analysis of a Replication-
Defective P. falciparumMutant
To explore the broader utility of the plaque assay, we applied it to the phenotypic characteriza-
tion of a genetically modified P. falciparum clone known to display a partially-defined growth
defect. Plasmodiummerozoites are uniformly coated with a glycolipid anchored surface protein
called MSP1. We have previously shown [8] that conditional genetic truncation of the P. falcip-
arumMSP1 gene to remove its C-terminal membrane-anchoring domain results in merozoites
that entirely lack surface-bound MSP1. These merozoites undergo highly inefficient egress
from the host erythrocyte, with a resulting defect in parasite replication under static conditions
in vitro. We predicted that this defect would manifest itself in the plaque assay as a reduction in
the number and/or size of plaques. To test this prediction, a culture of highly synchronized
ring-stage P. falciparumMSP1:loxPint parasites [8, 9], which possess a loxP-flanked 3’ segment
of theirMSP1 gene and constitutively express a rapamycin (RAP)-inducible form of Cre
recombinase (DiCre) [10], was divided into two. The cultures were then treated in parallel with
either RAP (to induce DiCre-mediated gene excision) or DMSO (control solvent) only. The
two treated cultures were washed, diluted identically to a theoretical ~75 parasitised cells per
ml (15 parasites/well, 0.75% haematocrit), dispensed into flat-bottomed microplates and the
Table 1. Poisson analysis of plaque formation shows that each plaque derives from a single parasite-
infected erythrocyte.
Plaque frequency
Plaques/well Observeda Expectedc
0 168 163
1 56b 63
2 11b 12
3 5b 2
aPlaque number in a total of 240 wells (4 microwell plates).
bThe total number of plaques in the four plates was 93, so the overall mean number of plaques/well (λ) is
given by 93/240 = 0.388.
cExpected values assuming a Poisson frequency distribution. A chi-squared goodness of ﬁt comparison of
the observed and expected data gave a value χ2 = 1.25 for 2 degrees of freedom, p>0.50, indicating no
signiﬁcant difference between the sets of values. Note that for the chi-squared calculations, data for the 2
plaques/well and 3 plaques/well were pooled in order to avoid using expected values of <5.
doi:10.1371/journal.pone.0157873.t001
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resulting plaques examined 14 days later. Imaged plaque numbers were determined by manual
counting, whilst the pixel area of individual plaques was quantified using the Magic Wand tool
of Adobe Photoshop CS5. As shown in Fig 2, plaques formed in the RAP-treated cultures were
smaller and less numerous (mean = 199.3, SD = 9.2, n = 54) than those formed in the control
wells (mean = 329.1, SD = 6.7, n = 205), with a two-tailed independent t-test revealing this dif-
ference to be highly significant (t = 9.290, d.f. = 257, p<0.0001). The differences in mean pla-
que area values indicate a fitness defect associated with truncation of MSP1, consistent with the
previously observed ~2-fold slower replication rate displayed by this mutant relative to the
parental parasite clone in standard parasite growth assays [8]. Collectively, these results show
that the plaque assay can be used as a simple means of rapidly characterizing even rather subtle
effects of mutagenesis on parasite fitness.
Rapid Phenotypic Analysis of a Conditional Lethal P. falciparumMutant
To further examine the applicability of the plaque assay, we used it to examine a second P. fal-
ciparummutant in which the DiCre system was used to conditionally disrupt a gene predicted
to be essential for in vitro growth. The malarial serine-rich antigen (SERA) family comprises a
group of papain-like proteins encoded by genes with variable numbers of orthologues in all
Plasmodium species examined [11]. Interest in the SERA proteins, which all share similarities
with papain-family proteases, has arisen from evidence that they play roles in parasite egress
and/or host cell invasion. Previous attempted direct gene disruption experiments using tar-
geted homologous recombination have suggested that two of the nine P. falciparum SERA
genes, SERA5 and SERA6, are essential in asexual blood stages [12, 13]. To extend our previous
work indicating that SERA6may have a function at egress [14], we produced transgenic P. fal-
ciparum parasites (called SERA6:loxP) in which the entire SERA6 locus was flanked by loxP
sites (manuscript in preparation; J. Thomas, C. Collins and M. Blackman). These parasites
were produced on the genetic background of the same DiCre-expressing parasite clone (called
1G5DC [10]) used to produce the MSP1:loxPint parasites described above. A synchronous cul-
ture of a SERA6:loxP clone was divided into two and treated in parallel with either RAP to
induce DiCre-mediated gene excision, or DMSO only. The treated cultures were washed,
diluted identically to a theoretical ~75 parasites per ml (15 parasites/well), dispensed into flat-
bottomed microplates and the resulting plaques imaged 14 days later. As shown in Fig 3A, the
results demonstrated a dramatic difference between the control DMSO-treated cultures, which
showed substantial numbers of plaques, and the RAP-treated parasites, in which only a single
plaque appeared in one well. RAP-mediated gene excision in the P. falciparum DiCre system,
whilst tightly regulated and highly efficient, is rarely complete in a treated population [8, 10].
This can result in heterogeneous parasite populations that contain both excised and non-
excised parasites, making it difficult to unambiguously assess the effects of gene modification
on parasite fitness in uncloned RAP-treated cultures. Based on the clear difference between the
RAP-treated and control SERA6:loxP parasites in the plaque assay, we hypothesized that the
single plaque formed in the RAP-treated cultures might be derived from a parasite that had not
undergone excision of the floxed SERA6 gene. To test this, parasites from the plaque-positive
well in the RAP-treated samples were expanded and analyzed by diagnostic PCR. This showed
that these parasites indeed possessed an intact, non-excised genomic SERA6 locus (Fig 3B).
These results convincingly demonstrate that loss of SERA6 expression produces non-viable
parasites that are completely unable to produce plaques. Importantly, because the plaque assay
allowed visualization of parasite fitness at the level of individual parasite clones, it enabled sim-
ple comparison of the RAP-treated and control cultures and allowed us to quickly demonstrate
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Fig 2. Phenotypic characterisation of an MSP1mutant using the plaque assay. Scatter plots showing
the distribution of plaque sizes obtained following treatment of MSP1:loxPint parasites with DMSO (control,
mock-treated) or RAP to induce DiCre-mediated truncation of MSP1. Plaque numbers (n = 205 for the
DMSO-treated samples and n = 54 for the RAP-treated samples) were counted manually. Plaque dimensions
were quantified using the Magic Wand tool of Photoshop CS5 (Adobe). Horizontal bars indicate mean plaque
area ± 1 SD.
doi:10.1371/journal.pone.0157873.g002
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Fig 3. Rapid phenotypic characterization of a lethal conditional P. falciparummutant using the plaque assay. (A) Left hand-
side; schematic of the results of plaque analysis of RAP-treated and DMSO (mock)-treated SERA6:loxP parasites. Microplate wells
coloured green indicate those that contained plaques 14 days following plating out the parasites at a theoretical 10 parasites/well.
White wells contained no plaques (wells shown in grey were not used for the cloning). Whereas plaques were present in every well of
the mock-treated culture, only a single plaque appeared in one well (well D8) of the RAP-treated culture. Right hand-side; example
wells from the RAP-treated and control plates (green channel only of the scanned image shown to enhance plaque visibility, displayed
as a grayscale image; see Materials and Methods for details). (B) Diagnostic PCR analysis of either the bulk SERA6:loxP parasite
population immediately following RAP or DMSO-treatment (before plaque assay), or parasites expanded from well D8 of the +RAP
plate. RAP-treatment significantly reduced the intact-SERA6 locus-specific signal in the parasite population and resulted in
appearance of a signal specific for the excised locus. Parasites rescued from well D8 of the RAP-treated parasites displayed a non-
excised genomic architecture. The results strongly suggest that excision of the SERA6 gene is lethal. Arrow-heads indicate the
oligonucleotide primers used for PR analysis: blue, SERA6-34; yellow, JTS5synthF; brown, JTPbDT3’R (see Materials and Methods
for primer sequences and PCR parameters). Expected sizes of the PCR amplicons are indicated.
doi:10.1371/journal.pone.0157873.g003
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that the only parasites in the RAP-treated population capable of surviving were those rare para-
sites in which excision of the SERA6 gene had not occurred.
Discussion
There has long been a need for a simple and robust plaque assay suitable for use with P. falcipa-
rum. Here we have developed such a system, using the simple expedient of culturing the para-
site under static, limiting dilution conditions in human erythrocytes in flat-bottomed
microplates. Visualisation of plaque formation was haematocrit-dependent, but we found that
plaques were easily detectable within ~2 weeks under optimised conditions (0.75% haemato-
crit). Based on a mean human erythrocyte volume of ~90 x 10−15 L [15], we calculate that
under the conditions used the settled erythrocytes formed layers that are at least 24 cells thick.
This likely allows productive parasite proliferation and plaque growth in 3 dimensions, as
opposed to the two dimensional plaque expansion allowed by the adherent erythrocyte mono-
layers used in previously-described P. falciparum plaque assays. The plaques, which presum-
ably comprise predominantly haemoglobin-free erythrocyte ghosts, cell debris and haemozoin
pigment, are completely stable under conditions of regular manual plate transferral to and
from incubators, even without the use of semi-solid media, probably because the small volumes
in each microplate well limit liquid movement and consequent disturbance of the erythrocyte
layer. Use of larger wells or flasks would probably destabilise plaques, which may explain why
the formation of these structures has not previously been described. Plaque integrity and stabil-
ity was further ensured in the assay by not replacing the medium during the 2–3 week period
of the assay. Although this may have the effect of limiting parasite growth rates, we found that
up to a plaque density of at least ~340 plaques per well, plaque frequency correlated with start-
ing parasite density, implying that—at least within this parasitaemia range—plaque formation
is not adversely affected by plaque density. Plaques produced by clonal parasite populations
were not completely homogeneous in size or shape, but this is a feature of many plaques,
including those produced by Toxoplasma. The P. falciparum plaques are easily visible using an
inverted light microscope and, similar to viral plaques [16], can be rapidly imaged with mini-
mal disturbance using an inexpensive, commercially available document scanner, avoiding the
need for laborious photographic imaging of individual wells. Indeed, using a high resolution
(4,800 dpi) flat-bed scanner in transmission light mode, we found that we were able to scan
and document up to 3 plates simultaneously in a single TIFF image, allowing for rapid docu-
mentation of multiple plates. The ready availability, low cost and lack of user training required
to use a flat-bed scanner makes this a highly accessible, medium-throughput means of docu-
menting the results of assays.
The P. falciparum plaque assay has important advantages compared to those commonly
used for viruses and other intracellular pathogens such as Toxoplasma. Mature erythrocytes do
not replicate, so there is no need to take into account changes in host cell confluency over the
course of the assay. Furthermore, there is no requirement to fix and stain the cells before plaque
analysis. The ability to easily visualise parasite clonal growth has other advantages. In our labo-
ratory we now regularly use the approach for rapid limiting dilution cloning of P. falciparum
lines without the need for laborious determination of starting parasitaemia values, simply by
performing serial dilutions of a parasite culture across a plate then picking clones only from
those wells that contain a single plaque. It is important to transfer these clones from the plaque
assay plates into cultures containing fresh erythrocytes before the plaque assay cultures begin
to undergo generalised erythrocyte lysis, which we found usually occurs between 16–21 days
after initiating the plaque assay. The plaque assay may be applicable to the study of other Plas-
modium species that can be cultivated in vitro, though our attempts to optimise it for use with
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culture-adapted lines of P. knowlesi [17] were not encouraging; in this case the plaques formed
were irregular and indistinct, perhaps a result of the well-documented greater extracellular
motility and longevity of free P. knowlesimerozoites [18, 19] which may allow more rapid dis-
persal of released merozoites within the wells than occurs with P. falciparum (unpublished
data, J. Thomas).
Reverse genetic technologies have become increasingly important in malarial research over
the past 2 decades. With the relatively recent introduction of Cas9-mediated mutagenesis [20,
21] and conditional gene modification technologies in P. falciparum [10, 22–24] we believe that
the development of simple assays such as that described here is particularly timely. The plaque
assay has multiple applications; here we have shown that it can be used to rapidly phenotype
genetic mutants without the need for complex equipment or facilities (e.g. flow cytometry or
spectrophotometry), but it also will be invaluable for the calculation of kill-curves with anti-para-
site drugs and antibodies, for the selection of drug-resistant or fast-growing mutants, for facile
comparison of parasite fitness under a range of growth conditions (e.g. in different defined
media) and numerous other uses. Differences in parasite growth rate are presumably propagated
over the course of the 4–7 cycles required to produce visible plaques, providing some advantages
over traditional growth assays in that the cultures do not need to be passaged or fed. Importantly,
the assay complements other widely used approaches for quantitation of parasite growth, includ-
ing light microscopy, flow cytometry and assays based on expression of parasite proteins or
enzymes [25, 26], incorporation of fluorescent dyes [27, 28] or radioactive hypoxanthine [29].
Although not explored here, the assay may be suitable for scaling up to high throughput image-
based screens using high content microscopy. We believe the plaque assay will prove a valuable
addition to the experimental tools available for studying this important pathogen.
Materials and Methods
P. falciparumMaintenance and Manipulation
Parasites (wild type clone 3D7, the DiCre-expressing clone 1G5DC [10], and MSP1:loxPint or
SERA6:loxP parasites which were produced on the 1G5DC genetic background [8, 9]) were
routinely cultured at 37°C in human erythrocytes at 1–4% haematocrit in RPMI 1640 (Life
Technologies) supplemented with 2.3 gL-1 sodium bicarbonate, 4 gL-1 dextrose, 5.957 gL-1
HEPES, 0.05 gL-1 hypoxanthine, 0.5% (w/v) Albumax II, 0.025 gL-1 gentamycin sulphate, and
0.292 gL-1 L-glutamine (complete medium) in a low oxygen atmosphere as previously
described [30, 31]. Parasitaemia was never allowed to exceed 10%. Human blood was obtained
from anonymised donors through the UK National Blood Transfusion service and was used
within 2 weeks of receipt. No ethical approval is required for its use. Routine microscopic
examination of parasite growth was performed by fixing air-dried thin blood films with 100%
methanol before staining with 10% Giemsa stain (VWR international) in 6.7 mM phosphate
buffer, pH 7.1. For routine microscopic determination of parasitaemia values, at least 5,000
erythrocytes were examined. Haematocrit values were determined using a haemocytometer
(Marienfield; 0.1 mm depth and 0.0025 mm2 area), assuming that 100% haematocrit equates to
1 x 1010 normocytes ml-1. For synchronisation, mature schizont stage parasites were isolated
on cushions of 70% (v/v) Percoll (GE Healthcare) adjusted to isotonicity as described [32, 33].
Lysis of mature forms of the parasite to enrich for ring forms after invasion was performed by
suspending parasites in 5% (w/v) D-sorbitol [32, 34].
Generation of Transgenic P. falciparum Clones and PCR Analysis
Production of the P. falciparumMSP1:loxPint clone which possess a loxP-flanked 3’ segment
of theMSP1 gene and constitutively expresses a RAP-inducible form of Cre recombinase has
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been described [8, 9]. Production of the SERA6:loxP line was achieved by introducing a loxP
site into the genome directly downstream of the SERA6 locus in the 1G5DC clone, which
already possesses a genomic loxP site downstream of the SERA5 locus. Details of the approach
used to generate the SERA6:loxP parasites will be provided separately (manuscript in prepara-
tion; J. Thomas, C. Collins and M. Blackman). When desired, transgenic parasites were treated
with RAP (100 nM final concentration) or DMSO (control vehicle, 1% v/v) for 4 h, as described
[10]. Genomic DNA was prepared from treated parasites for diagnostic PCR analysis as
described [10]. The intact modified SERA6 locus was amplified by PCR using oligonucleotide
primers JTPbDT3’R (5’-TTACAGTTATAAATACAATCAATTGG-3’) plus SERA6-34 (5’- GT
CCTGGAAGAAGAACGTTGCCGCCGCGAGACACAACACTGACTTCATG-3’). The
excised locus (following DiCre-mediated recombination) was amplified using primers
JTPbDT3’R plus JTS5synthF (5’- GAATGCTATTTCTGCTACGTG-3’). For diagnostic PCR
analysis a Kappa2G Fast HotStart ReadyMix PCR Kit (Kappa Biosystems) was used. Thermal
cycle conditions for amplification of the intact modified SERA6 locus were: initial denaturation
at 95°C for 60 sec, followed by 20 cycles of 95°C for 10 sec, 51°C for 10 sec and 72°C for 15 sec,
with a final extension at 72°C for 60 sec. Thermal cycle conditions for amplification of the
excised locus were: initial denaturation at 95°C for 60 sec, followed by 25 cycles of 95°C for
10 sec, 55°C for 10 sec and 72°C for 15 sec, with a final extension at 72°C for 60 sec.
Imaging, Documentation and Quantitation of Plaque Formation
To allow plaque formation, synchronous parasite cultures at ring stage were diluted to the
desired densities in complete medium with human erythrocytes at haematocrits between 0.5%
and 2%, then dispensed into flat-bottomed 96 well microplates (Costar 3596, Corning NY,
USA; 0.32 cm2 growth area per well, diameter 6.38 mm) using 200 μl culture per well. Plates
were incubated in gassed, humidified sealed modular incubator chambers (Billups-Rothenberg,
CA, USA). To limit evaporation, only the inner 60 wells of microplates were used for cultures
whilst sterile phosphate buffered saline was added to the outer wells of plates. Plaque formation
was assessed routinely by microscopic examination using a Nikon TMS inverted microscope
(40x magnification). When desired, plaque formation was documented without opening the
plates using a Perfection V750 Pro scanner (Epson) in top-down transmission light mode, sav-
ing images as 4,800 dpi RGB TIFF files. Usually 3 microplates were imaged simultaneously
with the scanner. Plaque visibility was generally enhanced by using the 'Split channels' function
of the Fiji distribution of ImageJ [35] to split the RGB TIFF file into red, green and blue data
channels, then using the green channel image for quantification of plaque dimensions, since
this provided maximum contrast between plaques and the surrounding erythrocyte layer. Pla-
ques were counted by visual examination of the images and plaque size quantified using the
Magic Wand tool in Adobe Photoshop CS5 using a tolerance setting value of 32. This tool
delineates the perimeter of selected plaques and calculates plaque area in pixels. No area value
was recorded for apparent plaques that could not be delineated by the tool. Statistical analysis
(linear regression analysis by analysis of covariance and t-test) was performed using GraphPad
Prism 7 software (CA, USA).
Supporting Information
S1 Fig. The experimentally observed frequency distribution of plaques in the plaque assay
follows a Poisson distribution.
(PDF)
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S2 Fig. Plaque frequency shows a linear correlation with parasite number.
(PDF)
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S1 Fig. The experimentally observed frequency distribution of plaques in the plaque assay follows a 
Poisson distribution. Depicted are plaque assay data from three independent experiments carried out 
on different days in which serially diluted 3D7 P. falciparum cultures (0.75% haematocrit) were 
cultured in flat-bottomed 96-well microplates as described in Materials and Methods. Plaques were 
enumerated at 14 days and mean values () calculated. Experimentally observed plaque frequency 
values are shown plotted (blue) alongside the expected frequency values of a Poisson distribution with 
the same mean value (red). Chi-squared goodness-of-fit tests showed no significant deviation of 
observed distributions from the expected distributions. Chi-squared (2) values, number of degrees of 
freedom (d.f) and p-values are indicated in each case. Note that for the purpose of statistical analysis, 
those categories where expected values were less than 5 were pooled to create a single category. 
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S2 Fig. Plaque frequency shows a linear correlation with parasite number. Depicted are plaque assay 
data from two independent experiments carried out on different days in which 2-fold serial dilutions 
of 3D7 P. falciparum cultures (0.75% haematocrit) were cultured in flat-bottomed 96-well microplates 
as described in Materials and Methods. Plaques were enumerated at 14 days. Plots of observed mean 
plaque frequency against dilution (blue) are shown alongside plots of plaque frequencies expected if 
there is a linear inverse correlation between plaque number and dilution (red). To establish the fit 
between the plots, linear regression was performed by analysis of covariance (ANCOVA) in GraphPad 
Prism. The results indicate a strong linear inverse correlation between dilution and plaque density in 
the assay, with no significant difference between the observed and expected curves. Values of the 
statistical data (R2, F statistics, number of degrees of freedom and p values) are shown. 
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